JP2019001739A - Application of cyclodextran and derivative of the same - Google Patents

Abstract

To provide a novel application of cyclodextran.SOLUTION: (1) A composition containing one or more types selected from the group consisting of cyclodextran and derivatives thereof. (2) the composition according to (1) in which the derivative of cyclodextran is α-1,3-branched cyclodextran or the like in which one to several pieces of glucose are bonded to cyclodextran in α-1,3-bond. (3) a medicine, a cosmetic, a food/drink product, ink, a sanitary product, conductive liquid, resin, column containing the composition described above. (4) a solubilization method of a hardly soluble compound containing the composition described above, a masking method of food/drink product or the like.SELECTED DRAWING: None

Description

  The present invention relates to the use of cyclodextran and its derivatives.

  Cyclodextran is a known cyclic isomalto-oligosaccharide in which 7 to 17 glucoses are linked cyclically by α-1,6 glucoside bonds. Cyclodextran, which is a cyclic oligosaccharide, is synthesized from dextran or starch by an enzyme produced by a microorganism belonging to the genus Bacillus (Patent Document 1 and Patent Document 2).

  Although this cyclodextran is expected to be used in the same applications as cyclodextrins having a similar structure, few have actually reported the use of cyclodextran.

Patent No. 3075873 Japanese Patent No. 3117328

  Accordingly, the present invention provides a new use for cyclodextran.

  The present inventors have found various uses of cyclodextran and have completed the present invention.

That is, the present invention is as follows.
(1) A composition comprising one or more selected from the group consisting of cyclodextran and derivatives thereof.
(2) The composition according to (1), wherein the derivative of cyclodextran is α-1,3-branched cyclodextran in which 1 to several glucoses are bonded to cyclodextran through α-1,3-linkages.
(3) An unbranched cyclodextran and an α-1,3-branched cyclodextran in which 1 to several glucoses are linked to cyclodextran by α-1,3-linkage (1) The composition as described.
(4) A pharmaceutical, cosmetic, food and drink, ink, sanitary product, conductive liquid, resin, column, which contains the composition according to any one of (1) to (3) above.
(5) A method for solubilizing a hardly soluble compound, comprising mixing the composition according to any one of (1) to (3) above and a hardly soluble compound.
(6) A method for masking a food or drink, comprising mixing the composition according to any one of (1) to (3) above with the food or drink.
(7) A method for stabilizing a food or drink, comprising mixing the composition according to any one of (1) to (3) above with the food or drink.
(8) A method for drying a component unsuitable for drying, comprising mixing the component unsuitable for drying and the composition according to any one of the above (1) to (3) and drying.
(9) A method for deodorizing an unpleasant odor, which comprises spraying a solution containing the composition according to any one of (1) to (3) onto an article that emits an unpleasant odor.
(10) A method for sustained release of a fragrance, comprising mixing the fragrance and the composition according to any one of (1) to (3) above.

  The composition of the present invention can be used in medicines, cosmetics, foods and drinks, inks, hygiene products, conductive liquids, resins, columns and the like.

  The composition of the present invention is used for solubilization of poorly soluble compounds, masking of foods and drinks, stabilization of foods and drinks, drying of components unsuitable for drying, deodorizing unpleasant odors, sustained release of fragrances, etc. it can.

  Cyclodextran that can be used in the composition of the present invention is a known cyclic isomalto-oligosaccharide in which 5 to 33 glucoses are cyclically linked by α-1,6 glucosidic bonds. For example, Patent No. 3075873 and Patent A product obtained from a culture solution of a microorganism belonging to the genus Bacillus described in No. 3117328, a reaction solution of cyclic isomalt sugar synthase, or a commercially available product can be used. Usually, when cyclodextran is obtained using microorganisms or enzymes, it is obtained as a mixture of unbranched cyclodextran (ordinary cyclodextran) and branched cyclodextran. Unbranched cyclodextran and branched cyclodextran can be separated by a column such as ODS (see JP 2012-140521 A).

  Cyclodextran derivatives include branched cyclodextran obtained by separation from the above cyclodextran mixture using a column such as ODS, and known derivatives of cyclodextrins, which can be converted into cyclodextran or branched cyclodextran. Substituted ones are listed.

  Among the derivatives of cyclodextran, α-1,3-branched cyclodextran in which 1 to several glucoses are bonded to cyclodextran by α-1,3-linkage is preferable. In this branched cyclodextran, the degree of polymerization of branched glucose is up to 9, and among them, α-1,3-branch in which one molecule of glucose is branched to cyclodextran by α-1,3-linkage. Cyclodextran is preferably used. The number of glucose molecules constituting the cyclic portion of the cyclic branched isomaltoligosaccharide is 5 to 33, preferably 5 to 17, desirably 5 to 12, and constitutes a preferred cyclic branched isomaltoligosaccharide. The number of molecules of glucose is 6 to 20, and preferably 6 to 13 in total in the molecule.

One or more of the above cyclodextran and derivatives thereof can be used in the composition of the present invention. Preferable examples of the composition of the present invention include the following. Hereinafter, these are collectively referred to as “cyclodextran”.
(A) cyclodextran (b) α-1,3-branched cyclodextran in which one to several molecules of glucose are linked to cyclodextran with α-1,3-linkage (c) unbranched cyclodextran; Mixture of α-1,3-branched cyclodextran in which one to several molecules of glucose are linked to cyclodextran by α-1,3-linkage

  The composition of the present invention can be blended in medicines, cosmetics, foods and drinks, inks, hygiene products, conductive liquids, resins, columns, etc., in which case cyclodextran may be blended as it is, Depending on the purpose, the substance to be mixed is incorporated into the ring to form an inclusion compound, or the substance to be mixed is mixed loosely with intermolecular forces such as hydrogen bonds and hydrophobic bonds. Also good. As a method of loosely binding, powder mixing, liquid-liquid or liquid-powder high-pressure emulsification, or the like that eliminates water molecules of the substance to be mixed as much as possible and makes intermolecular contact occur. During this emulsification, water molecules may be eliminated as much as possible by adding an emulsifier and salts.

<Pharmaceutical>
The composition of the present invention can be contained in a medicine. In medicine, the content of the composition of the present invention is not particularly limited as long as the effect of the intended component is achieved. There is also. In addition, the inclusion of the composition of the present invention in a medicine forms an inclusion compound with the active pharmaceutical ingredient, or without the inclusion compound, the bitterness, astringency, sourness, astringency, etc. of the active pharmaceutical ingredient Unpleasant taste can be masked, and further, the active pharmaceutical ingredient can be stabilized, solubilized, sustained-released, locally administered, temperature-responsive, and the like. Moreover, as a cyclodextran used for a medicine, you may mix suitably the thing of said (a)-(c). In addition, since cyclodextran itself has GLP-1 secretion promotion action etc., it can also be used as a pharmaceutical active ingredient.

  The form of the pharmaceutical is not particularly limited, and may be any dosage form such as a tablet, powder, liquid, suppository, injection, capsule, patch, eye drop and the like.

<Cosmetics>
The composition of the present invention can be contained in cosmetics. In cosmetics, the content of the composition of the present invention is not particularly limited, and is, for example, 0.000001 to 99.99999999%. In addition, by including the composition of the present invention in a cosmetic, it is possible to mask an odor etc. without forming an inclusion compound with the ingredients in the cosmetic, or further, in the cosmetic. These components can be stabilized, solubilized, sustained-released, locally administered, temperature-responsive, and the like. In addition, as a cyclodextran used for cosmetics, you may mix the said (a)-(c) thing suitably.

  The form of the cosmetic is not particularly limited, and lotion, milky lotion, cream, ointment, lotion, cosmetic liquid, pack, mascara, eyeliner, eye shadow, foundation, lipstick, lip balm, lip gloss, lipstick, lip treatment , Lip pencil, eye pencil, nail varnish, nail polish, toothpaste, oral rinse, etc.

<Food &Drink>
The composition of this invention can be contained in food-drinks. In the food and drink, the content of the composition of the present invention is not particularly limited, and is, for example, 0.000001 to 99.99999999%. The composition of the present invention can mask foods and drinks having an unpleasant taste or smell such as bitterness, astringency, acidity, unpleasant taste, and odor, and can stabilize and solubilize ingredients in the food and drink. . In addition, although the composition of the present invention can be blended in foods and drinks, it forms an inclusion compound with an ingredient having an unpleasant taste or smell such as bitterness, astringency, acidity, unpleasant taste, odor, etc. Without forming, bitterness, astringency, acidity, unpleasant taste, odor and the like can be masked and taste quality can be improved, and further, the above-mentioned components in food and drink can be stabilized and solubilized. In addition, as a cyclodextran used for food-drinks, you may mix the said (a)-(c) thing suitably.

  The food and drink is not particularly limited, and processed meat products such as ham and sausage, seasonings such as soy sauce, processed fishery products such as kamaboko and chikuwa, dairy products such as milk, butter and yogurt, bread, carbonated drinks, alcohol Beverages, fruit juice drinks, coffee drinks, sports drinks, tea drinks, nutrition drinks, tea drinks, soft drinks, dairy lactic acid bacteria drinks, lactic acid bacteria drinks, and other nutritional supplements such as tablets, chocolate, rice cakes, rice crackers, cookies, etc. Frozen foods such as confectionery, ice and soft ice cream, frozen noodles, frozen tangerines, frozen fried rice, frozen croquettes, liquid throat protection food, bad breath prevention food, etc. may be used.

<Ink>
The composition of the present invention can be contained in an ink. In the ink, the content of the composition of the present invention is not particularly limited, and is, for example, 0.000001 to 99.99999999%. Although the composition of the present invention can be blended in an ink, it can form a clathrate compound or a clathrate compound with an ink component such as a pigment, etc. Recording properties can be improved. In addition, as the cyclodextran used for the ink, the above (a) to (c) may be appropriately mixed.

  The ink is not particularly limited, and examples thereof include inkjet ink, fountain pen ink, and printing ink such as letterpress printing.

<Hygiene products>
The composition of the present invention can be contained in a sanitary product. In the sanitary product, the content of the composition of the present invention is not particularly limited, but is, for example, 0.000001 to 99.99999999%. Although the composition of the present invention can be blended in hygiene products, it forms an inclusion compound with the components in the hygiene product, or is absorbed into the hygiene product without forming an inclusion compound, skin, body fluid, urine Absorbs odors generated from In addition, as a cyclodextran used for a sanitary product, you may mix the said (a)-(c) thing suitably. Moreover, when mix | blending the composition of this invention with sanitary goods, combining with a fragrance | flavor is preferable. The cyclodextran and the fragrance may form an inclusion compound or may not form an inclusion compound. In addition, the composition of the present invention may be contained in the sanitary product itself or may be coated on the surface of the sanitary product. In addition, when the composition of the present invention is blended in a sanitary product, it is preferably combined with various carriers such as zeolite. Thereby, deodorant property improves.

  Sanitary products include masks, cotton swabs, tissues, disposable diapers, urine pads, incontinence pads, sanitary napkins, deodorant sprays, shoe insoles, and the like.

<Conductive liquid>
The composition of the present invention can be contained in a conductive liquid. In the conductive liquid, the content of the composition of the present invention is not particularly limited, and is, for example, 0.000001 to 99.99999999%. Although the composition of the present invention can be blended in a conductive liquid, it forms a clathrate compound with a component in the conductive liquid, for example, a conductive polymer, or without forming a clathrate compound. Improves gas and liquid permeability. In addition, as a cyclodextran used for an electroconductive liquid, you may mix the thing of said (a)-(c) suitably.

  Examples of the conductive liquid include those containing a conductive polymer, a dopant, a solvent, a dispersion medium, and the like. These conductive liquids are used for electrolytic capacitors and the like. Examples of the conductive liquid include those containing various metal salts and conductive salts. Such a conductive liquid is used as a plating liquid.

<Resin>
The composition of the present invention can be contained in a resin. In the resin, the content of the composition of the present invention is not particularly limited, and is, for example, 0.000001 to 99.99999999%. Although the composition of this invention can be mix | blended with resin, it forms the clathrate compound with the component in resin, or improves the abrasion resistance and deodorizing property of a resin, without forming a clathrate compound. In addition, as a cyclodextran used for resin, you may mix the said (a)-(c) thing suitably.

  Resin that can contain the composition of the present invention is not particularly limited, for example, polyalkylenes, polycaprolactones, polypropylene glycols, polyethylene glycols, polyisoprenes, polyesters, polyimides, Polyurethanes, polybutadienes, polytetrahydrofurans, polydimethylsiloxanes, polyethylenes, polypropylenes, polyamides, polyacryls, ABSs, polycarbonates, polymethyl methacrylates, polystyrenes, polyvinyl chloride, etc. Block copolymers, graft copolymers, alternating copolymers, random copolymers, and the like. The composition of the present invention may be added during polymerization of these resins or after polymerization.

  The resin may further be provided with functionality by blending a flavoring agent, an ultraviolet absorber, an ultraviolet reflector, an antibacterial agent, an antifungal agent, or the like that forms an inclusion compound with the cyclodextran. If a fragrance is added to the resin together with a cyclodextran, it becomes a scented resin, and if an ultraviolet absorber or an ultraviolet reflector is added to the resin together with a cyclodextran, the absorption of ultraviolet rays is suppressed, and the resin is combined with a cyclodextran. Add antibacterial and antifungal agents to make antibacterial and antifungal resins.

<Column>
The composition of the present invention can be contained (packed) in a column. In the column, the content of the composition of the present invention is not particularly limited, and is, for example, 0.000001 to 99.99999999%. The composition of the present invention can be used for stationary phases such as gas chromatography, liquid chromatography, and high performance liquid chromatography. Moreover, you may make the cyclodextran contained in the composition of this invention couple | bond or coat the stationary phase used for a conventionally well-known column. In this column, cyclodextran improves the separation ability of the component to be separated without forming the clathrate compound or the clathrate compound with the component to be separated. In addition, as a cyclodextran used for a column, you may mix the said (a)-(c) thing suitably.

  The carrier for the stationary phase of the column is not particularly limited, and examples thereof include silica gel, glass beads, diatomaceous earth, and alumina.

<Method of solubilizing poorly soluble compounds>
The composition of the present invention can solubilize a compound generally called a poorly soluble compound. Such a hardly soluble compound is not particularly limited, and is a pharmaceutically active ingredient classified into various hardly soluble substances, terpenoids, for example, hemiterpenes such as isoprene, prenol, 3-methylbutanoic acid, geranyl diphosphate, cineol, limonene. , Monoterpenes such as pinene, sesquiterpenes such as farnesyl diphosphate, artemisinin, bisabolol, geranylgeranyl diphosphate, retinol, retinal, phytol, paclitaxel, forskolin, diterpenes such as aphidicolin, triterpenes such as squalene, lanosterol, lycopene, carotenes Tetraterpenes such as lycopene, lutein, zeaxanthin, canthaxanthin, fucoxanthin, astaxanthin, anthaxanthin, violaxanthin and the like: steroidal alkaloids, for example, Lanine (aglycone and its glycoside), caconine (aglycone and its glycoside), solanidine (aglycone and its glycoside), solanocapsin (aglycone and its glycoside), tomatine (aglycone and its glycoside), Belarcamine (aglycone and its glycoside), cyclopamine (aglycone and its glycoside), cycloposin (aglycone and its glycoside), jervin (aglycone and its glycoside), murdamine (aglycone and its glycoside), Veratridine (aglycone and its glycoside), connesin (aglycone and its glycoside), samandaridin (aglycone and its glycoside), batracotoxin (aglycone and its glycoside), etc .: Icosanoids such as prostagland Prostanoids such as gin and thromboxane, leukotrienes, etc .: alkydyl alcohol, eg For example, decan-1-ol, undecan-1-ol, dodecan-1-ol, tridecan-1-ol, tetradecan-1-ol, pentadecan-1-ol, hexadecan-1-ol, heptadecan-1-ol, Octadecan-1-ol, nonadecan-1-ol, icosan-1-ol, heneicosan-1-ol, docosan-1-ol, tricosan-1-ol, tetracosan-1-ol, pentacosan-1-ol, hexacosan- Higher alcohols such as 1-ol, heptacosan-1-ol, octacosan-1-ol, nonacosan-1-ol, rearcontan-1-ol, 2-methylpropan-1-ol, 3-methylbutan-1-ol, etc .: ubiquinone : Ubiquinol: Unsaturated fatty acids such as crotonic acid, milli Monounsaturated fatty acids such as strenoic acid, palmitoleic acid, sapienoic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, erucic acid, nervonic acid, and diunsaturated fatty acids such as linoleic acid, eicosadienoic acid, docosadienoic acid, etc. , Linolenic acid, pinolenic acid, eleostearic acid, mead acid, dihomo-γ-linolenic acid, triunsaturated fatty acids such as eicosatrienoic acid, stearidonic acid, arachidonic acid, eicosatetraenoic acid, adrenic acid tetra Unsaturated fatty acids, boseopentaenoic acid, eicosapentaenoic acid, ozbond acid, sardine acid, hexaunsaturated fatty acids such as docosahexaenoic acid, nisinic acid, etc .: fat-soluble vitamins such as retinol, retinal Retinoic acid, 3-dehydro-retino , 3-dehydro-retinal, 3-dehydro-retinoic acid, tretinoin, α-carotene, β-carotene and other vitamin A, ergosterol, ergocalciferol, 7-dehydrocholesterol, previtamin D3, cholecalciferol, 25 -Vitamin D such as hydroxycholecalciferol, calcitriol, calcitriol, dihydroergocalciferol, dihydrotaxolol, calcipotriol, tacalcitol, paricalcitol, tocopherol (α, β, γ, δ), tocotrienol, tocopherol Vitamin E such as solan, vitamin K such as phylloquinone, menaquinone, menadione: polyphenols such as catechin, tannin, xanthohumol, polymethoxyflavone, rutin (aglycone and its glycosides ), Flavonoids such as hesperidin (aglycone and its glycoside), naringin (aglycone and its glycoside), isoflavone (aglycone and its glycoside), coumaric acid, cinnamic acid (and derivatives), caffeic acid, Eugenol, anethole, monolignol (aglycone), phenylpropanoids such as sesamin, podophyllotoxin, lignan and lignin, curcuminoids such as curcumin, stilbenoids such as resveratrol, phenolic acids such as chlorogenic acid, ellagic acid, coumarin: alpha lipoic acid : Propolis: Black ginger, etc.

  The method for solubilizing the poorly soluble compound is not particularly limited, and for example, the poorly soluble compound and the clathrate compound may be formed, or the slightly soluble compound may be loosely bonded to the compound. As a method for forming the clathrate compound, for example, cyclodextran may be added to a liquid in which a poorly soluble compound is dispersed in a solvent, followed by stirring and mixing. Examples of the solvent include water, organic solvents such as alcohol, a mixed solution thereof, and the like, and the solvent may be heated if necessary. On the other hand, as a method of loosely bonding, powder mixing, liquid liquid or liquid powder high-pressure emulsification, etc., which eliminates water molecules of a hardly soluble compound as much as possible and makes intermolecular contact occur. During this emulsification, water molecules may be eliminated as much as possible by adding an emulsifier and salts. In the case where the inclusion compound is formed with the poorly soluble compound or is loosely bonded to the poorly soluble compound, the mass ratio of the hardly soluble compound and the cyclodextran is not particularly limited, but is 0 with respect to 1 part by mass of the hardly soluble compound. 0.000001 part by mass to 100 parts by mass. It goes without saying that the solubility can be improved by the same method even if the compound is not a hardly soluble compound but a normal solubility compound. Moreover, as a cyclodextran used for solubilization, you may mix suitably the thing of said (a)-(c).

  The poorly soluble compound solubilized as described above can simultaneously mask unpleasant tastes such as bitterness, astringency, acidity, and astringent taste derived from the poorly soluble compound.

<Method for masking food and drink>
The composition of the present invention can mask food and drink. Although food / beverage products are not specifically limited, For example, the food / beverage products which mix | blended the component which has unpleasant tastes or smells, such as bitterness, astringency, acidity, an unpleasant taste, and a smell, are mentioned. Note that masking includes not only suppressing unpleasant taste or odor but also improving, for example, taste quality and taste. Examples of the component having an unpleasant taste or odor include water-soluble vitamins such as vitamin B such as pantothenic acid, thiamine, riboflavin and niacin: flavonoids such as anthocyanin, catechin, tannin, xanthohumol, polymethoxyflavone, rutin Flavonoids such as (aglycone and its glycoside), hesperidin (aglycone and its glycoside), naringin (aglycone and its glycoside), isoflavone (aglycone and its glycoside), coumaric acid, cinnamic acid ( And derivatives), caffeic acid, eugenol, anethole, monolignol (aglycone), phenylpropanoids such as sesamin, podophyllotoxin, lignan and lignin, curcuminoids such as curcumin, stilbenoids such as resveratrol, phenolic acids such as chlorogenic acid, ellagic acid Acid, Kumari : Alpha lipoic acid: Propolis: Royal jelly: Chitosan: Rahan fruit extract, thaumatin, licorice extract, glycyrrhizin, phyllozultin, monelin, aspartame, sucralose, saccharine, neotame, acesulfame potassium, tichro and other sweeteners: sphingolipid It is done. Moreover, when the component solubilized by the above-mentioned solubilization method has an unpleasant taste or odor such as bitterness, astringency, acidity, unpleasant taste, and odor, these are also masked.

  The method for masking the above components is not particularly limited.For example, in the method for producing a food or drink, cyclodextran may be simply added, or an ingredient having an unpleasant taste or odor in advance and an inclusion compound may be formed. You may mix | blend after loosely combining with the component which has an unpleasant taste or smell. When adding cyclodextran simply in the manufacturing method of food-drinks, the addition time is not specifically limited, For example, the method of adding simultaneously with adding various additives, etc. are mentioned. On the other hand, the method of forming the clathrate compound may be, for example, adding cyclodextran to a liquid in which a raw material for food and drink containing components having an unpleasant taste or odor is dispersed in a solvent, and stirring and mixing the mixture. . Examples of the solvent include water, organic solvents such as alcohol, a mixed solution thereof, and the like, and the solvent may be heated if necessary. In addition, as a method of loosely binding, powder mixing, liquid liquid or liquid powder high-pressure emulsification, etc., which eliminates water molecules of components having an unpleasant taste or odor as much as possible and makes intermolecular contact occur. During this emulsification, water molecules may be eliminated as much as possible by adding an emulsifier and salts. When a clathrate is formed with an ingredient having an unpleasant taste or odor, or when it is loosely combined with an ingredient having an unpleasant taste or odor, the mass ratio of the ingredient having an unpleasant taste or odor and the cyclodextran is particularly Although not limited, it is 0.000001 mass part-100 mass parts with respect to 1 mass part of components which have an unpleasant taste or smell. Moreover, what is necessary is just to add 0.00000-99.99999999% of cyclodextran in food-drinks, when only adding cyclodextran in the manufacturing method of food-drinks. In addition, as a cyclodextran used for masking, you may mix suitably the thing of said (a)-(c).

<Method for stabilizing food and drink>
The composition of the present invention can stabilize food and drink. Although food / beverage products are not specifically limited, For example, the food / beverage products which mix | blended the component etc. which become unstable by light, heat, etc. which exceed precipitation are mentioned. The component that becomes unstable by light, heat, or the like that exceeds the precipitation is not particularly limited, and examples thereof include the same components that are solubilized and masked. Moreover, the method of stabilizing food / beverage products can be performed similarly to the said masking method.

<Drying method of components unsuitable for drying>
The composition of the present invention can be dried by mixing with a component unsuitable for drying. A component unsuitable for drying is a component that cannot be dried by a normal drying method. Examples thereof include a component that decomposes at a temperature required for drying, a component that has a high viscosity and cannot be dried. Examples of such components include herbal extracts.
Needless to say, components that are not suitable for drying but are suitable for normal drying can be dried by the same method.
Although it does not specifically limit as a drying method, Spray drying, freeze drying, etc. are mentioned. In this drying, cyclodextran may be used as a drying aid. At the time of drying, the mass ratio of the component unsuitable for drying and the cyclodextran is not particularly limited, but is 0.000001 to 100 parts by mass with respect to 1 part by mass of the component having an unpleasant taste or odor. In addition, as a cyclodextran used for drying, you may mix the said (a)-(c) thing suitably.

<Deodorizing method of unpleasant odor>
The solution containing the composition of the present invention can deodorize an unpleasant odor by spraying it on an article that emits an unpleasant odor.
The solution may contain 0.00000 to 99.99999999% of cyclodextran. In addition, as the cyclodextran used for deodorization, you may mix suitably the thing of said (a)-(c).
Although the kind of solution is not specifically limited, Preferably it is water.
The solution preferably contains a preservative.
In addition, the solution may contain optional components such as metal salts, water-soluble cations and anionic polymers, water-soluble bicarbonates, zeolites, activated carbon, and mixtures thereof.
Unpleasant odors are, for example, cigarette odors, cooking and food odors, environmental odors such as body odors, amines, acids, alcohols, aldehydes, phenols, polycyclic compounds, indoles, aromatic compounds , Based on organic molecules having functional groups such as polycyclic aromatic compounds, thiols, mercaptans, sulfides and disulfides.
Articles include curtains, carpets, clothing, shoes, and the like.
Spraying may be performed by a trigger type, a pump type, a non-aerosol type self-pressurizing type, and an aerosol type spraying device.
Moreover, what is necessary is just to determine the spraying amount suitably according to the amount of unpleasant odor.

<Method for sustained release of perfume>
The composition of the present invention can release the fragrance gradually by mixing with the fragrance. An inclusion compound is formed with cyclodextran and a fragrance, and the fragrance is released by contact with sweat, contact with water, changes in temperature, humidity, etc., and other conditions.
The kind of fragrance | flavor is not specifically limited, For example, any of a synthetic fragrance | flavor, a natural fragrance | flavor, and these mixtures may be sufficient. The physical properties of the fragrance are not particularly limited, and may be volatile or non-volatile.
Although the mass ratio of a fragrance | flavor and cyclodextran is not specifically limited, It is 0.000001 mass part-100 mass parts with respect to 1 mass part of fragrance | flavor. In addition, as a cyclodextran used for a composition, you may mix suitably the thing of said (a)-(c).
These sustained-release methods of fragrances can be used for cosmetics, food and drink, hygiene products, and the like.

  Hereinafter, the use of cyclodextran will be described in detail.

High sweetness sweeteners such as Rahan fruit extract, stevia extract, thaumatin, licorice extract, glycyrrhizin, phyllozultin, monelin, aspartame, sucralose, saccharin, neotame, acesulfame potassium, ticlo
Cyclodextran to mask the bitterness of high-intensity sweeteners such as Rahan fruit extract, stevia extract, thaumatin, licorice extract, glycyrrhizin, phyllozultin, monelin, aspartame, sucralose, saccharin, neotame, acesulfame potassium, ticlo A sweetener composition in combination with
In this sweetener composition, the blending amount of the high-intensity sweetener and the cyclodextran is not particularly limited, but is 0.5 to 230 parts by mass with respect to 1 part by mass of the high-intensity sweetener. The sweetener composition preferably contains inositol. The cyclodextran is more preferably 0.2 to 3 parts by mass, and still more preferably 1 to 2 parts by mass with respect to 1 part by mass of inositol. By making the amount of inositol blended in a more preferable range, all the balances of bitterness and astringency masking and solubility of inositol that a high-intensity sweetener has are improved.
The sweetener composition masks the bitterness of high-intensity sweeteners and presents a sweetness without any sense of incongruity, so it can be blended as a sweetener in various foods and drinks.

Preferred embodiments of the sweetener composition include the following.
(Example 1)
Rahan fruit extract 1 part by weight Cyclodextran 0.3-150 parts by weight Inositol 70 parts by weight

Royal jelly:
In order to mask the peculiar smell of royal jelly, to suppress acidity and irritation, it is delicious, and to stabilize the active ingredient, royal jelly and cyclodextran are combined to form a food composition.
In this food composition, the blending amount of royal jelly and cyclodextran is not particularly limited, but is 1 to 500 parts by weight, preferably 5 to 100 parts by weight, more preferably 10 to 70 parts by weight with respect to 100 parts by weight of royal jelly. Part. Moreover, you may make this food composition contain a masking agent, a calcium containing compound, and an antioxidant.
Examples of the masking agent include acidic polysaccharides such as sodium alginate, carrageenan, pectin, gellan gum, and xanthan gum. Of these, sodium alginate or carrageenan is more preferred. The compounding quantity of a masking agent is 0.2-20 weight part with respect to 100 weight part of royal jelly, Preferably it is 0.5-10 weight part, More preferably, it is 1-5 weight part.
Examples of the calcium-containing compound include shell uncalcined calcium, eggshell uncalcined calcium, coral uncalcined calcium, bone uncalcined calcium, calcium lactate, shell calcined calcium, calcium carbonate, dolomite, and the like. Egg shell uncalcined calcium and calcium lactate are preferred. The compounding quantity of a calcium containing compound is 0.2-10 weight part with respect to 100 weight part of royal jelly, Preferably it is 0.5-5 weight part, More preferably, it is 1-2 weight part.
Examples of the antioxidant include γ-oryzanol, vitamin E, vitamin C, coenzyme Q10, lipoic acid and the like. γ-Oryzanol and vitamin E are preferred. The compounding quantity of an antioxidant is 0.1-10 weight part with respect to 100 weight part of royal jelly, Preferably it is 0.2-5 weight part, More preferably, it is 0.5-3 weight part.
The composition for foods is not only eaten as a food, but also as a mixture with other ingredients because the unique smell of royal jelly is suppressed, the sourness and irritation are suppressed and the active ingredients are stabilized. Because of its excellent stability, it is ideal because it does not foul other mixed materials and is not susceptible to other materials.

Preferred embodiments of the food composition include the following.
(Example 1)
Under ice cooling, 5.00 g of γ-oryzanol and 100 g of cyclodextran are added to 300 g of fresh royal jelly. While stirring, 300 g of a 2.5% aqueous solution of sodium alginate is added. Subsequently, 5.00 g of shell calcined calcium was crushed and added. After leaving still for 1 hour, it moves to a stainless steel tray, freezes at -80 degreeC, Then freeze-drys, The obtained 203g solid is grind | pulverized, and a foodstuff composition is obtained.

Chitosan:
In order to improve the problem of chitosan's unpleasant taste, unpleasant odor and / or precipitation, chitosan and cyclodextran are combined to form a chitosan-containing composition.
In this chitosan-containing composition, the blending amount of chitosan and cyclodextran is not particularly limited, but the cyclodextran may be 0.003 to 30 parts with respect to 1 part by weight of chitosan.
The chitosan-containing composition may further contain one or more selected from trehalose, erythritol, lactitol, palatinit and xylitol.
In this chitosan-containing composition, the contents of trehalose, erythritol, lactitol, palatinit and xylitol are not particularly limited, but 0.005 to 50 parts of trehalose, erythritol, lactitol, palatinit and xylitol with respect to 1 part by weight of chitosan. do it.
The chitosan-containing composition further comprises glycine, gluconic acid, sodium gluconate, potassium gluconate, L-glutamic acid, sodium L-glutamate, sodium inosinate, sodium guanylate, adenylic acid, ribonucleotide calcium and ribonucleotide sodium. One or more selected may be contained.
In this chitosan-containing composition, it is selected from glycine, gluconic acid, sodium gluconate, potassium gluconate, L-glutamic acid, sodium L-glutamate, sodium inosinate, sodium guanylate, adenylic acid, ribonucleotide calcium and sodium ribonucleotide The content of 1 or more is not particularly limited, but with respect to 1 part by weight of chitosan, glycine, gluconic acid, sodium gluconate, potassium gluconate, L-glutamic acid, sodium L-glutamate, sodium inosinate, sodium guanylate, One or more selected from adenylic acid, ribonucleotide calcium and ribonucleotide sodium may be 0.002 to 20 parts.
The chitosan-containing composition further contains one or more selected from xanthan gum, gellan gum, karaya gum, tragacanth gum, locust bean gum, gum arabic, pectin, gelatin, carrageenan, sodium alginate, farseleran, tamarind seed polysaccharide and agar. May be.
In the chitosan-containing composition, the content of one or more selected from xanthan gum, gellan gum, karaya gum, tragacanth gum, locust bean gum, gum arabic, pectin, gelatin, carrageenan, sodium alginate, farseleran, tamarind seed polysaccharide and agar is particularly Without limitation, one or more selected from xanthan gum, gellan gum, karaya gum, tragacanth gum, locust bean gum, gum arabic, pectin, gelatin, carrageenan, sodium alginate, farseleran, tamarind seed polysaccharide and agar per 1 part by weight of chitosan May be 0.003 to 30 parts.
The chitosan-containing composition has been improved in the unpleasant taste, odor and aftertaste peculiar to chitosan, and therefore can be blended in beverage granules such as tea, soup and miso soup, and retort food such as curry.

The following can be mentioned as a preferable aspect of the said chitosan containing composition.
(Example 1)
Chitosan powder 1 part by weight Cyclodextran 0.46 parts by weight Trehalose 0.52 parts by weight Glycine 0.13 parts by weight Sodium gluconate 0.13 parts by weight Tricalcium phosphate 0.05 parts by weight

Propolis:
In order to mask the unique odor and irritation of the propolis extract and to have excellent versatility, a propolis composition, coffee, and cyclodextran are combined to form a powdered propolis composition.
In this propolis composition, the blending amount of propolis, coffee, and cyclodextran is not particularly limited, but is 25 to 125 parts by weight of coffee and 50 to 300 parts by weight of cyclodextran with respect to 100 parts by weight of the solid content of propolis extract. do it.
In this propolis composition, sugar, fruit juice, honey, dairy products, salt, acidulant, fragrance, colorant, sweetener, seasoning, bitter, etc. May be blended.
This propolis composition is obtained by mixing a propolis extract and coffee, then mixing cyclodextran with a heated propolis coffee obtained by heating at 120 to 300 ° C. for 5 minutes or longer, and then drying and powdering. .
The mixing of the propolis extract and coffee is not particularly limited as long as a mixing device known in the food field is used. In addition, there is no limitation in particular also about mixing temperature and mixing conditions.
The mixture of the propolis extract and coffee is heated at a heating temperature of 120 to 300 ° C. and a heating time of 5 minutes or longer, preferably at 120 to 140 ° C. for 10 to 120 minutes. When the heating temperature is lower than 120 ° C., the masking effect by heating is insufficient, and when it is higher than 300 ° C., the masking effect is seen, but at the same time, a burning odor is generated and the flavor is impaired. On the other hand, if the heating time is shorter than 5 minutes, the masking effect by heating is not sufficiently exhibited.
The heating means may be any device that can achieve the target temperature, and examples thereof include a high-pressure steam sterilizer and a pressure cooker, but there is no particular limitation.
The mixing of the heated propolis / coffee product obtained above and the cyclodextran is not particularly limited as long as a known mixing device is used in the food field.
Drying of a mixture of heated propolis and coffee and cyclodextran is performed by known powdering methods such as a vacuum concentration method, spray drying method, freeze drying method, etc., including a direct concentration method in which moisture is evaporated by heating at normal pressure. This method is carried out. These drying methods can be properly used depending on the purpose and situation. For example, the freeze-drying method is preferable in obtaining a powder without impairing the active ingredients of propolis, and spray drying is preferred in order to prioritize efficient water removal. And the vacuum drying method is preferred.
The propolis composition is masked for its characteristic odor and irritation, and can be suitably used for candy, jelly, tablets, beverages, and other various foods, and the resulting propolis-containing food exhibits the function of propolis. In addition, the flavor is good without being impaired.

The following can be mentioned as a preferable aspect of the said propolis composition.
(Example 1)
40 g of propolis extract, 3.0 g of instant coffee and 40 g of water are heated and mixed (at 130 ° C. for 20 minutes), and 6.0 g of cyclodextran is added, followed by freeze-drying.

Alpha lipoic acid:
In order to obtain an α-lipoic acid aqueous solution, cyclodextran and a solubilization aid are used as a solubilization accelerator for α-lipoic acid.
The higher the concentration of α-lipoic acid in the α-lipoic acid aqueous solution, the better. However, it is preferably at least higher than 0.1 mg / mL, more preferably 1 mg / mL or more, particularly 5 to 6 mg / mL or more. preferable. In such an α-lipoic acid aqueous solution, the solubility of α-lipoic acid in water can be improved by using cyclodextran and a solubilizing aid.
The production of the α-lipoic acid aqueous solution is not particularly limited, but a high-concentration α-lipoic acid can be obtained by adding a solubilization accelerator and / or a solubilizing aid for α-lipoic acid to suspension water in which α-lipoic acid is dispersed. The method of manufacturing aqueous solution is mentioned. Further, there may be mentioned a method of adding water to a mixture of powdered α-lipoic acid and powdered α-lipoic acid solubilization accelerator and / or solubilizing aid, or a method of adding this mixture to water. Furthermore, if necessary, a method of stirring these for several minutes to several hours or days, a method of shaking, and the like can also be mentioned.
As the solubilizing aid, it is preferable to use at least one or more of natural additives, water-soluble polymers and metal ions, or an agent containing at least one or more of these as active ingredients. Examples of natural additives include acetic acid, lactic acid, citric acid, sodium acetate, sodium lactate, sodium citrate, amino acids, ammonia, or fatty acid glycerol. It is preferable to use at least one of these.
Examples of the water-soluble polymer include carboxymethylcellulose (CMC), polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), polyallylamine (PPA), polyvinyl alcohol (PVA), etc. Metal ions include NaCl, MgCl ₂ , ZnCl _{2 and the} like, and it is preferable to use at least one or more.
Any of these can be used. For example, when 1 w / w% Na citrate is used together with cyclodextran as a solubilization aid, Na citrate is used when used together with cyclodextran. This is preferable because it exhibits a solubility of 10 times or more as compared with the case of using only.
The α lipoic acid aqueous solution preferably further contains CoQ10.
Since the α-lipoic acid aqueous solution is solubilized and blended with α-lipoic acid at a high concentration and masked, it can be used for various foods and beverages, pharmaceuticals and the like.
The α-lipoic acid aqueous solution may be made into a confectionery such as candy, gummi, gum, etc. by adding a fragrance, a colorant, an antioxidant and other components. Further, the α-lipoic acid aqueous solution may be supplemented by adding additives usually used in preparations such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, and inorganic salts.
The alpha lipoic acid aqueous solution may contain a fragrance, a colorant, an antioxidant, and other components. For example, xanthine derivatives such as caffeine, ginseng, musk, beef yellow, eggplant, ground yellow, herbal medicine such as royal jelly, minerals such as calcium, magnesium, zinc, iron, copper, methionine, leucine, isoleucine, valine, lysine, phenylalanine, Amino acids such as threonine, tryptophan, and taurine, and oil-soluble vitamins such as vitamin A, vitamin D, vitamin E, and vitamin K may be added to provide foods and drinks such as supplements, functional foods, and nutritional drinks.

Preferred embodiments of the α lipoic acid aqueous solution include the following.
(Example 1)
Cyclodextran is added and mixed to 1 w / w% α-lipoic acid suspension water obtained by adding α-lipoic acid to water so that the concentration becomes 1 w / w%. If necessary, add and mix sodium citrate at 1% w / w.

Alpha lipoic acid complex:
Alpha lipoic acid R form or alpha lipoic acid S form, dihydro alpha lipoic acid R form or dihydro alpha lipoic acid S form, or an alkali metal salt or alkaline earth metal salt thereof is complexed (inclusion) with a high probability. For this purpose, α-lipoic acid R-form or α-lipoic acid-S-form, dihydro-α-lipoic acid R-form or dihydro-α-lipoic acid S-form, or an alkali metal salt or alkaline earth metal salt thereof is complexed with cyclodextran.
Examples of the method for producing the α lipoic acid complex include the following production methods.
1) Step of obtaining an aqueous solution by dissolving an alkali metal salt or alkaline earth metal salt of α-lipoic acid R-form or an alkali metal salt or alkaline-earth metal salt of α-lipoic acid S-form in water 2) of 1) above After the aqueous solution is cooled and adjusted to a certain temperature, cyclodextran is added, and a suspension of cyclodextran complex of alkali metal salt or alkaline earth metal salt of α lipoic acid R form, or α lipoic acid Step 3 of obtaining a suspension of cyclodextran complex of alkali metal salt or alkaline earth metal salt of S-form 3) The solution or suspension of 2) above is adjusted to pH 4.0 or less, stirred, suspended Step 4) to obtain a turbid solution After stirring the suspension of 3) above, or to dry the residue obtained by filter filtration 5) Suspension of 2) instead of 3) and 4) above Leave the liquid as it is Step of drying residue obtained by filtration or filtration 1) The step of 1) is an alkali metal salt or alkaline earth metal salt of α-lipoic acid R-form, or an alkali metal salt or alkaline earth of α-lipoic acid S-form. This is a step of dissolving a metal salt in water. Stirring is preferably performed until the water in which the alkali metal salt or alkaline earth metal salt of α-lipoic acid R-form or the alkali metal salt or alkaline-earth metal salt of α-lipoic acid S-form is dissolved becomes transparent.
The aqueous solution thus obtained preferably exhibits neutral to weak alkalinity even if the pH is not particularly adjusted with an alkaline substance or the like, and is particularly preferably an aqueous solution having a pH of 14.0 or less.
Step 2) is a step in which cyclodextran is added to the aqueous solution obtained in step 1) to obtain a solution or suspension. The cyclodextran is preferably added after the aqueous solution obtained in the step 1) is cooled and adjusted to a constant temperature, and the subsequent steps are preferably performed at the adjusted temperature. The temperature should just be 40 degrees C or less under atmospheric pressure. Preferably it is 25 degrees C or less, More preferably, it is less than 10 degreeC, More preferably, it is 0 to 9 degreeC, and it is especially preferable that it is 0 to 6 degreeC. In this step, it is preferable to add cyclodextran while stirring the aqueous solution. It is sufficient that stirring is performed for 1 hour or less after addition, preferably 30 minutes or less, particularly preferably about 5 to 10 minutes. Here, the cyclodextran to be added to the aqueous solution is an alkali metal salt or alkaline earth metal salt of α-lipoic acid R form (1.0 mol), or an alkali metal salt or alkaline earth metal salt of alpha lipoic acid S form ( 1.0 mol) to 0.5 mol to 1.4 mol, preferably 0.5 mol to 1.1 mol, and more preferably 0.6 mol to 0.7 mol. It is particularly preferable to add to the above. As the cyclodextran is added, in the solution or suspension, the α-lipoic acid R-form alkali metal salt or alkaline earth metal salt, or the α-lipoic acid S-form alkali metal salt or alkaline earth metal salt cyclo A dextran complex is formed.
Alkaline metal salt or alkaline earth metal salt of α-lipoic acid R, or alkali metal salt or alkaline earth metal salt of α-lipoic acid S-form, and cyclodextran are combined in this solution or suspension. It is preferable to add 5 to 50 wt%, preferably 5 to 35 wt%, particularly preferably 10 to 25 wt%. This is because handling is difficult at 50 wt% or more.
In the step 3), the alkali solution or alkaline earth metal salt of α-lipoic acid R-form, or the alkali metal salt or alkali of α-lipoic acid S-form is added to the solution or suspension obtained in the step 2). This is a step of gradually adding an equimolar or equimolar amount of acid to the earth metal salt to adjust the pH to 4.0 or less. Thus, the alkali metal salt or alkaline earth metal salt of α-lipoic acid R form, or the alkali metal salt or alkaline earth metal salt of α-lipoic acid S form is neutralized, and α-lipoic acid R-form or α-lipoic acid S It is possible to convert to α-lipoic acid complex in which α-lipoic acid R-form or α-lipoic acid S-form is complexed through this step. The acid is preferably added while stirring the solution or suspension, and any acid that can be used for pH adjustment may be used. For example, inorganic acids or organic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and acetic acid can be used. The acid is preferably added until the pH of the solution or suspension becomes 4.0 or less, and particularly preferably added uniformly until the pH becomes 3.5 or 3.5 or less. For example, when producing an α-lipoic acid complex in which α-lipoic acid R-form sodium salt is complexed, it is extremely preferable to adjust the pH to about 3.0 to 3.5. After the acid has been added, the resulting suspension may be stirred, and this stirring may be no more than 1 hour, and preferably no more than 18 hours.
Steps 4) and 5) are steps in which the α-lipoic acid complex contained in the suspension is dried as it is, or filtered to remove the residue containing the α-lipoic acid complex and dried. It is. The drying may be performed by any conventionally known method regardless of the presence or absence of an alkali salt. For example, a vacuum drying method, a freeze drying method, a spray drying method, an oven drying method, a belt drying method, a pulse drying method, or the like. Law.

Moreover, the following manufacturing method is mentioned as another manufacturing method of alpha lipoic acid complex.
1) Step of dissolving α-lipoic acid R-form or α-lipoic acid S-form in water while dropping alkali metal salt or alkaline earth metal salt 2) After cooling the aqueous solution of 1) above to a constant temperature A solution or suspension of a cyclodextran complex of an alkali metal salt or alkaline earth metal salt of α-lipoic acid R, or an alkali metal salt or alkaline earth of α-lipoic acid S-form. Step 3 for obtaining a solution or suspension of a cyclodextran complex of a metal salt 3) Adjusting the solution or suspension of 2) above to pH 4 or lower and stirring to obtain a suspension 4) Step 3) Drying the residue obtained by filtering the suspension of 3) as it is or by filtering the solution 5) Obtaining the suspension of 2) as it is or by filtering it instead of the above steps 3) and 4) Remaining Things step in step 1) of drying the is a step of an alkali metal salt or dropwise alkaline earth metal salts α-lipoic acid R-form or α-lipoic acid S-form is dissolved in water. Stirring is preferably performed until water in which α-lipoic acid R-form or α-lipoic acid S-form is dissolved becomes transparent. The pH of the solution obtained by this step is preferably 9-14.
In the step 2), cyclodextran is added to the aqueous solution obtained in the step 1), and a solution or suspension of cyclodextran complex of alkali metal salt or alkaline earth metal salt of α-lipoic acid R form is added. This is a step of obtaining a suspension or a solution or suspension of a cyclodextran complex of an alkali metal salt or alkaline earth metal salt of α-lipoic acid S form.
The cyclodextran is preferably added after the aqueous solution obtained in the step 1) is cooled and adjusted to a constant temperature, and the subsequent steps are preferably performed at the adjusted temperature. The temperature should just be 40 degrees C or less under atmospheric pressure. Preferably it is 25 degrees C or less, More preferably, it is less than 10 degreeC, More preferably, it is 0 to 9 degreeC, and it is especially preferable that it is 0 to 6 degreeC. In this step, it is preferable to add cyclodextran while stirring the aqueous solution. It is sufficient that stirring is performed for 1 hour or less, preferably 30 minutes or less, particularly preferably about 5 to 10 minutes. The aqueous solution or suspension thus obtained preferably exhibits neutral to weak alkalinity even if the pH is not particularly adjusted with an alkaline substance or the like, and particularly preferably an aqueous solution having a pH of 9 to 14.
Here, the cyclodextran to be added to the aqueous solution is preferably added in an amount of 0.5 mol to 1.4 mol with respect to α-lipoic acid R-form or α-lipoic acid S-form (1.0 mol). It is particularly preferable to add such that the amount is from 5 mol to 1.1 mol, and further from 0.6 mol to 0.7 mol. As cyclodextran is added, a cyclodextran complex of α-lipoic acid R-form or α-lipoic acid S-form is formed in the lysate or suspension. α-lipoic acid R-form or α-lipoic acid S-form and cyclodextran are combined in the solution or suspension in an amount of 5 to 50 wt%, preferably 5 to 35 wt%, more preferably 10 to 25 wt%, 20 to 20 wt%. It is particularly preferable to add so as to contain 25 wt%. This is because handling is difficult at 50 wt% or more.
The step 3) is a solution or suspension of a cyclodextran complex of an alkali metal salt or alkaline earth metal salt of α-lipoic acid R obtained by the step 2) or α-lipoic acid S-form. Alkaline metal salt or alkaline earth metal salt of α-lipoic acid R-form or alkali metal salt of α-lipoic acid S-form in a solution or suspension of cyclodextran complex of alkali metal salt or alkaline earth metal salt Alternatively, it is a step of gradually adding an equimolar or equimolar amount of acid to the alkaline earth metal salt to adjust the pH to 4.0 or less. Thus, the alkali metal salt or alkaline earth metal salt of α-lipoic acid R form, or the alkali metal salt or alkaline earth metal salt of α-lipoic acid S form is neutralized, and α-lipoic acid R-form or α-lipoic acid S is neutralized. It is possible to convert to α-lipoic acid complex in which α-lipoic acid R-form or α-lipoic acid S-form is complexed through this step. The acid is preferably added while stirring the solution or suspension, and any acid that can be used for pH adjustment may be used. For example, inorganic acids or organic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and acetic acid can be used.
The acid is preferably added until the pH of the solution or suspension becomes 4.0 or less, and particularly preferably added uniformly until the pH becomes 3.5 or 3.5 or less. For example, when producing an α-lipoic acid complex in which α-lipoic acid R-form sodium salt is complexed, it is extremely preferable to adjust the pH to 3.0 to 3.5. After the acid has been added, the resulting suspension may be stirred, and this stirring may be no more than 1 hour, and preferably no more than 18 hours.
Steps 4) and 5) are steps in which the α-lipoic acid complex contained in the suspension is dried as it is, or filtered to remove the residue containing the α-lipoic acid complex and dried. It is. The drying may be performed by any conventionally known method regardless of the presence or absence of an alkali salt. For example, a vacuum drying method, a freeze drying method, a spray drying method, an oven drying method, a belt drying method, a pulse drying method, or the like. Law.

  The α-lipoic acid complex can be widely used in medicines, health foods and the like as a component that is stable to heat and artificial gastric acid solution and exhibits a sufficient effect.

Preferred embodiments of the production of the α lipoic acid complex include the following.
<Method for producing α-lipoic acid complex (A)>
The α-lipoic acid complex is produced by the following steps 1) to 4).
1) While stirring water, α-lipoic acid R-form sodium salt or α-lipoic acid S-form sodium salt is added to dissolve α-lipoic acid R-form sodium salt or α-lipoic acid S-form sodium salt.
2) The solution of 1) above is cooled and adjusted to a certain temperature, then cyclodextran is added and stirred, and a solution or suspension of cyclodextran complex of α-lipoic acid R-form sodium salt, Alternatively, a solution or suspension of a cyclodextran complex of α-lipoic acid S-sodium salt is obtained. The pH of this solution or suspension is approximately 7-8.
3) Hydrochloric acid (1N) is added dropwise to the solution or suspension of 2) above, adjusted to pH 4.0 or lower, and stirred to obtain a suspension.
4) The suspension of 3) above was filtered (manufactured by ADVANTEC, Polymer: MEMBRANE FILTER MIXED CELLULOSE ESTER, d = 0.45 μm), and the residue was washed with water and dried to obtain α-lipoic acid R Body or α lipoic acid complex containing α lipoic acid S form is produced.
<Method for producing α-lipoic acid complex (B)>
Similarly to the production method (A) of the α-lipoic acid complex, after performing the steps 1) to 3), the step 4) is performed as follows. 4) The suspension of 3) above is dried as it is to produce an α-lipoic acid complex.
<Method for producing α-lipoic acid complex (C)>
In the same manner as in the method for producing α-lipoic acid complex (A), after performing steps 1) to 2), in step 3), the suspension was stirred without dropping hydrochloric acid (1N), The process of 4) was performed.
<Method for producing α-lipoic acid complex (D)>
The α-lipoic acid complex is produced by the following steps 1) to 4).
1) Add α-lipoic acid R-form or α-lipoic acid-S form while stirring water, and dissolve α-lipoic acid R-form or α-lipoic acid S-form while dropping potassium hydroxide.
2) The solution of 1) above is cooled and adjusted to a certain temperature, then cyclodextran is added and stirred, and a solution or suspension of cyclodextran complex of α-lipoic acid R-form potassium salt, Alternatively, a solution or suspension of a cyclodextran complex of α-lipoic acid S-form potassium salt is obtained. The pH of this solution or suspension is approximately 7-9.
3) Hydrochloric acid is added dropwise to the solution or suspension of 2) above, adjusted to pH 4.0 or lower, and stirred to obtain a suspension.
4) The suspension of the above 3) is filtered through a filter (manufactured by ADVANTEC, Polymer: MEMBRANE FILTER MIXED CELLULOSE ESTER, d = 0.45 μm), and the residue is washed with water and dried. An acid complex is produced.
<Method for producing α-lipoic acid complex (E)>
Similarly to the production method (D) of the α-lipoic acid complex, after the steps 1) to 2) are performed, the suspension is stirred without dropping hydrochloric acid in the step 3). Perform the process.
<Method for producing α-lipoic acid complex (F)>
The α-lipoic acid complex is produced by the following steps 1) to 3).
1) Add cyclodextran with water and dissolve it.
2) The solution or suspension of 1) above is cooled and adjusted to a certain temperature, and then dihydro-α-lipoic acid R-form or dihydro-α-lipoic acid-S form is added and stirred, A suspension of a cyclodextran complex or a suspension of a cyclodextran complex of dihydroalpha lipoic acid S form is obtained.
3) The α-lipoic acid complex including the target dihydro-α lipoic acid R-form or dihydro-α-lipoic acid S-form is produced by drying the suspension of 2) above.
<Method for producing α-lipoic acid complex (G)>
The α-lipoic acid complex is produced by the following steps 1) to 3).
1) Add cyclodextran with water and dissolve it.
2) After cooling and adjusting the solution or suspension of 1) above to a certain temperature, dihydro α-lipoic acid R-form or dihydro-α lipoic acid S-form is added and stirred while potassium hydroxide is added dropwise. Dihydro alpha lipoic acid R form or dihydro alpha lipoic acid S form is dissolved. The pH of this solution or suspension is approximately 9-10.
3) Hydrochloric acid (1N) was added dropwise to the solution or suspension of 2) above, the pH was adjusted, and the suspension was obtained by stirring. The pH of this solution or suspension is approximately 3-4.
4) The suspension of the above 3) is dried to produce an α-lipoic acid complex containing the target dihydro-α-lipoic acid R form.

Fat-soluble substances:
Provision of an aqueous solution containing a high concentration of fat-soluble substances such as polyphenols, flavonoids, tocopherols, retinols, menaquinones, carotenoids, cinnamic acid derivatives or propolis, diterpenes, terpenes, coenzyme Q10 or alpha lipoic acid and In order to increase the absorption of fat-soluble substances into the skin, a combination of fat-soluble substances and cyclodextran, a combination of fat-soluble substances with cyclodextran, or a combination with a super-dissolving aid. And an aqueous solution containing a fat-soluble substance.
Examples of polyphenols include curcumin, rose polyphenol, ferulic acid, quercetin, cacao mass, etc., and flavonoids include isoflavones, isoflavone aglycones, flavanones, anthocyanidins, catechins, chalcones, nobiletins, etc. Examples include tocotrienol, γ-tocotrienol, tocopherol, α-tocopherol, tocopherol acetate, tocopheryl linoleic acid, tocopheryl nicotinate, and the like. Retinols include retinol, retinyl acetate, retinyl palmitate, and menaquinone. Examples include phylloquinone, menaquinone, menadione and the like, and carotenoids include astaxanthin, lutein, fucoxanthin, lycopene. Cinnamic acid derivatives include CAPE, artepilin C, coumaric acid, propolis containing cinnamic acid derivatives as active ingredients, and diterpenes include phytol, abietic acid, levobimalic acid, gibberellin and the like. Examples of the triterpenes include squalene, lanosterol, cucurbitacin, limonin, and loquat leaf culture extract. One or more of these fat-soluble substances can be used.
In the aqueous solution containing the fat-soluble substance, the blending amount of the fat-soluble substance is not particularly limited, but is 9 μg / mL or more, 12 μg / mL or more, 15 μg / mL or more, 50 μg / mL or more, 100 μg / mL or more, 150 μg / mL or more. is there.
Super solubilizers include bile acids such as taurocholic acid, glycocholic acid, cholic acid, deoxycholic acid, lithocholic acid or their alkali salts, hesperidin, polyphenol glycosides, glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid Emulsifiers such as esters and sucrose fatty acid esters, enzymatically decomposed lecithin, lecithin derived from soybean, lecithin such as lecithin derived from egg yolk, glycyrrhizic acid or alkali salts thereof, saponins such as soybean saponin or quillaja saponin, casein or alkaline salts thereof , Polysorbates (fatty acid polyoxyethylene sorbitans), celluloses such as methylcellulose, carboxymethylcellulose, hydroxyethylcellulose or their alkali salts, pectin, carrageenan Others can be mentioned polysaccharide thickener such as selected from any of the xanthan gum. One or more kinds of these super-dissolution aids can be used.
An aqueous solution containing a fat-soluble substance can be produced by performing a treatment by mixing, a treatment by heating, a physical treatment such as stirring as necessary. As the mixing and stirring device, a conventional device such as a shaking stirring device, an ultrasonic device, a magnetic stirrer, a mechanical stirrer, a vortex mixer, an ultra turrax (registered trademark), or a high-pressure homogenizer can be used.
In the production, the temperature is not particularly limited. For example, it is preferably performed in a temperature range of 10-80 ° C, particularly preferably in a temperature range of 15-40 ° C, and further room temperature (about 25 ° C). Is preferably carried out.
The stirring time is not particularly limited, but it is preferably performed within 5 seconds to 24 hours. The stirring time is particularly preferably 1 to 8 hours, and more preferably 1 to 6 hours.

  Since the aqueous solution containing a fat-soluble substance has enhanced solubility of the fat-soluble substance in water, it can also be an aqueous solution that can contain the fat-soluble substance in a high concentration. It can also be an aqueous solution characterized by enhanced absorption of fat-soluble substances into the skin. Therefore, it can be used for cosmetics, foods, and pharmaceuticals using this as a raw material.

The following can be mentioned as a preferable aspect of the aqueous solution containing the said fat-soluble substance.
(Example 1)
In 49.6 mg of curcumin (water 4 mg, curcumin 5.6 mg, cyclodextran 40 mg), 50 mM 2-morpholinoethanesulfonic acid (MES) buffer (containing 300 mM NaCl, 140 mM KSCN, 5 mM CaCl ₂ ) or the same buffer 1450 μL each of superdissolving aid (0.83% NaTC or 1.66% NaTC) dissolved therein is added, sonicated with an ultrasonic device for several seconds, and allowed to stand at 40 ° C. for 2 hours. Then, it filters with a 0.2 micrometer filter and obtains the aqueous solution containing a fat-soluble substance.

Black ginger:
In order to specifically solubilize a higher concentration of black ginger-containing components in water, it is a water-soluble composition containing black ginger (Kaempferia parviflora) and cyclodextran, and the amount of 5,7-dimethoxyflavone is 0. The water-soluble composition is 3 wt% or more, and the mass ratio of unbranched cyclodextran and branched cyclodextran contained in cyclodextran is 1: 0.01 to 6.
The use part of black ginger is not particularly limited, and examples thereof include roots, leaves, stems, flowers, branches, etc., but preferably a large amount of polymethoxyflavonoid (PMF) such as 5,7-dimethoxyflavone (57DMF). Contains rhizomes.
The black ginger can be, for example, a processed product (dried product, cut product, etc.) or its powder, juice, extract, etc., in addition to the unprocessed raw material. Here, the extract is not particularly limited as long as the components in black ginger are extracted. For example, an extract obtained by extracting black ginger and its processed product with a solvent, a diluted solution and a concentrated solution thereof. Or a dry product thereof or a powder thereof. The black ginger used in the present invention is preferably an extract such as black ginger extract or squeezed juice or a dried product of the extract in consideration of applicability of foods and drinks, medicines and the like.
The black ginger powder is obtained by, for example, drying a black ginger sliced after washing with sun or a dryer, and using a pulverizer to obtain a processed product obtained by cutting it into an appropriate shape or size. It can be obtained by grinding. As the pulverizer, those usually used can be widely used. For example, a pulverizer constituted by a raw material hopper, a pulverizer, a classifier, a product holder and the like can be used.
The black ginger extract is obtained by extracting black ginger and its processed product with a solvent. Examples of the solvent used for extraction include lower alcohols such as ethanol, methanol, isopropanol, and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; mixed solvents of these with water. Water is also exemplified as the extraction solvent, and may be hot water or warm water. Since the water-soluble composition of the present invention may be taken orally by humans, the raw ginger extract is water alone, ethanol alone or a mixed solvent of water and ethanol ( It is preferably one extracted with so-called hydrous ethanol. In particular, it is preferable to use hydrous ethanol having a concentration of 40 to 70 vol% as a solvent.
When a mixed solvent is used as the solvent, for example, an acetone / water (2/8 to 8/2, volume ratio) mixture, an ethanol / water (2/8 to 8/2, volume ratio) mixture, or the like may be used. it can. In the case of ethanol / water, it is preferable to add a solvent having a mass of 2 to 20 times the mass of black ginger rhizome and extract it at room temperature or under heating for about 10 minutes to 48 hours.
Although the extraction method is not particularly limited, for example, it is preferable to perform the extraction operation under as mild a condition as possible from the viewpoint of safety, convenience, and industrialization. For example, a portion of black ginger and its dried product are crushed, crushed, shredded, etc., and a 2 to 20-fold mass solvent is added thereto, and the temperature ranges from 0 ° C to the reflux temperature of the solvent for 10 minutes to 48 hours. Extraction is performed under any conditions such as standing, shaking, stirring, refluxing and the like. After extraction, solid-liquid separation operations such as filtration and centrifugation are performed to remove insoluble solids. By performing operations such as dilution and concentration as necessary, an extract is obtained. Further, the same operation may be repeated for insoluble matter, and the extract may be used in combination with the previous extract. These extracts may be further purified by a purification method usually used by those skilled in the art.
The obtained extract can be used as it is or after being concentrated, for example, in the form of a liquid, a concentrate, and a dried product obtained by drying these. Drying is not particularly limited, and for example, it is performed by a method commonly used by those skilled in the art such as spray drying, freeze drying, reduced pressure drying, fluidized drying and the like. Furthermore, the dried product obtained by the above method can be used by pulverizing it using a method known to those skilled in the art.
The content of the black ginger extract used in the water-soluble composition is not particularly limited. For example, the ratio of the 57DMF content to the total amount of the composition is 0.3 wt% or more, preferably 0.5 wt% or more, more preferably 0. It is preferable that the amount be 0.7 wt% or more, 30 wt% or less, preferably 20 wt% or less, more preferably 10 wt% or less.
The method for producing the water-soluble composition of the present invention is not particularly limited. For example, black ginger, preferably black ginger extract, and two types of cyclodextran, preferably unbranched cyclodextran, at room temperature or under heating. And a mixture of branched cyclodextran can be dissolved in water to obtain a water-soluble composition. In addition to these, one of black ginger extract or cyclodextran is dissolved or dispersed in water, and then the other is added and mixed to obtain a water-soluble composition. In addition, the obtained water-soluble composition is good also as a powder by performing a drying process. Examples of the drying method include, but are not limited to, spray drying and freeze drying.
In the water-soluble composition, the blending amount of black ginger extract and cicyclodextran is not particularly limited. For example, the mass ratio thereof (black ginger extract: cyclodextran) is 1: 1 to 100, preferably Is 1: 5-50, more preferably 1: 3-20.
In addition to black ginger and cyclodextran, various water-soluble compositions can be blended as long as the object of the present invention can be achieved. For example, another substance having a pharmacological action such as black ginger and a substance capable of enhancing the solubility of black ginger as well as cyclodextran may be blended. Examples of black ginger solubilizers include organic solvents such as ethanol. Accordingly, the water-soluble composition may be an ethanol-containing water-soluble composition containing several vol% to several tens vol% ethanol.
The water-soluble composition can be used as it is, or as a mixture with other components, as a parenteral composition or oral composition, depending on the application. A water-soluble composition is one that dissolves or disperses in water so that the solution becomes clear or clear when dissolved in water.
The water-soluble composition can be used as a parenteral composition, for example, in a form suitable for cosmetics. For example, it can be processed into various forms such as lotions, emulsions, gels, creams, ointments and the like. Specifically, it can be used as a lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, facial cleanser, foundation, hair restorer, aqueous ointment, spray and the like.
The water-soluble composition can be used as an oral composition, for example, in a form suitable for food and drink. For example, the water-soluble composition can be used as it is or as a normal food and drink such as dextrin, starch, saccharide, calcium phosphate, and other excipients, extenders, binders, thickeners, emulsifiers, colorants, fragrances, and fragrance oils. It can be made into the composition for food-drinks by mixing with the additive used for a process. For example, royal jelly, vitamins, proteins, calcium, chitosan, lecithin and the like may be included to impart a function as nutritional supplement. Moreover, you may contain a sugar liquid, a seasoning, etc. for the purpose of adjusting the taste of a water-soluble composition. The usage-amount of an additive is adjusted suitably.
The water-soluble composition is obtained by contacting black ginger, preferably black ginger extract, unbranched cyclodextran and at least two cyclodextrans, such as branched cyclodextran, in an aqueous solvent, It is obtained as a component of black ginger dissolved in an aqueous solvent. Another aspect is to contact black ginger, such as black ginger extract, unbranched cyclodextran and at least two types of cyclodextran, such as branched cyclodextran, in an aqueous solvent. A method for solubilizing a black ginger component, comprising the step of solubilizing the component. By this method, a water-soluble composition can be produced.
A water-soluble composition can be made into forms, such as cosmetics, food-drinks, and a pharmaceutical, for example.

The following can be mentioned as a preferable aspect of the said water-soluble composition.
(Example 1)
After cleaning the rhizome of black ginger, slice it into about 1 to 10 mm and let it dry in the sun for one day. Then, it dries for 4 to 6 hours with an oven drier set to 40 to 100 ° C., and after coarse pulverization, sterilization is performed at 130 to 200 ° C. for 5 to 20 seconds. The sterilized coarsely pulverized product is pulverized by a pulverizer to obtain a black ginger rhizome pulverized product. By the same method, black ginger stem pulverized product, leaf pulverized product and flower pulverized product are obtained. These shall be crushed black ginger.
300 g of black ginger pulverized product obtained by the above method is weighed and put into an Erlenmeyer flask together with 3 L of 50 vol% ethanol. The first extraction is performed by allowing to stand at room temperature for 24 hours while stirring several times along the way. This is filtered under reduced pressure to obtain a first extract. The residue after filtration under reduced pressure is immersed in 3 L of 50 vol% ethanol, and left at room temperature for 24 hours to perform the second extraction. This is filtered under reduced pressure to obtain a second extract. The extract mixture obtained by combining the first and second extracts is concentrated to about 1/6 under reduced pressure to obtain a black ginger extract. The obtained black ginger extract has a 57DMF content of 1.9 wt%.
A mixture of the black ginger extract 8 wt% obtained above and cyclodextran (77.8 wt% containing unbranched cyclodextran and branched cyclodextran) is added to 4 L of water up to 90 ° C. By heating and stirring and filtering the insoluble part, a black ginger aqueous solution is obtained as a purple clear homogeneous solution. The obtained black ginger aqueous solution is pulverized by spray drying to obtain a black ginger water-soluble composition.

Terpenes:
As a method for improving body odor, the release of terpenes from the body surface after oral ingestion is significantly promoted, so terpenes included with cyclodextran are included, and cyclodextran is included in the total weight of the composition for oral ingestion. It is set as the composition for oral consumption containing 0.004-95.0 weight%.
Examples of the terpenes include geraniol, linalool, citronellol, terpinen-4-ol, limonene, 1,8-cineole, α-terpineol, menthol and the like, and geraniol, linalool, citronellol and terpinene-4-ol are preferable.
The method of including terpenes with cyclodextran is to mix a terpene and cyclodextran first, and then mix with other ingredients when producing an oral intake composition. However, in the case of an aqueous composition such as a jelly or a beverage, the reaction proceeds and is included by taking time after mixing, such as leaving it after production, even without pre-mixing. Moreover, it can confirm that it is included by masking the fragrance and bitterness of terpenes in the composition for oral intake by sensory evaluation.
The content of terpenes in the composition for oral intake is preferably 0.0007 to 6% by weight based on the total weight of the composition for oral intake, from the viewpoint of in vitro release effect. More preferably, the content is 0.0007 to 1% by weight in view of the extracorporeal release effect and flavor. In addition, the intake of terpenes varies depending on age, body weight, intensity of body odor, etc., but generally, it is preferably 0.3 to 90 mg per time, in order to increase the in vitro release effect and safety. This is preferable in terms of points.
The ratio of terpenes and cyclodextrans contained in the composition for oral consumption is preferably 1: 2 to 600, more preferably 1:12 to 80. Is preferable in terms of the flavor (masking of the bitter taste of terpenes) from which the good scent possessed by is released from the body. In addition, the said ratio calculates cyclodextran as solid content with respect to the state of the component of 100% of terpenes.
The composition for ingestion is not particularly limited as long as it can be ingested. For example, beverages (soups, coffee, teas, juices, cocoa, alcoholic beverages, sports drinks, etc.), powdered foods (sugars, cereals) Powder, starch, powdered beverages, powdered seasonings, powdered oils and fats), confectionery (hard candy, soft candy, gummy, jelly, chewing gum, tablet confectionery, chocolate, etc.), frozen confectionery, bakery food (bread, cookies, etc.), noodles And other starch-based foods, functional foods (capsules, health foods, nutritional supplements, nutritional functional foods, nutritional health foods, etc.), pharmaceuticals (tablets, chewable tablets, capsules, pharmaceutical beverages) and the like. Among these, beverages, powdered beverages, soft candy, jelly, chewing gum, tablet confectionery, frozen confectionery, and capsules are preferable because they are easy to eat and can be taken in the body quickly. More preferably, beverages, powdered beverages, jelly, and frozen desserts are ingested more quickly and have good release outside the body because the inclusions of terpenes and cyclodextran are dispersed and dissolved in the solution at the time of eating. It is suitable at the point which becomes. Moreover, in the case of foods with low sound quality such as frozen desserts, jellies, refrigerated beverages and the like, there is no perspiration after meals. However, if an oral intake composition is used, an in vitro release effect can be obtained.

  The composition for oral ingestion obtained as described above releases terpenes ingested in the body about 30 minutes to 5 hours after eating. The composition for ingestion contains a specific amount of cyclodextran, and contains terpenes clathrated with cyclodextran, so that it does not contain cyclodextran, compared to a composition containing only terpenes, Since the extracorporeal release is dramatically promoted, it is possible to cause the fragrance of the released terpenes to drift throughout the body, which is effective in improving body odor.

Preferred embodiments of the composition for oral intake include the following.
(Example 1)
Geraniol 0.042% by mass, cyclodextran 2.6% by mass, erythritol 7.2% by mass, gelling agent 1% by mass, collagen 2.2% by mass, polydextrose 1.2% by mass, acidulant 0.3% Add mass% and fragrance 0.6 mass% to water and dissolve with heating and stirring. Next, the solution is sterilized by heating and hot-packed into an aluminum stick container. The stick jelly is obtained by cooling after that.

Xanthohumol:
In order to improve the water solubility of xanthohumol, hop crushed and / or hop extract and cyclodextran are mixed in water of pH 1.0 to 8.5 and / or a hydrophilic solvent, and hops are mixed. Xanthohumol contained in the crushed material and / or hop extract is solubilized as an inclusion complex with cyclodextran. In addition, after the obtained xanthohumol / cyclodextran inclusion complex is treated with an adsorption resin and adsorbed, xanthohumol is eluted to obtain a highly pure xanthohumol-containing composition.
Hops (Humulus lupulus) is a perennial plant belonging to the family Mulberry, and its buds (female flowers), berries (mature unripe female flowers), leaves, stems, pods, etc. contain xanthohumol, It is known as a natural product raw material of xanthohumol. Here, hop crushed material and / or hop extract is used as a raw material of xanthohumol.
The hop crushed material is a crushed material obtained by drying and crushing hop-derived materials such as hop buds (female flowers), berries (mature of unfertilized female flowers), leaves, stems, buds, etc. There is no particular limitation on the form as long as it is prepared so that tofumol can be extracted.
In addition, as a hop extract, the components in the hop are extracted with a solvent such as water, saline, alcohol, ether, acetone, ethyl acetate, hexane, carbon dioxide, and the extract is filtered and concentrated as necessary. The extract is obtained by subjecting it to processing such as drying, and may be any extract prepared so that xanthohumol can be extracted, and the form is not particularly limited. In addition, this hop extract may be used after being extracted and dried, and depending on the extraction method, the extract may be used as it is or as a concentrated liquid.
The hop pulverized product and / or the hop extract may be used as they are prepared as described above, but appropriately washed with an appropriate amount of pure water, particularly warm water at the time of use, and the liquid part is separated by filtration. It is preferable to use after removing the water-soluble component in advance. Through this washing step, contaminants (water-soluble components) other than xanthohumol in the hop pulverized product and / or hop extract can be removed, so that xanthohumol / cyclodextran inclusion complex is more efficient. You can get a body. In this cleaning step, it is preferable to use hot water of 40 to 60 ° C. in consideration of cleaning efficiency and cost merit.

The method for producing the xanthohumol / cyclodextran inclusion complex-containing composition will be described in more detail.
Hop crushed and / or hop extract and cyclodextran are mixed in water and / or hydrophilic solvent at pH 1.0-8.5.
This means that hop crushed and / or hop extract and cyclodextran are dispersed or dissolved in a liquid and mixed, and brought into contact with each other under the condition of pH 1.0 to 8.5. means. As a solvent for this purpose, water or a hydrophilic solvent in which xanthohumol is difficult to dissolve and cyclodextran is dissolved is preferable, and examples include, but are not limited to, pH-adjusted water and pH-adjusted buffer. . You may adjust pH suitably using an acid and / or an alkali. Specifically, taking one embodiment as an example, a solution in which cyclodextran is dissolved in water and pH is adjusted is prepared, and 100 parts by mass of hop crushed material of about 0.1 to 10 parts by mass and / or An example of adding to the hop extract and stirring and mixing with industrially available stirring and mixing means can be exemplified.
Thus, by bringing the hop crush and / or hop extract into contact with the cyclodextran in water and / or a hydrophilic solvent having a pH of 1.0 to 8.5, the hop crush and / or the hop extract are contacted. Xanthohumol contained therein is solubilized as an inclusion complex with cyclodextran.
This contact is made by holding for a predetermined time. In this case, it is preferable to hold the mixed liquid while stirring and mixing, but it can also be held in a stationary state. The contact time varies depending on conditions, but is preferably about 0.1 hour to 7 days, and more preferably 7 hours to 48 hours.
The pH condition of the water and / or the hydrophilic solvent for bringing the hop crushed material and / or hop extract into contact with the cyclodextran needs to be pH 1.0 to 8.5. A pH below 1.0 is not preferable because xanthohumol is decomposed. A pH exceeding 8.0 is not preferable because the yield of the inclusion complex is greatly reduced. Furthermore, as will be apparent from the examples described later, in order to obtain more inclusion complex, the pH is preferably 3.5 to 5.5, and particularly preferably 3.8 to 5.2.
The temperature at which the hop crushed material and / or hop extract and the cyclodextran are brought into contact with each other in water and / or a hydrophilic solvent is not particularly limited as long as it is an industrially feasible temperature. As shown in the examples, considering that the amount of inclusion complex produced is affected by temperature conditions, 20 to 65 ° C. is preferable, 30 to 55 ° C. is more preferable, and 45 to 55 ° C. is further increased. Is more preferable.
The concentration conditions for cyclodextran when hop crushed and / or hop extract and cyclodextran are contacted in water and / or a hydrophilic solvent are as long as the inclusion complex is obtained. Although there is no special restriction | limiting, 0.1-10 W / V% is preferable and 1-5 W / V% is more preferable. If the concentration is less than 0.1 W / V%, it is not preferable because an inclusion complex cannot be obtained efficiently. In addition, as the amount of cyclodextran added increases, the amount of inclusion complex also increases. Therefore, it is desirable that the amount of cyclodextran added be large, but the amount of inclusion complex obtained and the amount of cyclodextran obtained are desirable. It is desirable that the cost is 10 W / V% or less.
Since the xanthohumol / cyclodextran inclusion complex formed as described above is dissolved in the liquid of the above solvent, the liquid part is collected by solid-liquid separation and concentrated to obtain a product. Alternatively, the liquid part may be directly or concentrated and spray-dried or freeze-dried to obtain a powdered product. Moreover, it may be purified by a known means to increase the purity of the xanthohumol / cyclodextran inclusion complex, and the product may be commercialized without any particular limitation.
By such a method, a xanthohumol / cyclodextran inclusion complex-containing composition containing a xanthohumol / cyclodextran inclusion complex can be obtained. This xanthohumol / cyclodextran inclusion complex-containing composition is preferably 0.1 to 99.9% by mass, more preferably 0.1 to 75% by mass, and still more preferably 1% in the solid content. Contains ~ 75% by weight xanthohumol / cyclodextran inclusion complex. In addition, this xanthohumol / cyclodextran inclusion complex-containing composition is dissolved as an inclusion complex with cyclodextran in water and / or a hydrophilic solvent having a pH of 1.0 to 8.5. Since xanthohumol that is not an inclusion complex of cyclodextran is hardly solubilized under the above conditions, the content of xanthohumol that is not an inclusion complex with cyclodextran is extremely high. Few.
On the other hand, the xanthohumol / cyclodextran inclusion complex-containing composition obtained as described above is treated with an adsorbent resin and separated into xanthohumol and cyclodextran, thereby containing high-purity xanthohumol. A composition can be obtained. Specifically, after the xanthohumol / cyclodextran inclusion complex is adsorbed to the adsorption resin, the cyclodextran is eluted with running water and a 40% ethanol solution, and then xanthohumol is eluted with 100% ethanol. By making it, a highly purified xanthohumol containing composition can be obtained. The purity of xanthohumol is usually about 90 to 99.9%, more preferably 90 to 95%, and still more preferably 92.5 to 95%. In addition, the separated cyclodextran is recovered and contacted with hop crushed material and / or hop extract again to form a xanthohumol / cyclodextran inclusion complex, and further xanthohumol is produced from the complex. It can be reused efficiently such as separation as described above.
Since this method does not require special organic solvents or explosion-proof equipment, it is superior in terms of safety, economy, and environmental impact compared to general methods such as organic solvent extraction and supercritical extraction. .
A commercially available synthetic adsorbent is used as the adsorbent resin. For example, Diaion HP20 (Mitsubishi Chemical), Diaion HP21 (Mitsubishi Chemical), Sepa Beads SP825 (Mitsubishi Chemical), Sepa Beads SP850 (Mitsubishi Chemical), Sepa Beads SP700 (Mitsubishi Chemical), Sepa Beads SP207 (Mitsubishi Chemical) ), Sepabead SP70 (Mitsubishi Chemical), Diaion HP2MG (Mitsubishi Chemical), Amberlite XAD2000 (Rohm and Haas), Amberlite XAD4 (Rohm and Haas), Amberlite FPX66 (Rohm and Haas), Amber Light XAD1180N (Rohm and Haas), Amberlite XAD7HP (Rohm and Haas), Amberlite XAD-2 (Rohm and Haas), etc. can be used.
The xanthohumol / cyclodextran inclusion complex-containing composition or xanthohumol-containing composition obtained by the above method includes various sugars, proteins, fats and oils, vitamins, inorganic salts, fragrances, coloring agents, etc. May be further blended, and there are no particular restrictions on the combination of blended ingredients.
To the xanthohumol / cyclodextran inclusion complex-containing composition or xanthohumol-containing composition obtained by the above method, a pharmaceutically acceptable base or carrier is added as necessary. , Tablets, granules, powders, liquids, powders, granules, capsules, etc., which can be used in medicine, creams, gels, packs, lotions, cosmetics, etc. This can be used as a cosmetic.
The xanthohumol / cyclodextran inclusion complex-containing composition or xanthohumol-containing composition obtained by the above method is used as a health food (for example, food for specified health use, nutritional functional food, nutritional supplement), function It can also be used as a sexual food, a food for the sick, etc. Examples of the form include tablets, liquids, capsules (soft capsules, hard capsules), powders, granules, sticks, jelly, and the like. The “special health food” refers to a food that may be subject to some legal restrictions from the viewpoint of health when the function or the like is displayed to manufacture or sell the food.
In addition, the xanthohumol / cyclodextran inclusion complex-containing composition or xanthohumol-containing composition obtained by the above method may be contained in a normal food or drink as a food additive. The food and drink include carbohydrate-based foods such as rice, noodles, breads and pasta; Western confectionery such as cookies and cakes; Japanese confectionery such as buns and sheep candy; Various confectionery such as frozen confectionery and ice confectionery; whiskey, bourbon, spirits, liqueur, wine, fruit liquor, Japanese sake, Chinese sake, shochu, beer, alcoholic beverages such as non-alcoholic beer with alcohol content of 1% or less, sparkling liquor, strawberry high Drinks containing fruit juice, drinks containing vegetable juice, drinks containing fruit juice and vegetable juice, soft drinks, milk, soy milk, milk drinks, drink-type yogurt, coffee, cocoa, tea drinks, energy drinks, sports drinks, mineral water, etc. Non-alcoholic beverages; processed products using eggs, seafood (squid, octopus, shellfish, eel, etc.) and livestock meat (including liver and other organs) It can be exemplified pyrotechnic (including delicacies), such as, but not limited thereto.
According to a more preferred embodiment, alcoholic beverages (beer, sparkling liquor, etc.) and non-alcoholic beverages (for example, soft drinks, fruit juice-containing drinks) , Beverages containing vegetable juice, beverages containing fruit juice and vegetable juice, tea beverages, milk beverages, non-alcoholic beer-taste beverages, etc.). At this time, since the xanthohumol / cyclodextran inclusion complex contained in the composition of the present invention is water-soluble, it can maintain a stable dissolved state even when added to these beverages.
The content of the xanthohumol / cyclodextran inclusion complex-containing composition as a food additive is not particularly limited, and may be appropriately selected according to the purpose. For example, it is 0.1-10.0 mass% in conversion of xanthohumol in solid, More preferably, it is 0.1-5.0 mass% in conversion of xanthohumol in solid. Further, for the xanthohumol-containing composition, as a food additive, there is no particular limitation on the content when contained in food and drink, and may be appropriately selected according to the purpose. It is 0.1-10.0 mass% in conversion of xanthohumol in solid, More preferably, it is 0.1-5.0 mass% in conversion of xanthohumol in solid.

Preferred embodiments of the xanthohumol / cyclodextran inclusion complex include the following.
(Example 1)
160 mL each of a solution prepared by adding cyclodextran at a concentration of 2 W / V% to 10 mM phosphate buffer (pH 7.0) or 10 mM carbonate-bicarbonate buffer (pH 10.0) is prepared. In addition to 500 mg of hop extract (containing xanthohumol 1.8 to 2.0%), the mixture is stirred and mixed for about 10 to 30 seconds, stored at 30 ° C. for one day, and then filtered through a 0.45 μm filter. A dextran inclusion complex is obtained.

Slightly water-soluble flavonoids:
A water-soluble flavonoid composition comprising a poorly water-soluble flavonoid, cyclodextran, and α-glucosyl hesperidin in order to improve solubility in water as compared with a normal flavonoid.
The slightly water-soluble flavonoid refers to a flavonoid having a solubility in neutral water of 0.1 g / L or less at room temperature. Although it does not specifically limit as a poorly water-soluble flavonoid, Hesperidin, naringin, diosmin, myricetin, myricitrin, daidzein etc. are mentioned. One or more of these can be used.
α-Glucosyl hesperidin is a compound in which one or more glucoses are bonded to the glucosyl group in the rutinose unit of hesperidin through an α1 → 4 bond. Of these, those in which only one glucose is bonded are referred to as “monoglucosyl hesperidin”.
α-Glucosyl hesperidin is a glycosyltransferase such as cyclodextrin glucanotransferase (CGTase, EC 2.4.1.19) in the presence of α-glucosyl sugar compounds (cyclodextrin, partially decomposed starch, etc.). It is produced by reacting enzymes with other similar effects. By this enzyme treatment, one or a plurality (about 2 to 20) of glucose is bound per molecule of hesperidin.
Monoglucosyl hesperidin reacts with α-glucosyl hesperidin to which two or more glucoses are bonded with a sugar hydrolase, such as glucoamylase (EC 3.2.1.3) or other enzyme having the same action, to form rutinose. It is produced by leaving only one glucose directly bonded to the glucosyl group in the unit and cleaving the other α1- → 4-linked glucose.
In addition, α-glucosyl hesperidin is usually an aggregate of monoglucosyl hesperidin and other α-glucosyl hesperidin having different numbers of bound glucoses, and is generally an enzyme treatment as described above. Therefore, it exists as a mixture with unreacted hesperidin and other derivatives.
Effects such as improvement in water solubility are exhibited regardless of whether α-glucosyl hesperidin is monoglucosyl hesperidin or other. However, when comparing the effects of a certain amount of α-glucosyl hesperidin (monoglucosyl hesperidin and other mixtures), a mixture containing more monoglucosyl hesperidin having a lower molecular weight is more water-soluble. Efficiency can be improved efficiently. Therefore, as α-glucosyl hesperidin in the present invention, those having a high ratio of monoglucosyl hesperidin are preferable, and those in which monoglucosyl hesperidin is 75% or more (molar ratio) of the whole α-glucosyl hesperidin are particularly preferable. In addition, the ratio of monoglucosyl hesperidin in α-glucosyl hesperidin can be adjusted by methods known to those skilled in the art, such as the above-described enzyme treatment conditions (such as reaction time) with glucoamylase.

<Method for producing water-soluble flavonoid composition>
The water-soluble flavonoid composition can be produced by mixing a poorly water-soluble flavonoid, cyclodextran, and α-glucosyl hesperidin. For example, the water-soluble flavonoid composition can be efficiently produced by a method including the following step 1 and step 2. Can be manufactured automatically.
<Step 1: Inclusion with cyclodextran>
In the method for producing a water-soluble flavonoid composition of the present invention, first, a cyclodextran is used for inclusion of poorly water-soluble flavonoids, and therefore a step of mixing them in a solvent is performed.
The slightly water-soluble flavonoids can be extracted directly from plant raw materials, but in order to make it easy to adjust the blending amount to a preferred range as described later, it is prepared by separately extracting and purifying in advance. It is convenient to obtain it as a product. By adding such a poorly water-soluble flavonoid and cyclodextran to a solvent and mixing them by stirring or the like, an inclusion body of the poorly water-soluble flavonoid and the cyclodextran is produced.
Here, general poorly water-soluble flavonoids tend to be easily dissolved in alkali (high pH) (pH 9.5 to 12.5). It can also be dissolved in a high-concentration water / organic solvent mixed solution (for example, aqueous solution of methanol concentration 50 to 98%, other aqueous solution of hydrophilic organic solvent such as ethanol, isopropanol, acetone, etc.). Further, it can be dissolved in an aqueous solvent under supercritical or subcritical conditions at high temperature and high pressure (for example, 150 to 180 ° C., 20 MPa). Therefore, in this process, depending on the type of the poorly water-soluble flavonoids to be targeted, the conditions of alkali dissolution, organic solvent dissolution, and dissolution at high temperature and high pressure are adjusted to dissolve more poorly water-soluble flavonoids and improve efficiency. In particular, it is desirable to be able to include cyclodextran.
The poorly water-soluble flavonoid and cyclodextran form a clathrate in the molar ratio of 1: 1 in theory, but these reactions are performed so that a sufficient amount of the poorly water-soluble flavonoid can react with the cyclodextran. In view of efficiency, it is desirable to add more cyclodextran than poorly water-soluble flavonoids. On the other hand, if the amount of cyclodextran added is too large, cyclodextran tends to precipitate. Therefore, in this step, the amount of cyclodextran added to 1 mol of poorly water-soluble flavonoid is preferably 1.5 to 5.0 mol, more preferably 1.5 to 2.0 mol.
Whether or not the poorly water-soluble flavonoids are included by cyclodextran is determined by, for example, subjecting the finally obtained water-soluble flavonoid composition to X-ray diffraction, nuclear magnetic resonance (NMR), differential scanning calorimetry (DSC). ) Etc. can be confirmed by using a known method.
<Step 2: Addition of α-glucosyl hesperidin>
After the step (1), a step for further adding α-glucosyl hesperidin to the mixture of the poorly water-soluble flavonoid and cyclodextran is performed.
In this step, it is preferable to use α-glucosyl hesperidin prepared in advance by a known enzyme treatment as described above. For example, specific embodiments of an enzyme treatment method for producing α-glucosyl hesperidin from hesperidin and further producing monoglucosyl hesperidin, and a purification method for increasing the content of monoglucosyl hesperidin in a mixture obtained by the enzyme treatment For example, JP-A-10-323196 can be referred to. Further, as α-glucosyl hesperidin having a high monoglucosyl hesperidin content produced by such a method, a product “αG Hesperidin PS” (about 85% by weight of monoglucosyl hesperidin, about 1% hesperidin produced by Toyo Seika Co., Ltd.) % By weight, a composition containing about 10% by weight of hesperetin-7-glucoside). In addition, hesperetin-7-glucoside contained in the composition of α-glucosyl hesperidin such as this product can also be handled as a part of the poorly water-soluble flavonoid mentioned here.
The amount of α-glucosyl hesperidin contained in the water-soluble flavonoid composition is based on 1 mol of the poorly water-soluble flavonoid from the viewpoint of stabilizing the solubility of the poorly water-soluble flavonoid included in the cyclodextran. The amount is preferably 0.1 to 1.0 mol, and more preferably 0.3 to 0.5 mol. In this step, α-glucosyl hesperidin in such an amount may be added.
The method for adding α-glucosyl hesperidin is not particularly limited. For example, α-glucosyl hesperidin may be added to and mixed with the clathrate solution obtained in the step (1). In addition, when an alkaline solution is used in step (1), α-glucosyl hesperidin may be added while the solution is alkaline, or while neutralizing the solution with an organic acid or an inorganic acid, or after neutralization, -Either glucosyl hesperidin may be added.

The above-described method for producing a water-soluble flavonoid composition may be provided with additional steps as necessary in addition to the two steps as described above.
For example, the solution obtained by the above two steps, the concentrated solution thereof, and the like are also an embodiment of the water-soluble flavonoid composition, but from the viewpoint of handleability, these liquids are dried and powdered with a spray dryer or the like. It is preferable to provide a process for this purpose.
In addition, in the above process, particularly when the preferred blending amount as described above is applied, the occurrence of precipitation is suppressed even if the obtained water-soluble flavonoid composition is used as it is. In order to remove contaminants contained in the extract, such as simple cyclodextran, a purification step using an adsorption resin or an ion exchange resin may be provided.

Various sparingly water-soluble flavonoids such as hesperidin and naringin have been used in foods, medicines, cosmetics, feeds, etc., but water-soluble flavonoid compositions should be used especially for foods and drinks. Is preferred. Since the water-soluble flavonoid composition has high water-solubility, it becomes possible to add a hardly water-soluble flavonoid to a food or drink at a relatively high concentration while suppressing precipitation and precipitation over a long period of time. Therefore, although it changes also with kinds of the slightly water-soluble flavonoid to be used, it becomes possible to efficiently impart functionalities such as taste improvement, antioxidant, and physiological activity as described later to food and drink. In addition, from the viewpoint of physiological activity and the like, the water-soluble flavonoid composition is also preferably used by being added to cosmetics and pharmaceuticals in addition to food and drink.
The food and drink to which the water-soluble flavonoid composition can be added is not particularly limited, and examples thereof include fruit drinks, oolong tea, green tea, black tea, cocoa, vegetable juice, green juice, soy milk, milk drink, and lactic acid drink. And beverages such as near water, sports drinks and nutrition drinks, Western confectionery such as jelly, pudding and yogurt, Japanese confectionery, seasonings, fish meat, processed fish products, processed livestock products, and the like. As for cosmetics and pharmaceuticals, a water-soluble flavonoid composition can be added to various known embodiments. For cosmetics, for example, powders, emulsions, liquids, creamy foundations and sunscreens, for pharmaceuticals, for example, liquids, syrups, drinks, tablets, capsules, powders, fine granules, granules Oral preparations such as
Moreover, the addition of the water-soluble flavonoid composition to foods and drinks, cosmetics, pharmaceuticals and the like can be performed according to various known techniques, and the mode is not particularly limited. For example, it may be added together with the raw material at the beginning of the production process, added during the production process, or added at the end of the production process. What is necessary is just to select appropriate things, such as application | coating, according to aspects, such as food-drinks, cosmetics, and a pharmaceutical.

Preferred embodiments of the water-soluble flavonoid composition include the following.
(Example 1)
1 mol of hesperidin and 1.5 to 2.5 mol of cyclodextran are dissolved in water (70 ° C.) in an amount such that hesperidin is 3% by weight using 20% NaOH, and 70 ° C., 30 The mixture was left stirring for a minute. Thereafter, 24.5% H ₂ SO ₄ was added to adjust the pH to 7.0. Subsequently, 0.5 mol of α-glucosyl hesperidin is added, stirred and dissolved, then cooled and allowed to stand at room temperature to obtain a water-soluble flavonoid composition.

Isoflavone derivatives:
In order to suppress a decrease in solubility of cyclodextran inclusion complex of isoflavone derivative over time, to improve stability over time, and to improve palatability, cyclodextran inclusion complex of isoflavone derivative, and A beverage composition containing an organic acid or a salt thereof is used.
The inclusion product of the isoflavone derivative is not particularly limited, but among them, the inclusion product of genistein, daidzein, glycitein aglycone is preferable, and the ratio of genistein to daidzein is 1: 0.6 to 1: 1. Most preferred is a clathrate of the mixture. In this case, not only the above-mentioned aglycone of genistein, daidzein, glycitein, but also an extract from soybean and a crude product thereof can be used. The inclusion product of the isoflavone derivative can also be produced from the isoflavone derivative and cyclodextran in the production process of the beverage composition. In this case, not only the above-mentioned aglycone of genistein, daidzein, glycitein, but also an extract from soybean and a crude product thereof can be used.
A method for clathrating isoflavones can be obtained by a conventional method. For example, in the production process of a beverage composition, a paste in which water is added to cyclodextran in advance is prepared, and one or more isoflavone derivatives are added and fully The clathrate can be obtained by a kneading method or a method of dissolving and drying in a hot water alcohol solution or an alkali solution.
The isoflavone content of the isoflavone inclusion product used in the beverage composition can be 3 to 6% by weight based on the total amount of the inclusion product. Moreover, 0.18-1.5 w / v% of isoflavone inclusions can be mix | blended with a drink composition with respect to the composition whole quantity, and 0.2-1.2 w / v% is preferable. If the blending amount is less than 0.18 w / v%, it becomes necessary to ingest a large amount of beverage composition in order to ingest the amount of isoflavone that can be expected to prevent or improve diseases such as osteoporosis and periodontal disease. Even if it exceeds 5 w / v%, no further effect can be expected. Therefore, 5 to 40 mg at which the effectiveness of isoflavone can be expected is an appropriate amount.
The organic acid is not particularly limited, but lactic acid, tartaric acid and salts thereof are preferable. The compounding amount of the organic acid and its salt is preferably 0.2 to 4.0 w / v%, particularly preferably 0.25 to 2.5 w / v%, based on the total amount of the composition. If the blending amount is less than 0.2 w / v%, the effect of suppressing the precipitate of the isoflavone inclusion product cannot be sufficiently exerted, and if it exceeds 4.0 w / v%, the flavor is not preferable.
The beverage composition can be produced by a conventional method, is provided as an acidic beverage having a pH of 2.5 to 4.0, particularly pH 3.0 to 4.0, and is drunk so that an amount of isoflavone can be ingested 5 to 40 mg per day. Is preferred.
In the beverage composition, in addition to the above essential components, components used in beverages can be blended within a range that does not impair the effect. For example, citric acid, malic acid, gluconic acid, fumaric acid and salts thereof as acidulants, calcium gluconate, ascorbic acid, vitamin D3, vitamin K etc. as fortifying agents, erythritol, sucralose, stevia extract, reduced starch syrup as sweeteners Examples thereof include ethyl maltol as a flavoring agent, sodium benzoate as a preservative, and cochineal dye as a coloring agent.

  The beverage composition is effective for prevention of diseases associated with bone resorption such as osteoporosis and periodontal disease, and relief of symptoms.

Preferred embodiments of the beverage composition include the following.
(Example 1)
In a portion of heated purified water, 1.2% by mass of isoflavone inclusions weighed, 0.5% by mass of lactic acid (50% aqueous solution), 7% by mass of erythritol, 0.04% by mass of sucralose, reduced water candy 3 Mass%, fragrance 0.2 mass%, and benzoic acid Na 0.07 mass% are sequentially added and completely dissolved, and then purified water is added again and the mixture is sterilized by heating and adjusted to 100 ml with purified water.

Citrus juice drink:
In order to suppress precipitation in the product without affecting the flavor and appearance of the citrus fruit juice and other qualities in the citrus fruit juice drink, the carotenoid pigment and / or Add flavonoid pigment and cyclodextran.
The citrus fruit juice beverage is not particularly limited as long as it contains citrus fruit juice such as oranges and oranges.
Among the carotenoid pigments and / or flavonoid pigments, examples of the carotenoid pigment include β-carotene and the like, and examples of the flavonoid pigment include safflower yellow.
The amount of cyclodextran added is preferably in the range of 50 to 1000 ppm.
There are no particular restrictions on the timing of addition of carotenoid pigments and / or flavonoid pigments or cyclodextran in the production of citrus juice beverages, but they may be added at the raw material stage of the juice. It may be added at the final stage of the production process. Moreover, there is no limitation in particular also about conditions, such as temperature conditions and pH at the time of adding, The manufacturing conditions normally used in manufacture of a citrus fruit juice drink can be used.
Precipitation is suppressed in citrus fruit juices to which carotenoid pigments and / or flavonoid pigments and cyclodextran are added. Particularly preferred is a citrus fruit juice drink in a transparent sealed container.

The following can be mentioned as a preferable aspect of the citrus fruit juice drink by which the said precipitation generation | occurrence | production was suppressed.
(Example 1)
Carotenoid pigment (β-carotene), flavonoid pigment (safflower yellow), and 100 ppm cyclodextran are added to and mixed with concentrated mandarin orange juice, and then a fruit juice drink is prepared, followed by sterilization by a conventional method. Thereafter, the transparent container is filled.

Licorice oily extract:
To combine licorice oily extract with various liquid products such as beverages, liquid seasonings, cosmetics and quasi drugs, a licorice oily extract that combines licorice oily extract, saponin and cyclodextran A solubilized composition.
Licorice, which is an extraction raw material of licorice oily extract, is a plant belonging to the genus Glycyrihiza, for example, G. licorice. glabra, G.G. uralensis, G. et al. inflata and the like, and any of these roots, rhizomes, leaves, and stems can be used as a raw material, and it is particularly preferable to use roots and / or rhizomes as a raw material. In addition, as raw materials for extraction, raw or dried ones may be used, but dry roots and dried rhizomes that are raw materials for industrially produced glycyrrhizin, glycyrrhizin, etc. The water extraction residue after extraction with water can also be used as a raw material to obtain
In addition, licorice is often called with the name of the production area, and examples thereof include Tohoku licorice, northwest licorice, Xinjiang licorice, Mongolian licorice, Russian licorice, and Afghanistan licorice.
In addition, the licorice water extraction residue is a solid residue after the licorice is extracted with cold water, hot water and hot water, or neutral or slightly alkaline cold water, hot water and hot water, or a combination of these and repeated. It means a solid residue after extraction. The residue after extraction may be either water-containing or dry. In order to obtain a licorice oily extract from a licorice or licorice water extraction residue, various organic solvents may be used alone or in combination.
Examples of the organic solvent include benzene, toluene, xylene, ethyl ether, methyl ethyl ketone, methyl isobutyl ketone, dichloromethane, dichloroethane, chloroform, ethyl acetate, propyl acetate, butyl acetate, acetone, methanol, ethanol, propanol, hydrous methanol, hydrous ethanol. And hydrous propanol. Furthermore, carbon dioxide can also be used as the supercritical fluid. Among these organic solvents, it is preferable to use ethanol or hydrous ethanol because there are few problems in the Food Sanitation Law.
The conditions for obtaining the licorice oily extract from the licorice or licorice water extraction residue with the above-mentioned organic solvent are not particularly limited, but 2 to 10 times the amount of the organic material extracted from the extraction raw material is indicated by a standard method. There are a method of extracting at room temperature while adding a solvent and stirring, and a method of extracting by heating to reflux. Further, it is more preferable that these methods are repeated alone or in combination to improve extraction efficiency.
The obtained extract can be used as it is as a licorice oily extract after removing insolubles by centrifugation and filtration, and can also be concentrated and used by a conventional method. These may be appropriately subjected to purification such as deodorization and decolorization as long as the target physiological effect does not decrease. In this purification step, it is common to use activated carbon, synthetic adsorption resin, ion exchange resin and the like. If the extract is dried by an appropriate method, a tan extract powder can be obtained as a licorice oily extract.
As the licorice oily extract, the liquid extract thus obtained is used as it is, or the liquid extract is concentrated, and further, a liquid extract powder or a solid dry product is used.
Examples of saponins include Quillaja saponin, Yucca saponin, soybean saponin, Enju saponin, tea seed saponin, beet saponin, carrot saponin, licorice saponin (glycyrrhizin), etc. It is preferable to use naturally derived saponins described in the list of existing additives. The purity of the saponin is not particularly limited as long as it has surface-active ability, and taking into consideration the taste peculiar to saponin, a higher purity is more preferable because the amount used can be reduced. Among the saponins, kiraya saponin is particularly preferable because it has excellent surface activity and is easily available.
In addition to the licorice oily extract, saponin, and cyclodextran, the solubilized composition of licorice oily extract may further contain a solubilizing agent such as propylene glycol, glycerin, saccharides, sugar alcohol, and dextrin. .
In addition to the above components, the solubilized composition of licorice oil-based extract can further contain various additives such as a pH adjuster, a stabilizer, and an antioxidant as necessary. .
When solubilizing the licorice oil extract in various liquid products such as beverages, liquid seasonings, cosmetics, and quasi-drugs, the saponin and solubilizing agent can be used in advance as follows. A method of preparing a solubilized composition of licorice oily extract by uniformly mixing the agent and adding this composition to various liquid products is preferred.
The method of mixing the licorice oily extract, saponin and the dissolution aid for preparing the solubilized composition of the licorice oily extract is not particularly limited, but for example, a fine powdered licorice oily extract and saponin and dissolution After mixing the auxiliary agent with a stirrer, or after dissolving the dried licorice oily extract in a volatile organic solvent such as ethanol, acetone and isopropyl alcohol or a mixed solvent of volatile organic solvent and water A method of mixing and stirring with saponin and a dissolution aid and distilling off the solvent using a vacuum dryer or the like, or mixing and stirring a liquid licorice oily extract or its concentrate with saponin and a dissolution aid and then drying under reduced pressure There is a method of distilling off the solvent using a machine or the like.
The licorice oily extract prepared by these methods is in a liquid state, but can be dried into a powder by using a vacuum concentrator, a hot air dryer, a freeze concentrator, or the like.
The mixing ratio of licorice oily extract, saponin and solubilizing agent in the solubilized composition of licorice oily extract is determined based on the saponin and solubility that are surface active when there are many poorly water-soluble substances in the contents of licorice oily extract. If the ratio of the auxiliary agent is increased and the amount of poorly water-soluble substances is small, the ratio of the saponin having a surface activity and the dissolution auxiliary agent may be decreased, and can be appropriately adjusted according to the properties of the licorice oily extract. The mixed mass ratio of licorice oily extract, saponin and dissolution aid (licorice oily extract: saponin: dissolution aid) is preferably 1: 1-20: 5-40, and 1: 1-3: 5. 10 is more preferable.
The licorice oil-based extract solubilized composition thus prepared has extremely high solubility in various liquid products such as beverages, liquid seasonings, cosmetics, and quasi drugs, and is added to the target at an arbitrary ratio. It is possible. If the solubilized composition of the licorice oil extract is difficult to handle, an alcohol such as water or ethanol may be added at the time of use to make the composition easy to handle.

Even in the presence of coexisting substances such as licorice oil-based extract, acid, salt, saccharides and minerals, there is very little effect on the clarity of liquid products, so beverages, liquid seasonings, cosmetics, pharmaceutical departments It can be contained without affecting the properties of liquid products obtained by adding licorice oily extract to various liquid products such as external products. In addition, examples of beverages that can be contained without affecting the taste and flavor include teas such as gyokuro, matcha tea, sencha, kettle tea, and bancha; semi-fermented teas such as oolong tea, confectionery tea, and white tea ; Fermented teas such as Chinese tea and British tea; Microorganism fermented teas such as black tea and puer tea; Processed teas such as roasted tea, brown rice tea and incense tea; Grain tea such as barley tea; Mixed tea, health tea and medicinal tea , Coffee, coffee drinks, cocoa, natural fruit juice, natural fruit juice drinks, soft drinks with fruit juice, fruit drinks, fruit drinks with fruits, tomato juice, vegetable juice, milk, processed milk, milk drinks, lactic acid bacteria drinks, soy milk, soy milk drinks Sports drinks, carbonated drinks, nutritional drinks, alcoholic drinks, and the like.
0.01-20 mass% is preferable with respect to the whole drink, and, as for the addition amount of the solubilized composition of a licorice oily extract, 0.05-10 mass% is more preferable.
Liquid seasonings include, for example, boiled dashi, kelp dashi, Chinese dashi, consomme, etc .; mayonnaise, tartar sauce, ketchup, wooster sauce, okonomiyaki sauce, yakisoba sauce, steak sauce, hamburger sauce, spaghetti sauce, domiglas sauce , Gratin sauce, white sauce, curry sauce, etc .; Chinese cooking mix, cooked rice cooking mix, miscellaneous cooking mix, etc .; grilled meat sauce, sukiyaki sauce, yakitori sauce, eel grilled eel Sauces such as sauce, dumpling sauce; noodle soup, ramen soup, hot pot soup, tempura soup, sukiyaki soup, oden soup, etc .; seasoning for pickles such as shallow pickles and kimchi sauce; soy sauce And soy sauce with soup stock and seasonings such as ponzu.
0.01-20 mass% is preferable with respect to the whole seasoning, and, as for the addition amount of the solubilized composition of a licorice oil-based extract, 0.05-10 mass% is more preferable.
Cosmetics include, for example, basic skin lotions such as face-wash cream, face-wash foam, lotion, beauty pack, massage cream, milky lotion, moisturizing cream; body cosmetics such as liquid face wash, sunscreen cream; shampoo, rinse, hair treatment And other cosmetics for hair such as hair tonic and scalp tonic, and aromatic cosmetics such as perfume and eau de cologne.
0.01-20 mass% is preferable with respect to the whole cosmetics, and, as for the addition amount of the solubilized composition of a herbal oil extract, 0.05-10 mass% is more preferable.
Quasi-drugs include, for example, skin disinfectants, wound disinfectants, ointments, vitamin-containing health agents, bath preparations, hair restorers, hair nourishing agents, medicated cosmetics, medicated toothpastes, mouthwashes, mouth fresheners, For example, sweat spray.
The addition amount of the solubilized composition of the licorice oily extract is preferably 0.01 to 20% by mass, more preferably 0.05 to 10% by mass with respect to the entire quasi-drug.

Preferred embodiments of the solubilized composition of the licorice oily extract include the following.
(Example 1)
Add licorice oily extract to 10 parts by mass of solid extract, add 40 parts by mass of Kirayasaponin (solid content of 20% by mass) and 50 parts by mass of cyclodextran, and heat to 60 ° C. And stir to mix them uniformly. By concentrating this mixed solution under reduced pressure and distilling off water and ethanol contained in the extract, a solubilized composition of licorice oily extract containing 10% by mass of licorice oily extract is obtained.

Thiamine derivatives:
In order to mask the specific bitter taste of a thiamine derivative, a thiamine derivative-containing composition in which a thiamine derivative and a cyclodextran are combined is used.
Examples of thiamine derivatives include S-acyl thiamine derivatives such as dicetiamine hydrochloride.
The compounding quantity of cyclodextran is 5 mass parts or more with respect to 1 mass part of thiamine derivatives.
The thiamine derivative-containing composition may further contain sweeteners, carnitines, mucopolysaccharides and the like. The compounding amount of the sweetener is 50 parts by mass or more with respect to 1 part by mass of the thiamine derivative in terms of sucrose, and the compounding amount of carnitines is 1 part by mass or more with respect to 1 part by mass of the thiamine derivative. The amount of the mucopolysaccharide is 5 parts by mass or more per 1 part by mass of the thiamine derivative.
The thiamine derivative-containing composition can be manufactured and prepared by a conventional method by blending a thiamine derivative and cyclodextran.
Thiamine derivative-containing compositions expected the effects of thiamine, such as beverages such as health foods, nutritional supplements, functional foods, drinks, syrups, suspensions, and other drugs and quasi drugs It can be used for oral compositions.

Preferred embodiments of the thiamine derivative-containing composition include the following.
(Example 1)
Dicetiamine hydrochloride 11mg
Sucrose 10,000mg
Carnitine chloride 200mg
Cyclodextran 150mg
Citric acid 210mg
Aqueous sodium hydroxide solution (pH 3.2)
100 mL of purified water (total amount)

Carotenoids:
In order to improve the bioavailability of carotenoids, a cyclodextran / carotenoid complex is used, and a carotenoid-containing nutritional supplement containing this is used.
Examples of carotenoids include astaxanthin, lycopene, zeaxanthin, β-carotene, lutein and the like.
A carotenoid-containing nutritional supplement is produced as follows.
a) A predetermined amount of cyclodextran and water are mixed to form a water / cyclodextran slurry at 50 ° C. b) A predetermined amount of at least one carotenoid is mixed with the water / cyclodextran slurry to prepare a cyclo Forming a preblend composition comprising a dextran / carotenoid complex c) evacuating the preblend composition and thoroughly mixing the preblend composition for a minimum of 1 hour d) the dried Forming a final blend by mixing the pre-blend composition and additional nutrients under vacuum at a temperature of about 40 ° C. to 45 ° C. e) grinding the final blend in vacuum f) the grinding Carotenoid-containing nutritional supplements that encapsulate the final blend include fish oil, beeswax, vitamin A, vitamin E, D-limo You may mix | blend additional nutrients, such as a nene.
This carotenoid-containing nutritional supplement can be used in the fields of chemistry, food science, biology and nutrition.

Preferred embodiments of the carotenoid-containing nutritional supplement include the following.
(Example 1)
5.640 kg of water is added to the blender and heated to 50 ° C. The temperature is confirmed before adding the cyclodextran. The blender blade is removed from the blender vessel and 4.070 kg of cyclodextran is added and mixed first by hand, then mechanically mixed for at least 30 minutes or until a cyclodextran water slurry is formed. . The slurry is caramel colored. Carotenoid (β carotene 30% suspension 0.273 kg, β carotene (coconut fruit) 0.689 kg, astaxanthin 5% oil 0.224 kg, lycopene 20% suspension oil, 0.560 kg, zeaxanthin 20% suspension) Added, evacuated on the mixing vessel, the composition is mixed at a low speed (9.6 rpm) for at least 1 hour at a temperature of 4-45 ° C., and a carotenoid cyclodextran complex is formed. After at least one hour of mixing, the mixer vessel containing the carotenoid-cyclodextran complex is immediately removed and added to the main mixer containing the fish oil beeswax blend. A blend of fish oil and beeswax is made by adding approximately 6.1 kg beeswax and 73.2 kg fish oil to a mixer and blending at 60 ° C. until thoroughly mixed. The carotenoid-cyclodextran complex is then added after the composition is cooled to 40-45 ° C. A small amount of the fish oil / beeswax composition is used to rinse the carotenoid-cyclodextran complex into the mixer vessel. After the addition of the carotenoid / cyclodextran complex, a vacuum is drawn on the mixer vessel and the mixture is mixed at 20-45 ° C. for 20 minutes using high shear. The mixture is then cooled to 25-28 ° C, removed from the mixer and ground to reduce the particle size. After grinding, the mixture may be stored under nitrogen in a sealed container or may be immediately encapsulated. Encapsulation takes place in soft gelatin capsules. Each soft gelatin capsule contains about 1.2 g of the milled final composition.

Polymethoxyflavonoids:
In order to solubilize polymethoxyflavonoids in water, polymethoxyflavonoids and cyclodextrans are used as inclusion compounds.
Polymethoxyflavonoids include nobiletin, tangeretin, 5-demethylnobiletin, 8-demethoxynobiletin (sinensetin), 6-demethoxytangeretin, 6-demethoxynobiletin, citromitin, 5,6,7,8,4- And pentamethoxyflavanone.
These polymethoxyflavonoids may be extracted from citrus fruits such as Shikuwasha, other fruits, leaves, roots, stems, etc. of plants containing the aforementioned substances, or may be produced by chemical synthesis.
The seeker extract can be produced, for example, by extracting from the seeker fruit and / or leaves with water and / or an organic solvent. The organic solvent may be a hydrate.
The fruit and / or leaf may be the whole or part of the fruit and / or leaf. For example, the fruit may be pulp or peel. Furthermore, the fruit and / or leaf may be used as it is, or a crushed material, for example, a fruit and / or leaf that has been refined to the nanometer order. Further, the fruit and / or leaf may be a fruit and / or leaf, or a squeezed residue of a part thereof. Hereinafter, these fruits and / or leaves, a part thereof, a crushed material thereof, and a squeezed residue thereof may be referred to as “seek washer fruits and / or leaves etc.”.
Examples of the organic solvent include alcohols such as methanol, ethanol, propanol, isopropanol, and butanol, esters such as ethyl acetate, acetone, hexane, chloroform, diethyl ether, acetonitrile, or a hydrated product thereof, or these organic solvents. And a combination of any of these hydrates, among which ethanol is preferred. The water content of the organic solvent is not particularly limited, but is preferably 0 to 90% by mass, more preferably 0 to 40% by mass.
In the organic solvent extraction, the amount of the organic solvent relative to the sikhwasher fruits and / or leaves is not particularly limited, but the ratio (weight ratio) of the sikhwasher fruits and / or leaves to the organic solvent is preferably 1: 0. 5 to 1: 100, more preferably 1: 1 to 1:20.
The extraction method is not particularly limited. For example, an organic solvent is added to Sikhshahr fruits and / or leaves, and preferably after 5 minutes to 3 hours of stirring and extraction, followed by solid-liquid separation means such as filtration or centrifugation A method of collecting a liquid layer is mentioned.
In addition, it is preferable to add cyclodextran to solubilize the polymethoxyflavonoid after extraction or before the drying step. Cyclodextran is expected to have an effect of improving water solubilization, digestibility and absorption, or improving flavor. The amount of the cyclodextran is preferably 0.1 to 95% by mass, more preferably 1 to 90% by mass, based on the total amount of the solid product of the obtained Sikhwasher extract and the cyclodextran.
In addition, the above-mentioned Sikhwasher extract is obtained by pulverizing the Sikhwasher fruit and / or leaf part after freezing, or lyophilizing or hot-air drying the Sikhwasher fruit and / or leaf part to form a powder. Things can also be produced by the supercritical extraction method.
The above-described seeker extract or polymethoxyflavonoid can be used as it is as an IGF-1 production promoter, or as an active ingredient in food or drink or feed. The Seekwasher extract or polymethoxyflavonoid may be a solution, and can be stored and used as a powder after freeze-drying or spray-drying by a conventional method.

Preferred embodiments of the clathrate compound include the following.
(Example 1)
Cyclodextran is added to the extract extracted with water-containing ethanol from pomace of Sikhwasher fruit to obtain an inclusion compound. This inclusion compound has a composition of 92% by mass or more of solids, 50% by mass of cyclodextran, and 10% by mass or more of polymethoxyflavonoid.

Polyphenol:
In order to obtain a tea beverage with a high concentration of polyphenols, roasted tea leaves are added to the tea beverage containing a high concentration of polyphenols in order to suppress the smell, bitterness and astringency derived from polyphenols despite having a high concentration of polyphenols. It is set as the tea drink which added the tea leaf extract component and cyclodextran which contain.
The tea beverage containing a high concentration polyphenol contains 0.4 g or more and 5.0 g or less of polyphenol per liter of tea beverage.
Tea leaves used in tea beverages include roasted tea leaves, but tea leaves other than roasted tea leaves include all conventional tea leaves and are not particularly limited. Specific examples include various tea leaves such as green tea leaves, hoji tea leaves, semi-fermented tea leaves (Oolong tea leaves), black tea leaves, wheat tea leaves, grain tea leaves and the like.
The roasted tea leaves are those obtained by roasting the tea leaves (widely, including those that have been burned), and roasting produces a unique aroma for the tea leaves. Specifically, roasting reduces the smell of tea leaves and the altered odor produced from lipids during storage, and volatile pyrazine, pyrrole, furan compounds, etc. are produced by the heat reaction between sugar and amino acids. To this, dimethyl sulfide and the like from sulfur-containing amino acids are added to produce an aroma component. Since pyrazine, which is a typical aromatic component, is produced at 100 ° C. or higher, it is preferably roasted at 100 ° C. or higher. The flavor of a tea drink is improved by including in the tea drink an extracted component obtained by extracting such roasted tea leaves with water or the like. Further, the flavor can be further improved by a synergistic effect with cyclodextrans described later.
Moreover, the flavor of a high concentration polyphenol containing tea beverage can be adjusted by adjusting the content of the roasted tea leaf extract component in the tea beverage. Specifically, the content of the roasted tea leaf extract component is adjusted within the range of 0.1% by mass or more and 1.0% by mass or less as the soluble solid content in the tea beverage. When the content of the roasted tea leaf extract component is less than 0.1% by mass, the flavor is not sufficiently improved by the roasted incense. On the other hand, if it exceeds 1.0% by mass, the roasted fragrance is too strong, and on the other hand, the flavor is impaired, making it unsuitable for drinking.
Tea beverages contain high concentrations of polyphenols and are expected to have anti-arteriosclerosis, anti-allergy, blood flow enhancement, anti-cancer effects and the like. The content of polyphenol is such that when it is added alone (when roasted tea leaf extract component and cyclodextran are not added), it senses odor, bitterness, astringency, etc., specifically, It contains 0.4 g or more and 5.0 g or less, preferably 0.6 g or more and 3.0 g or less per liter of tea beverage. When the content of polyphenol is less than 0.4 g, it is difficult to feel the odor, bitterness, astringency, etc. of polyphenol, and palatability is ensured, but in order to fully demonstrate the function of polyphenol, a large amount of drinking is required Necessary and inefficient. On the other hand, when the content of polyphenol exceeds 5.0 g, the function of the polyphenol can be sufficiently expected, but the odor, bitterness, astringency, etc. are too strong and are not suitable for drinking.
The polyphenol may be only the polyphenol derived from the tea leaves, but preferably comprises a separately added polyphenol. The polyphenol added separately is not particularly limited, but is preferably at least one polyphenol selected from the group consisting of tea polyphenol, grape polyphenol, and apple polyphenol.
Examples of the tea polyphenol include green tea polyphenol, oolong tea polyphenol, black tea polyphenol, and the like. This tea polyphenol is obtained by extracting and concentrating various tea leaves by a conventionally known method. It can also be obtained as a commercial product. Tea polyphenols include various catechins, specifically, non-polymers of catechins such as epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, catechin, gallocatechin, etc. .
Grape polyphenols and apple polyphenols can be obtained by extracting and concentrating grapes and apples by a conventionally known method in the same manner as tea polyphenols. It can also be obtained as a commercial product. Plant-derived polyphenols such as grape polyphenol and apple polyphenol also have the same effect as tea polyphenol.
The content of the separately added polyphenol is added so that the total of the polyphenol derived from the tea leaf extract component including the roasted tea leaves is 0.4 g or more and 5.0 g or less. Preferably, it is 0.1 g or more and 3.0 g or less per liter of beverage, more preferably 0.2 g or more and 2.0 g or less per liter of beverage.
The content of cyclodextran is preferably 0.1 g or more and 10.0 g or less, more preferably 0.2 g or more and 5.0 g or less per liter of tea beverage. When the content of cyclodextran is less than 0.1 g per liter of tea beverage, the flavor of the tea beverage is not sufficiently improved. On the other hand, if it exceeds 10.0 g, further improvement in flavor cannot be expected.
The tea beverage is sterilized by a conventionally known method and then filled in a sealed container to obtain a tea beverage in a container. As the sealed container, conventionally known containers such as PET bottles, aluminum cans, steel cans and the like are used. By filling these sealed containers, it is possible to fully enjoy an excellent scent.

The following can be mentioned as a preferable aspect of the said tea drink.
(Example 1)
A tea beverage containing 1 g / L of catechin preparation and 1 g / L of cyclodextran is produced. A tea beverage is produced by adding a roasted tea leaf extract thereto. Roasted tea leaf extract roasted pearl barley, green tea, barley, brown rice, black beans, hub tea, oolong tea, kelp, ganoderma, kumamushi, bamboo leaf, sesame, safflower, ashitaba, mandarin peel, and guava leaf These are extracted from these. The addition amount of the roasted tea leaf extract is 0.23% by mass as soluble solid content using 10 g of roasted tea leaf per liter of beverage.

Stevia-derived sweet substances:
In order to mask the bitterness specific to stevia-derived sweet substances, a combination of stevia-derived sweet substances and cyclodextran having an average particle size of 30 μm or less, 0.5 to 20% by mass with respect to the mass of the stevia-derived sweet substances Use as a sweetener.
Stevia-derived sweet substances refer to sweet substances contained in Stevia, which is a genus Stevia. Stevia-derived sweet substances are known to have a sweetness intensity about 50 to 450 times that of sugar. Specific examples include stevioside, rebaudioside A, rebaudioside C, rebaudioside D, rebaudioside E, and zulcoside A. Among these, rebaudioside A is most preferable in terms of taste.
In the sweetener, stevia-derived sweet substances can be used alone or in combination of two or more.
Stevia-derived sweet substances are known substances and can be easily obtained in the market, or can be purified from stevia according to the method described in, for example, Japanese Patent No. 3436317.
Stevia-derived sweet substances are preferably enzymatically treated from the viewpoint of improving taste quality.
Examples of the enzyme used for the treatment include glucoamylase and α-glucosidase.
The enzyme treatment can be carried out, for example, according to the method described in Japanese Patent Publication No. 57-18787 (Patent No. 1169566).
Cyclodextrans have an average particle size of 30 μm or less, preferably 10 μm or less, particularly preferably 5 μm or less.
The average particle diameter of the cyclodextran can be measured using a particle size distribution measuring apparatus based on a laser diffraction / scattering method. For example, it can be measured by a wet method using a laser diffraction / scattering particle size distribution measuring device (product name: HORIBA LA910, source: Horiba, Ltd.).
When the average particle size is 30 μm or less, the bitterness inherent to stevia-derived sweet substances can be masked even in a small amount (that is, 0.5 to 20 mass% with respect to the mass of stevia-derived sweet substances).
The above-mentioned commercially available cyclodextrans generally have an average particle diameter of 50 to 500 μm. In this case, it is necessary to pulverize cyclodextran. The fine pulverization of cyclodextran can be performed using a fine pulverization means generally used in the art, for example, a jet mill, a ball mill, an automatic mortar, an oscillator, a combil, a hammer mill, an atomizer and the like. Among these, a jet mill that does not generate heat during pulverization and can be efficiently pulverized is particularly preferable.
The compounding amount of cyclodextran in the sweetener is 0.5 to 20% by mass, preferably 0.5 to 10% by mass, particularly preferably 0.5 to 5% by mass with respect to the mass of the stevia-derived sweet substance. . When the blending amount is 0.5 to 20% by mass with respect to the mass of the stevia-derived sweet substance, the bitter taste of the stevia-derived sweet substance is masked without impairing the flavor inherent to the food to which the sweetener is added. be able to.
The sweetener can be produced by mixing or kneading a stevia-derived sweet substance and finely pulverized cyclodextran.
As the mixing means, those generally used in the technical field can be used without particular limitation.
In addition, in order to achieve uniform blending of stevia-derived sweet substances and finely pulverized cyclodextran in sweeteners, stevia-derived sweet substances and finely pulverized cyclodextran are kneaded in the presence of a wetting agent. It is preferable to dry the kneaded product.
As the wetting agent, water and ethanol are preferable from the viewpoint of safety. The wetting agent can be used alone or in combination of two or more (for example, a mixture of water and ethanol).
As the kneading means, those generally used in the technical field can be used without particular limitation.
As the drying means, those generally used in the technical field can be used without particular limitation.
The sweetener may appropriately contain a sweet substance other than the stevia-derived sweet substance. Examples of sweet substances other than stevia-derived sweet substances include sugar, glucose, fructose, maltitol, xylitol, and erythritol.
In the sweetener, sweet substances other than stevia-derived sweet substances can be used alone or in combination of two or more.

  The sweetener can be used as a sugar substitute sweetener in foods, luxury products, food additives, drugs and the like. In these, it can use suitably for foods with much moisture (For example, drinks, such as coffee and tea, yoghurt, citrus fruits, etc.), especially the food with much moisture which was cooled.

The following can be mentioned as a preferable aspect of the said sweetener.
(Example 1)
100 g of cyclodextran is pulverized with a ball mill at 50 rpm for 30 minutes. The average particle size of the finely pulverized cyclodextran obtained is 30 μm as measured by a wet method using a laser diffraction / scattering particle size distribution analyzer.
1 part by weight of this finely pulverized cyclodextran and 5 parts by weight of a stevia-derived sweet substance are mixed using a vertical granulator for 3 minutes under the conditions of blade: 400 rpm, cross screw: 400 rpm, and contain a stevia-derived sweet substance Get a sweetener. The content of finely pulverized cyclodextran in the stevia-derived sweet substance-containing sweetener is 20% by mass with respect to the mass of the stevia-derived sweet substance.

Tea polyphenols:
In order to suppress the bitter taste of tea polyphenol, a jelly-like food containing 0.1 to 10 parts by weight of cyclodextran with respect to 1 part by weight of tea polyphenol is used.
The concentration of tea polyphenol contained in the jelly-like food is 50 to 1000 mg%, preferably 100 to 800 mg%, and more preferably 150 to 600 mg%. If the tea polyphenol concentration is less than 50 mg%, it will be difficult to enjoy the desired physiological function, and it will be difficult to feel the cool flavor derived from tea. On the other hand, if the tea polyphenol concentration exceeds 1000 mg%, the bitter and astringent taste gives the tongue an unfavorable residual astringent feeling and the palatability is inferior. As a method for adding tea polyphenol to an addition object (liquid), a method using a solution or dispersion of tea polyphenol in water is preferable because tea polyphenol can be uniformly dispersed. The timing of addition may be any stage in the production process as long as it is before gelation.
Tea polyphenols contained in jelly-like foods are preferably those containing 50% by weight or more of catechins that are easily prepared in large quantities and have many physiological effects, and more preferably those containing 70% by weight or more. Preferably, it contains 80% by weight or more. The catechin content in the tea polyphenol can be determined from the catechin content in the tea extract and the tea polyphenol content in the tea extract determined by the above method. The content of catechins in the tea extract was determined by filtering the sample aqueous solution with a 0.45 μm filter and then using HPLC to select 8 types of catechins ((±) -catechin, (−)-epicatechin, (−) −). Epigallocatechin, (±) -gallocatechin, (−)-epicatechin gallate, (−)-catechin gallate, (−)-epigallocatechin gallate, (−)-gallocatechin gallate) Can be obtained as
0.1-10 weight part is preferable with respect to 1 weight part of tea polyphenols, and, as for content of cyclodextran, 1-5 weight part is more preferable. When the content ratio is less than 0.1 parts by weight, the effect of suppressing the bitter and astringent taste of tea polyphenols is hardly exhibited. On the other hand, when the content ratio exceeds 10 parts by weight, the texture tends to be loose and the taste and aroma are blurred.
Examples of the gelling agent contained in the jelly-like food include glucomannan, carrageenan, locust bean gum, xanthan gum, guar gum, gellan gum, tara gum, tragacanth gum, curdlan, nata de coco, gelatin, pectin, sodium alginate, agar and the like. These may be used alone, but when used in combination, a high gel strength may be provided due to a synergistic effect. Glucomannan, in particular, gives strong elasticity and water retention when used in combination with other gelling agents such as carrageenan and xanthan gum, so it can form a gel with excellent disintegration resistance and diffuses bitter and astringent ingredients into the oral cavity. Preventive action is excellent. Factors that affect gel strength include factors that greatly affect the choice of gelling agent, blending ratio, and blending amount, but can be easily adjusted to the desired gel strength by appropriately selecting and adjusting these factors. can do. Examples of use of the gelling agent include, for example, 1 to 1.5 parts by weight of carrageenan per 1 part by weight of glucomannan, and 0.8 to 1.5 parts by weight of xanthan gum per 1 part by weight of glucomannan. By mixing such a gelling agent in water at a ratio of preferably 0.5 to 3 parts by weight, more preferably 0.8 to 2 parts by weight with respect to 100 parts by weight of water. High gel strength can be obtained. In addition, other factors that change the gel strength include the strength of heating, pH, sugar, sodium chloride, etc., depending on the gelling agent used, but generally low pH, too strong heating conditions, Addition of excess sugar or salt may reduce the gel strength and result in a brittle gel.
The gel strength in the jelly-like food is 15000 to 200000 N / m ² , preferably 17500 to 150,000 N / m ² , and more preferably 20000 to 100000 N / m ² . When the gel strength is less than 15000 N / m ² , the gel strength tends to collapse when it is contained in the mouth, and the bitter and astringent components easily diffuse into the oral cavity. On the other hand, when the gel strength exceeds 200,000 N / m ² , the unpleasant odor peculiar to the gelling agent is conspicuous, the flavor of tea and other ingredients is impaired, and the palatability is inferior.
In addition to tea polyphenols, gelling agents and sweetening ingredients, jelly-like foods contain fruit juice, food flavorings, food extracts, alcoholic beverages, pigments, acidulants, pH adjusters, nutrient enhancers, preservatives, etc. Also good. In particular, by adding fruit juices such as citrus fruits exemplified in plum, peach, apricot, grape, muscat, aloe, lychee, apple, grapefruit, berries exemplified in blueberries, and food-like flavors such as fruit-like flavors. The jelly-like food of the present invention, combined with a refreshing flavor derived from tea, exhibits a bitter and astringent taste suppressing effect, and has a refreshing and good flavor. There are no particular restrictions on the amount of fruit juice or flavor used for food, but because of the physical properties of jelly, the ingredients are difficult to volatilize, so the fruit juice is 0.1 to 50% by weight of the jelly food, Although depending on the titer, it is preferable to add about 50 to 1000 ppm as a jelly-like food rich in palatability. In addition, since the flavor of fruit juices and food flavors is likely to deteriorate due to excessive heating, the addition is preferably performed after the gelling agent is heated and dissolved and then cooled to an appropriate temperature. In addition, it is also possible to give a variation in taste by adding food extracts exemplified by palatability drinks such as tea and coffee and extract extracts of other kinds of foods.

The following can be mentioned as a preferable aspect of the said jelly-form food.
(Example 1)
25 parts by weight of liquid sugar (same sweetness as sucrose) and 0.8 parts by weight of gelling agent (containing 24% by weight carrageenan, 22% by weight glucomannan, 6.5% by weight locust bean gum) Water (total amount: 72.3 parts by mass) was added and allowed to swell at room temperature for about 10 minutes after stirring. 0.85 parts by mass of tea extract prepared in advance, 0.85 parts by mass of cyclodextran, anhydrous citric acid Add 0.2 parts by weight of acid. The blend is heated at 80 ° C. for 10 minutes with good stirring and mixing to dissolve the gelling agent, and then cooled to obtain a jelly-like food (tea polyphenol concentration 302 mg%).

Catechin:
In order to make a beverage having a high concentration of catechins and having a good taste, it is a packaged beverage containing a green tea extract containing 30 to 50% by weight of non-polymer catechins, the following ingredients ( A) and (B), (A) 0.092 to 0.5% by weight of non-polymer catechins, (B) oxalic acid, and the weight ratio of components (B) and (A) [(B ) / (A)] is further contained in a packaged beverage having a value of 0.002 to 0.05, cyclodextran.
Non-polymer catechins include non-epithetic catechins such as catechin, gallocatechin, catechin gallate, gallocatechin gallate and epi-catechins such as epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, etc. Is a general term.
The weight ratio [(B) / (A)] of the component (B) and the component (A) of the packaged beverage is 0.002 to 0.05, preferably 0.002 to 0.04, more preferably. Is 0.0025 to 0.03, particularly preferably 0.0025 to 0.02. The content ratio of the components (B) and (A) can be adjusted by purifying the green tea extract. If the ratio of oxalic acid in the green tea extract to be used is too low, umami components other than the non-polymer catechins in the green tea extract will be removed together with oxalic acid, and the taste when blended in a beverage The improvement is not enough. Further, if the ratio of oxalic acid in the green tea extract to be used is too high, it is not preferable because it feels an unpleasant astringency like that felt in a green tea concentrate, and also a beverage without a refreshing feeling.
The packaged beverage contains 0.092 to 0.5% by weight of (A) non-polymer catechins that are non-polymeric and dissolved in water, but preferably 0.1 to 0.00%. The content is 4% by weight, more preferably 0.11 to 0.3% by weight, and particularly preferably 0.12 to 0.3% by weight. When the content of non-polymer catechins is within this range, a large amount of non-polymer catechins can be easily taken and strong bitterness, astringency and strong astringency do not occur. The density | concentration of the said non-polymer catechin can be adjusted with the compounding quantity of a green tea extract.
The green tea extract referred to here is a product obtained by further purifying an extract extracted from tea leaves with hot water or a water-soluble organic solvent, or a product obtained by directly purifying the extracted concentrate. It can be obtained by adjusting the ratio of non-polymer catechins (A) and oxalic acid (B) by applying the methods exemplified in detail in Documents 3 to 5 and the like. Also, using non-polymerized catechins (A) and oxalic acid (B) using green tea concentrates such as commercially available Mitsui Norin Co., Ltd. “Polyphenone”, ITO EN Co., Ltd. “Theafuran”, Taiyo Kagaku Co., Ltd. “Sunphenon” The green tea extract suitable for the purpose of the present invention can also be obtained by adjusting the components of
As a means for purifying the green tea concentrate, for example, a method of suspending the green tea concentrate in a mixture of water and an organic solvent, removing the precipitate generated by adding the organic solvent to the mixture, and then distilling off the solvent; Examples include a method in which a product is dissolved in a mixture of water and an organic solvent, a precipitate generated by adding the organic solvent to the mixture is removed, and then the solvent is distilled off.
Examples of the form of the green tea extract include various forms such as a solid, an aqueous solution, and a slurry.
Examples of green tea include Camellia, such as C.I. sinensis, C.I. Examples include tea leaves made from tea leaves obtained from assamica and Yabita species, or hybrids thereof. The tea leaves produced include green teas such as sencha, bancha, gyokuro, tencha, and kettle roasted tea.
The concentration of oxalic acid is 0.05 to 1.5% by weight, preferably 0.05 to 1.0% by weight, more preferably 0.05 to 0.5% by weight, and particularly preferably 0.08 to 0. 3% by weight is good. When the concentration of oxalic acid in the green tea extract exceeds 1.5% by weight, the influence of other taste components contained in the green tea extract comes to the fore, and a high concentration of non-heavy blended with this Combined catechin beverages tend to have an unpleasant astringency and become a refreshing beverage. When the concentration of non-polymer catechins in the green tea extract is less than 0.05% by weight, umami components other than the non-polymer catechins in the green tea extract tend to be removed together with oxalic acid.
Cyclodextran is contained in the beverage in an amount of 0.01 to 0.5% by weight, preferably 0.01 to 0.3% by weight.
The pH of the beverage is preferably 2 to 7, preferably 3 to 7, more preferably 5 to 7 at 25 ° C. in view of the chemical stability of the non-polymerized catechins.
In a packaged beverage, in accordance with ingredients derived from tea, ingredients that may be added in the formulation include antioxidants, fragrances, various esters, organic acids, organic acid salts, inorganic acids, inorganic acid salts, inorganic salts, Additives such as pigments, emulsifiers, preservatives, seasonings, sweeteners, acidulants, fruit juice extracts, vegetable extracts, nectar extracts, pH adjusters, quality stabilizers, etc. alone or in combination Also good.
Examples of the sweetener include sugar, glucose, fructose, isomerized liquid sugar, glycyrrhizin, stevia, aspartame, fructooligosaccharide, galactooligosaccharide and the like. Examples of acidulants include fruit juices extracted from natural ingredients, citric acid, tartaric acid, malic acid, lactic acid, fumaric acid, and phosphoric acid. The beverage should contain 0.01 to 0.5% by weight, preferably 0.01 to 0.3% by weight.
Examples of inorganic acids and inorganic acid salts include phosphoric acid, disodium phosphate, sodium metaphosphate, and sodium polyphosphate. The beverage should contain 0.01 to 0.5% by weight, preferably 0.01 to 0.3% by weight.
Containers used for packaged beverages are usually molded containers (so-called PET bottles) mainly composed of polyethylene terephthalate, metal cans, paper containers combined with metal foil or plastic film, bottles, etc. Can be provided. The term “packaged beverage” as used herein means a beverage that can be drunk without dilution.
Container-packed beverages are produced under the sterilization conditions stipulated in the Food Sanitation Law if they can be sterilized by heating after filling the containers like metal cans, for example. For PET bottles and paper containers that cannot be sterilized by retort, sterilize under the same conditions as above, for example, after sterilizing at high temperature and short time with a plate heat exchanger, etc. The method is adopted. Moreover, you may mix | blend another component with the filled container under aseptic conditions. Furthermore, after sterilization by heating under acidic conditions, the pH can be returned to neutrality under aseptic conditions, or after sterilization by heating under neutral conditions, the pH can be returned to acidic conditions under aseptic conditions.
The above-mentioned packaged beverage is a beverage containing the specific green tea extract, and the purified product is blended with a tea extract selected from green tea, semi-fermented tea and fermented tea; and non-tea beverages Is mentioned. Among these, a beverage in which the purified product is blended with the tea extract is preferable, and a green tea beverage in which the purified product is blended with the green tea extract is particularly preferable. Semi-fermented tea includes oolong tea, and fermented tea includes black tea. Examples of non-tea beverages include soft drinks such as carbonated drinks, fruit extract drinks, vegetable extract juices, near water, sports drinks, and diet drinks.

The following can be mentioned as a preferable aspect of the said packaged drink.
(Example 1)
3.98% by mass of purified green tea extract, 1.48% by mass of dried green tea extract, 2.5% by mass of cyclodextran, 0.3% by mass of sodium ascorbate, and an appropriate amount of sodium bicarbonate A predetermined post-treatment is performed to obtain a packaged beverage having a pH of 6.2.

Green tea flavor:
(A) Epigallocatechin gallate 0.01 to 0.1% by mass, (B) methyl Cyclodextran is further contained in the container-packed black tea beverage containing the catechins and having a mass ratio [(A) / (B)] of component (A) to component (B) of 1 to 100.
Epigallocatechin gallate is an ester of epigallocatechin and gallic acid, and specifically refers to epigallocatechin-3-O-gallate. Epigallocatechin gallate is a kind of non-polymer catechins abundantly contained in tea leaves, but in tea leaves, epigallocatechin gallate is converted to thealvidin by the fermentation process, so epigallocatechin gallate is mostly included. Absent.
The content of epigallocatechin gallate is 0.01 to 0.1% by mass, but from the viewpoint of strengthening epigallocatechin gallate, 0.02% by mass or more is preferable, 0.03% by mass or more is more preferable, and 0 0.035% by mass or more is more preferable, and from the viewpoint of suppressing green tea flavor and imparting a refreshing black tea taste, 0.9% by mass or less is preferable, 0.8% by mass or less is more preferable, and 0.7% by mass or less. Is even more preferred. The range of the content of such epigallocatechin gallate is preferably 0.02 to 0.9% by mass, more preferably 0.03 to 0.8% by mass in the packaged black tea beverage, Preferably it is 0.035-0.7 mass%. The content of epigallocatechin gallate can be analyzed by liquid chromatography, LC / MS, or the like, and can be specifically measured by the method described in the examples below.
Methylated catechins include epigallocatechin-3-O- (3-O-methyl) gallate, epicatechin-3-O- (3-O-methyl) gallate, epicatechin-3-O- (4-O -Methyl) gallate and epigallocatechin-3-O- (4-O-methyl) gallate are generic names. In the present invention, at least one of the above four types of methylated catechins may be contained, but all four types are preferably contained.
The content of methylated catechin is preferably 0.0005% by mass or more, more preferably 0.0008% by mass or more, still more preferably 0.002% by mass or more, from the viewpoint of imparting a clean black tea taste. 0.05 mass% or less is preferable, 0.008 mass% or less is more preferable, and 0.007 mass% or less is still more preferable. The range of the content of the methylated catechin is preferably 0.0005 to 0.05% by mass, more preferably 0.0008 to 0.008% by mass in the packaged black tea beverage of the present invention. More preferably, the content is 0.002 to 0.007% by mass.
The content of methylated catechin is preferably 0.0005 to 0.05% by mass, more preferably 0.0008 to 0.04% by mass in the packaged black tea beverage from the viewpoint of suppressing green tea flavor. More preferably, it is 0.005-0.03% by mass.
In addition, content of methylated catechin is defined based on the total amount of said 4 types of methylated catechin. Further, the content of methylated catechin can be analyzed by liquid chromatography, LC / MS, or the like, and specifically, can be measured by the method described in Examples below.
The mass ratio [(A) / (B)] of the component (A) and the component (B) in the packaged black tea beverage is 1 to 100, but from the viewpoint of imparting a more neat tea taste. 4 or more is preferable, 7 or more is more preferable, 9 or more is further preferable, 10 or more is particularly preferable, 90 or less is preferable, 80 or less is more preferable, 70 or less is further preferable, and 60 or less is particularly preferable. . The range of the mass ratio [(A) / (B)] is preferably 4 to 90, more preferably 7 to 80, and still more preferably 9 to 70, in the packaged black tea beverage. Most preferably, it is 10-60.
The mass ratio [(A) / (B)] of the component (A) and the component (B) in the packaged black tea beverage is preferably 2 to 60, more preferably 3 from the viewpoint of suppressing the green tea flavor. -10.
The packaged black tea beverage contains cyclodextran as the component (C). The content of the cyclodextran is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, still more preferably 0.3% by mass or more, and more preferably 0.4% by mass or more from the viewpoint of improving the flavor. More preferably, it is preferably 5% by mass or less, more preferably 4% by mass or less, further preferably 3% by mass or less, and particularly preferably 2% by mass or less. The range of the content of cyclodextran is preferably 0.05 to 5% by mass, more preferably 0.1 to 4% by mass, and still more preferably 0.3 to 5% in a packaged black tea beverage. It is 3% by weight, and more preferably 0.4-2% by weight.
In addition, content of cyclodextran can be measured with the following method. That is, the sample is filtered through a membrane filter (pore diameter 0.8 μm), and measured at a column temperature of 80 ° C. using a high performance liquid chromatograph. The mobile phase is distilled water, the flow rate is 0.6 mL / min, the sample injection volume is 10 μL, and the detector is RI. The content of cyclodextran is calculated from a calibration curve using a standard product.
The mass ratio [(C) / (A)] of the component (A) and the component (C) in the packaged black tea beverage is preferably 1 or more, more preferably 5 or more, from the viewpoint of improving the flavor. Is more preferably, 15 or more, particularly preferably 100 or less, more preferably 80 or less, still more preferably 70 or less, and still more preferably 60 or less. The range of the mass ratio [(C) / (A)] is preferably 1 to 100, more preferably 5 to 80, and still more preferably 10 to 70 in the packaged black tea beverage of the present invention. And most preferably 15-60.
The containerized tea beverage may contain caffeine as the component (D), but from the viewpoint of imparting a more refreshing tea taste, the content of caffeine is contained in the containerized tea beverage. It is preferable to set it as 0.03 mass% or less, 0.02 mass% or less is more preferable, and 0.015 mass% or less is still more preferable. In addition, although 0 mass% may be sufficient as content of this caffeine, from a viewpoint of production efficiency, 0.001 mass% or more is preferable and 0.005 mass% or more is still more preferable.
The content of caffeine in the packaged black tea beverage is preferably 0.03% by mass or less in the packaged black tea beverage from the viewpoint of suppressing the green tea flavor, and the content of caffeine is 0.017 mass. % Or more is preferable.
The content of caffeine can be analyzed by liquid chromatography, LC / MS or the like, and specifically can be measured by the method described in the examples below.
The mass ratio [(D) / (A)] of the component (A) and the component (D) in the packaged black tea beverage is preferably 2 or less from the viewpoint of imparting an even cleaner tea taste. The following is more preferable, 0.8 or less is further preferable, and 0.7 or less is particularly preferable. The mass ratio [(D) / (A)] may be 0, but is preferably 0.1 or more, and more preferably 0.2 or more, from the viewpoint of production efficiency.
The mass ratio [(D) / (A)] of the component (A) and the component (D) in the packaged black tea beverage is preferably 2 or less, more preferably 1 or less, from the viewpoint of suppressing the green tea flavor. .8 or less is more preferable. The mass ratio [(D) / (A)] may be 0, but is preferably 0.1 or more, more preferably 0.2 or more, and 0.45 or more from the viewpoint of suppressing green tea flavor. Even more preferred.
In addition, packaged black tea beverages are optionally sweeteners, flavors, vitamins, minerals, excipients, antioxidants, esters, fruit juices, fruit pieces, fruit powders, organic acids, organic acid salts, inorganic acids, inorganic acid salts. In addition, one or more additives such as a pH adjuster and a quality stabilizer can be contained. In addition, the compounding quantity of an additive can be suitably selected within the range which does not disturb the objective of this invention.
The pH (20 ° C.) of the packaged black tea beverage is preferably 2 or more, more preferably 2.5 or more, still more preferably 3.0 or more, particularly preferably 3.1 or more, and 7 or less from the viewpoint of flavor. Is preferably 6.5 or less, more preferably 6.4 or less, and particularly preferably 6.3 or less. The pH range is preferably 2 to 7, more preferably 2.5 to 6.5, still more preferably 3.0 to 6.4, and even more preferably 3.1 to 6 .3. In addition, pH shall be measured by measuring about 100 mL of packaged black tea drinks in a 300 mL beaker and adjusting the temperature.
The container-packed black tea beverage contains, for example, the components (A) and (B), and other components as desired, and the content of the component (A) and the mass ratio [(B) / (A)] are within a specific range. It can be manufactured by adjusting.
Container-packed black tea beverages are provided by filling ordinary packaging containers such as molded containers (so-called PET bottles), metal cans, and bottles mainly composed of polyethylene terephthalate.
Container-packed black tea beverages may be heat sterilized, and the heat sterilization method is not particularly limited as long as it conforms to the conditions stipulated in applicable laws and regulations (the Food Sanitation Law in Japan). It is not something. Examples thereof include a retort sterilization method, a high temperature short time sterilization method (HTST method), an ultra high temperature sterilization method (UHT method), and a post-filling sterilization method (pastration).
It is also possible to select a heat sterilization method as appropriate. For example, after filling a container with a beverage, such as a metal can or a bottle, the container can be heat sterilized (for example, 60 to 140 ° C., 1 to 60 minutes). In that case, retort sterilization or post-filling sterilization (pasting) can be employed. In the case of pasteurization after filling, for example, the pasteurization can be performed by heat sterilization at 65 ° C. for 1 to 60 minutes, preferably at 65 ° C. for 5 to 30 minutes, and more preferably at 65 ° C. for 10 to 20 minutes.
Moreover, about what cannot retort sterilize like a PET bottle, a drink is previously sterilized equivalent to the above (for example, 65-140 degreeC for 0.1 second-30 minutes, Preferably it is 70-125 degreeC for 1 second-25 minutes. More preferably, aseptic filling, hot-pack filling, or the like that is sterilized by heating at 75 to 120 ° C. for 10 seconds to 20 minutes and filled in a sterilized container in an aseptic environment can be employed.

The following can be mentioned as a preferable aspect of the said packaged black tea beverage.
18 g of black tea leaves are put into hot water at 98 ° C. and 1000 g, stirred at 300 rpm for 3 minutes, and filtered through No. 2 filter paper to obtain a black tea extract. After preparing a tea beverage of 18% by weight of black tea extract, 1% by weight of purified green tea extract and 0.9% by weight of cyclodextran, it is filled into a 200 mL PET bottle and sterilized by heating (post-mix method). Get an instrumented tea drink. Sterilization conditions are 65 ° C. and 20 minutes.

Yeast extract:
In order to make the flavor last longer even if the liquid seasoning containing soup is heated for a long time, a liquid seasoning is prepared by combining ascorbic acid, a salt or ester thereof, cyclodextran, and yeast extract.
As ascorbic acid, L-ascorbic acid is preferable. As the salt of ascorbic acid, alkali metal salts of ascorbic acid such as sodium ascorbate and potassium ascorbate are preferable. Examples of the ester of ascorbic acid include ascorbic acid fatty acid esters such as ascorbic acid stearic acid ester and ascorbic acid palmitic acid ester, and ascorbic acid phosphoric acid ester. Further, ascorbic acid (vitamin C) is contained in citrus fruit juice and the like, and the fruit juice may be used. Of these, L-ascorbic acid, L-ascorbate, and L-ascorbic acid ester are preferably used, and L-ascorbic acid is particularly preferably used in terms of flavor.
The content of ascorbic acid in the liquid seasoning is 0.02 to 0.02 in terms of the concentration of ascorbic acid as a concentration at the time of eating or using, from the viewpoint of the balance between the long-lasting effect and the chemical odor and egg flavor unique to ascorbic acid. 3 mass% is preferable, 0.06-0.25 mass% is more preferable, 0.07-0.20 mass% is further more preferable. Here, the concentration at the time of eating or using means that the normal liquid seasoning is not eaten as it is, but diluted and used, and thus means the concentration after dilution. For example, when the liquid seasoning for soup is an 8-fold concentrated type, it is eaten or used at a concentration diluted 8 times, that is, a 1-fold concentration (straight conversion).
The content of cyclodextran is preferably 0.05 to 0.5% by mass as a concentration at the time of eating or using from the point of balance of flavor lasting effect, feeling of soy sauce, strength of soy sauce, and thickness of taste. 0.1 to 0.4 mass% is more preferable, and 0.15 to 0.4 mass% is more preferable.
The yeast extract may be any extract extracted from yeast as a raw material, for example, yeast that has been subjected to self-digestion, enzyme treatment, hydrothermal treatment, acid or alkali hydrolysis, cell membrane destruction treatment, etc. What collected the liquid part from the processed material may be used. As yeast to be used, any of brewer's yeast, baker's yeast, torula yeast, etc. or a mixture thereof may be used.
The content of the yeast extract is preferably 0.003 to 2.5% by mass in terms of the solid content of the yeast extract as a concentration at the time of eating or using, from the viewpoint of the balance of flavor lasting effect, raw odor, and thickness of taste. 0036-2.0 mass% is more preferable, and 0.006-2.0 mass% is more preferable.
The content ratio of ascorbic acid, a salt or ester thereof, cyclodextran, and yeast extract is 0.4 to 4 for cyclodextran with respect to 1 part by mass of ascorbic acid from the viewpoint of long-lasting effect of flavor and balance of taste. The mass part, the yeast extract (solid content) is preferably 0.02 to 20 parts by mass, the cyclodextran is preferably 0.8 to 3.2 parts by mass, the yeast extract is more preferably 0.05 to 16 parts by mass, and the cyclodextran. 1.2 to 3.2 parts by mass of the kind, and 0.05 to 12 parts by mass of the yeast extract are more preferable.
The liquid seasoning is preferably a dashi-containing liquid seasoning, more preferably a dashi-containing soy sauce-based liquid seasoning. Here, the soy sauce-type liquid seasoning containing dashi means a liquid seasoning containing soy sauce and soy sauce, and examples include soups described below.
As the raw material for the soup stock used in the liquid seasoning, those using seafood are preferred among those used for soup stock. For example, crushed or shaved buns such as bonito, soda bun, bonito, bonito, bonito, bonito, etc. Use one or more types. In addition to this, seaweeds such as kelp, mushrooms such as shiitake mushrooms, cows, pigs, chickens and the like may be additionally used.
The soy sauce used in the liquid seasoning is not particularly limited, and either raw soy sauce or fired soy sauce may be used, and normal soy sauce such as dark soy sauce, light soy sauce, re-prepared soy sauce, tame soy sauce, etc. Any of these soy sauces subjected to membrane treatment such as ultrafiltration and microfiltration may be used, or one or more of these may be used. In particular, deep-sealed soy sauce is preferably used.
As the liquid seasoning, mirin, fermented seasoning, sweet sugar, salt and the like can be used depending on the application. The mirin and fermented seasoning may be those used for ordinary soy sauce and sauces. For example, in addition to the usual main mirin, an alcoholic-containing sweet seasoning is used.
Examples of the sweet saccharide include sugar, maltose, fructose, isomerized liquid sugar, glucose, syrup, sugar alcohols such as dextrin, sorbitol, maltitol, and xylitol. In addition, sweeteners such as glycyrrhizin, stevioside, aspartame, sucralose are also used, and these sweet saccharides, sweeteners and the like are used alone or in combination of two or more.
Further, liquid seasonings include umami seasonings such as protein hydrolysates, amino acid seasonings such as glycine, alanine and sodium glutamate, nucleic acid seasonings such as sodium inosinate and sodium guanylate, sodium succinate, etc. An organic acid seasoning may be contained.
The blending time of each component in the liquid seasoning is not particularly limited, but it is preferably blended before the heating step by sterilization or the like.
Liquid seasoning forms include soups (including soups used for noodles, salmon soup, boiled soup, tempura soup, hot pot soup, etc.), boiled seasonings, soup, and cooked rice Elemental etc. are included.

The following can be mentioned as a preferable aspect of the said liquid seasoning.
(Example 1)
150 parts of bonito are added to 900 parts of boiling hot water, heated for 30 minutes, filtered through a filter cloth, cooled, and water is added to make 900 parts to produce a stock. To 200.0 parts by mass of soy sauce, 180.0 parts by mass of soy sauce, 160.0 parts by mass of sugar, 90.0 parts by mass of sodium chloride, 45.0 parts by mass of seasonings (such as glutamic acid), 0.3 parts by mass of yeast extract, Add 2.0 parts by mass of cyclodextran, 2.0 parts by mass of vitamin C, and 321 parts by mass of water, mix and dissolve, hold at 60 ° C. for 60 seconds, cool with water, and add liquid seasoning (8 times) Concentrated soup).

Aspirin, naproxen sodium, acetaminophen, ibuprofen, diprofloxacin:
A water-resistant pharmaceutical composition for masking the unpleasant taste of therapeutic agents such as aspirin, naproxen sodium, acetaminophen, ibuprofen, diprofloxacin and the like, comprising aspirin, naproxen sodium, acetaminophen, ibuprofen, diprof Loxacin and an unpleasant taste masking agent having cyclodextran are contained in a water-resistant pharmaceutically acceptable gel matrix, wherein the water-resistant pharmaceutically acceptable gel matrix has a polysaccharide. A water resistant pharmaceutical composition having an ion specific gel, preferably gellan.
Components other than the cyclodextran as an unpleasant taste masking agent include, for example, aspartame, compressed sugar, dextreate, lactose, mannitol, sucrose, maltose, sodium saccharin, sorbitol, and sweeteners such as xylitol, nanolipid particles and flavoring agents. Can be mentioned.
In certain preferred embodiments relating to water resistant pharmaceutical compositions, the unpleasant taste masking agent comprises cyclodextran. In some preferred embodiments, the cyclodextran forms a complex or chelate with the therapeutic agent. Typically, these complexes can be represented as a 1: 1 host-guest complex. Some general guidelines are useful for providing at least a portion of the complex formed in the composition of the invention. The molar ratio of cyclodextran (ie other host molecule) to the therapeutic agent (ie guest molecule) in this composition or the method of producing the complex of cyclodextran and therapeutic agent is not important, but the host: guest A molar ratio of about 20: 1 to 1:20 is typically utilized. A preferred ratio is about 1:10 to about 10: 1, more preferably about 1: 5 to about 5: 1, more preferably about 2: 1 to about 1: 2, Used. In theory, a molar ratio of cyclodextran: therapeutic agent of 1: 1 is sufficient to prepare a complex in which the preparation solution contains substantially all of the therapeutic agent, but in some embodiments Then, it is preferable to add at least a slight excess of the host molecule to increase the likelihood that substantially all of the guest therapeutic will form a complex. Such complex formation helps to improve the stability, solubility, and / or taste masking of the therapeutic agent. For general guidance purposes, the cyclodextran is typically about 10%, 20, 30, 50, 75, or even 100% molar excess of the cyclodextran on a molar basis relative to the therapeutic agent. Substantially all of the therapeutic agents in the class will be sufficient to form a complex. In certain other embodiments, the cyclodextran: therapeutic agent molar ratio is about 1.8: 1 to about 1: 1.8, more preferably about 1.5: 1 to about 1: 1.5, still more Preferably, 1.25: 1 to about 1: 1.25 are utilized, more preferably about 1.1: 1 to about 1: 1.1.
The water resistant pharmaceutical composition has masked the unpleasant taste of therapeutic agents such as aspirin, naproxen sodium, acetaminophen, ibuprofen, diprofloxacin and the like.

Conductive polymer solution:
In order to improve the gas / liquid permeability of the conductive polymer composition, a conductive polymer liquid containing a conductive polymer, a dopant, a cyclodextran, and a solvent or a dispersion medium is used.
The conductive polymer liquid includes a conductive polymer, a dopant, a compound that can include other molecules, and a solvent or a dispersion medium (hereinafter, also collectively referred to as “liquid medium”). In the present specification, the “conductive polymer liquid” means that the conductive polymer is completely dissolved or dispersed in the main solvent or the main dispersion medium. The conductive polymer liquid is preferably in a dissolved state or a stable dispersed state, but may be in a temporarily dispersed state by mechanical stirring. The conductive polymer solution is suitable as a conductive polymer solution for electrolytic capacitors.
Examples of the conductive polymer contained in the conductive polymer solution include polypyrrole, polythiophene, polyaniline, and derivatives thereof. Among these, poly (3,4-ethylenedioxythiophene) or a derivative thereof is preferable. The conductive polymer may be a homopolymer or a copolymer. Moreover, 1 type may be used independently and 2 or more types may be used together.
The content of the conductive polymer in the conductive polymer liquid is preferably 0.1 to 30 parts by mass, and more preferably 0.5 to 20 parts by mass with respect to 100 parts by mass of the liquid medium.
The dopant is not particularly limited as long as at least a part of the conductive polymer is doped to develop conductivity. Examples thereof include inorganic acids, low molecular sulfonic acids or salts thereof, low molecular carboxylic acids or salts thereof, polyacids containing sulfonic acids and carboxylic acids, or salts thereof. These may be used alone or in combination of two or more.
Examples of the inorganic acid include proton acids such as sulfuric acid, nitric acid, phosphoric acid, perchloric acid, tetrafluoroboric acid, and hexafluorophosphoric acid.
Examples of the low molecular sulfonic acid include alkyl sulfonic acid, benzene sulfonic acid, naphthalene sulfonic acid, anthraquinone sulfonic acid, camphor sulfonic acid, and derivatives thereof.
Examples of the low molecular carboxylic acid include acetic acid, propionic acid, acrylic acid, methacrylic acid, maleic acid, succinic acid, citric acid, benzoic acid, phthalic acid, and isophthalic acid.
Examples of the polyacid include polycarboxylic acids such as polyacrylic acid, polymethacrylic acid, and polymaleic acid; polysulfonic acids such as polyvinyl sulfonic acid and polystyrene sulfonic acid; and copolymers having these structural units. Of these, polystyrene sulfonic acid is preferable.
It is preferable that the addition amount of a dopant is 40-5000 mass parts with respect to 100 mass parts of conductive polymers, and it is more preferable that it is 200-1000 mass parts. When the amount of the dopant is 40 to 5000 parts by mass with respect to 100 parts by mass of the conductive polymer, sufficient conductivity and dispersibility can be obtained.
The conductive polymer solution may further contain a compound that can include other molecules.
A compound that can include other molecules is defined as a compound that can include other molecules than itself. The compound that can include other molecules is not particularly limited as long as it is a substance that can include other molecules than itself. Examples thereof include macrocyclic compounds having 12 or more members such as crown ether, calixarene, calixresorcinarene, calic spirol, thiacalixarene, homooxacalixarene, and derivatives thereof.
A substance that can be incorporated into a compound that can incorporate other molecules differs depending on the difference in hydrophilicity / hydrophobicity between the inside of the compound and the substance to be incorporated, or the size of pores inside the compound. Therefore, a suitable material may be appropriately selected depending on the substance to be incorporated into the compound.
The conductive polymer solution contains a compound that can include other molecules, which improves the gas / liquid permeability of the resulting conductive polymer membrane, and allows water and electrolyte to reach the dielectric surface where the defect exists. Can be reached. As a result, the chemical conversion ability is exhibited and the leakage current is reduced. Further, since the gas permeability is improved, peeling due to the internal gas can be suppressed, so that it is possible to suppress an increase in ESR during reflow.
A solid electrolyte layer containing a conductive polymer composition obtained by drying the conductive polymer solution is formed, but it is preferable to penetrate the conductive polymer film with a compound that can include the other molecules. That is, the length of the compound that can include other molecules (L) is a certain ratio or less with respect to the thickness of the conductive polymer film used (the thickness of the solid electrolyte layer, T). It is preferable. When the length L of the compound that can include other molecules with respect to the film thickness T of the conductive polymer film is a ratio of a certain value or less, the content of the compound that can include other molecules can be reduced. It is possible to prevent a decrease in electrical conductivity and a decrease in film strength of the molecular composition.
The ratio (T / L) between the thickness T of the conductive polymer film and the length L of the compound capable of including other molecules is preferably 10,000 or less, more preferably 4000 or less, and 100 or more. It is especially preferable that it is 4000 or less. When the ratio between the conductive polymer film thickness and the length of the compound that can include other molecules is larger than 10,000, it becomes difficult to connect the compounds that can include other molecules, A compound capable of incorporating a large amount of other molecules is required. As a result, the conductivity is deteriorated. In the present invention, the length L of the compound that can include other molecules can be measured using, for example, an atomic force microscope (AFM), a scanning tunneling microscope (STM), or the like.
As a method of setting the length of the compound that can include other molecules to a certain ratio or less with respect to the film thickness of the conductive polymer film, for example, a compound that can include other molecules is cross-linked using a cross-linking agent. To increase the length of the compound that can include other molecules. Crosslinking between compounds that can include other molecules may be achieved by bonding each functional group by a known method, but as an efficient method of crosslinking, for example, inclusion complexes can be formed in compounds that can include other molecules. And a method of crosslinking a compound that can be included after the linear polymer has been included.
The solvent or dispersion medium is not particularly limited as long as it dissolves the conductive polymer. Specifically, water, methanol, ethanol, propanol, acetic acid and other protic polar solvents; ethylene glycol, N-methyl Examples include aprotic polar solvents such as -2-pyrrolidone, N, N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and acetone. These may be used alone or in combination of two or more.
The pH of the conductive polymer solution is not particularly limited as long as it does not inhibit the crosslinking reaction, but is preferably 1 to 12 from the viewpoint of suppressing dedoping from the conductive polymer. Moreover, when using for an aluminum electrolytic capacitor, it is preferable to make pH of a conductive polymer liquid into 3 or more from a viewpoint of preventing the raise of the leakage current by melt | dissolution of an aluminum oxide film.
The pH can be adjusted using an acid, an alkali, a pH buffering agent, or the like.
The acid is not particularly limited, but examples thereof include carboxylic acids such as acetic acid, citric acid, phthalic acid, and succinic acid, phosphoric acid, boric acid, sulfuric acid, nitric acid, hydrochloric acid, alkylsulfonic acid, benzenesulfonic acid, Examples thereof include naphthalene sulfonic acid, anthraquinone sulfonic acid, camphor sulfonic acid, polystyrene sulfonic acid, polyacrylic acid, and derivatives thereof.
Examples of the alkali include, but are not limited to, alkali metals such as sodium hydroxide, potassium hydroxide, and calcium hydroxide; aliphatic amines such as ammonia, ethylamine, diethylamine, methylethylamine, triethylamine, and derivatives thereof. , Aniline, benzylamine, pyrrole, imidazole, pyridine and other aromatic amines or derivatives thereof, or metal alkoxides.
Examples of pH buffering agents include aminoethanesulfonic acid, aminopropanesulfonic acid,
Tris, tricine or glycine, or a derivative thereof can be used.
The conductive polymer solution may contain a polyhydric alcohol. Examples of the polyhydric alcohol include ethylene glycol, butylene glycol, propylene glycol, 3-methyl-1,3-butanediol, hexylene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, inositol, xylose, glucose, mannitol, trehalose. Erythritol, xylitol, sorbitol, pentaerythritol, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, and derivatives thereof.
The polyhydric alcohol is preferably trivalent or more, and more preferably erythritol or pentaerythritol. A resin obtained by polycondensation of a trivalent or higher water-soluble polyhydric alcohol and a later-described polyvalent carboxylic acid has a crosslinked structure, and thus has excellent film strength. In addition, erythritol and pentaerythritol interact with undoped polyacid anions (resistance component) existing in the vicinity of the conductive polymer particles in the conductive polymer liquid, thereby causing resistance between the conductive polymer particles. In addition, the conductivity of the conductive polymer is increased and the conductivity can be further increased.
Since erythritol has higher crystallinity than, for example, sorbitol, maltose, etc., it has low hygroscopicity and is easy to handle. Erythritol is known as a food additive used as a sweetener and is excellent in safety and stability. Furthermore, erythritol is also several times higher in solubility in water than ethylene glycol, glycerin, and the like, and has an advantage that the degree of freedom in designing the addition amount is high.
Pentaerythritol has the characteristic of gradually subliming when heated and dehydrating and polymerizing when heated above its melting point. Therefore, the addition of pentaerythritol has the advantage that the physical properties of the organic material change, and the density and strength are improved. Such a change in physical properties is caused by the chemical structure of pentaerythritol, and, for example, hardly occurs when erythritol or sorbitol is used.
The conductive polymer solution may contain a polyvalent carboxylic acid. The polyvalent carboxylic acid is not particularly limited, but ortho-phthalic acid, hemimellitic acid, trimesic acid, merophanic acid, benzenepentacarboxylic acid, melittic acid, 4-sulfophthalic acid, and 1,4-naphthalenedicarboxylic acid. 2,3-naphthalenedicarboxylic acid, 2,6-naphthalenedicarboxylic acid, 1,8-naphthalenedicarboxylic acid anhydride 3-hydroxy-2,7-naphthalenedicarboxylic acid, 4-chloro-1,8-naphthalenedicarboxylic acid anhydride , Aromatic compounds such as 4-sulfo-1,8-naphthalenedicarboxylic acid anhydride, naphthalene-1,4,5,8-tetracarboxylic acid and derivatives thereof; 2,3-anthracene dicarboxylic acid anhydride Having anthracene ring: naphthacene, pentacene, benzopyrene, chrysene, pyrene, triphenyl Examples thereof include carboxylated polycyclic aromatic hydrocarbons such as len, corannulene, coronene, and ovalen, and derivatives thereof.
When the conductive polymer solution contains a polyhydric alcohol and a polyvalent carboxylic acid, the polyhydric alcohol and the polyvalent carboxylic acid can be dissolved in a liquid medium and chemically reacted in the drying process. The conductive polymer composition obtained by drying contains a water-insoluble resin without uneven distribution, so that a conductive polymer composition having excellent adhesion to a substrate and film strength can be obtained.
The conductive polymer liquid may contain a flame retardant. Since the electrolytic capacitor contains a tantalum sintered body and an organic solvent, an electrolytic capacitor having self-extinguishing performance is desired. By adding a flame retardant, it is preferable because self-extinguishing performance can be imparted to the electrolytic capacitor.
The flame retardant is not particularly limited as long as it is dispersed by using a compound that can include other molecules and does not adversely affect the device. For example, bromine compounds such as pentabromodiphenyl ether, octabromodiphenyl ether, decabromodiphenyl ether (DBDPE, DBDPO), tetrabromobisphenol A (TBBPA), hexabromocyclododecane (HBCD), hexabromobenzene; trimethyl phosphate, trihexyl phosphate Phosphoric esters such as tri-n-butyl phosphate, triethyl phosphate, methyl polyphosphate, poly-n-butyl phosphate, ethyl polyphosphate and tricresyl phosphate, phosphorus compounds such as red phosphorus, phosphazene and polycyclophosphazene Chlorinated compounds such as chlorinated paraffin; antimony compounds such as antimony trioxide and antimony pentoxide; metal hydroxides such as aluminum hydroxide and magnesium hydroxide; nitrogenation such as melamine cyanurate Thing, and the like.
These flame retardants may be incorporated into a compound that can include other molecules before the compound is dispersed or dissolved in the conductive polymer solution, and the conductive polymer composition is dried by drying the conductive polymer solution. May be incorporated into the compound after preparation. The flame retardant can be dispersed or dissolved in the conductive polymer liquid by incorporating a suitable other molecule into the compound that can be incorporated. In addition, when the conductive polymer solution is dried and the flame retardant is incorporated into a compound that can include other molecules, a high flame retardant effect is expected by incorporating the flame retardant into the conductive polymer composition. it can.
The conductive polymer composition can be obtained by drying the conductive polymer solution and removing the liquid medium. The drying temperature is not particularly limited as long as it is not higher than the decomposition temperature of the conductive polymer, but is preferably 300 ° C. or lower, and more preferably 50 ° C. or higher and 200 ° C. or lower.
The conductive polymer composition is suitable as a conductive polymer composition for electrolytic capacitors.

The following can be mentioned as a preferable aspect of the said conductive polymer composition.
(Example 1)
An aqueous dispersion of PEDOT / PSS (polyethylenedioxythiophene doped with polystyrene sulfonic acid as a dopant) was prepared so that the solid content was 1% by mass. 100 g of the prepared PEDOT / PSS aqueous dispersion is weighed into a glass beaker, 0.1 g of cyclodextran is added and sufficiently stirred to obtain a conductive polymer solution.

Absorbent articles:
In order to increase the contact efficiency between the fragrance and the body fluid and to generate an aroma effectively with a small amount of fragrance, and to obtain an absorbent article with a simplified manufacturing process, a wet paper is formed from the raw material, After adding cyclodextran containing perfume to the paper, a paper making process for obtaining a pulp original sheet through dehydration and drying of the wet paper, and depulverizing the pulp original sheet, The manufacturing method of the absorbent article characterized by including the process of manufacturing the absorbent article which manufactures an absorber by carrying out a fiber.
Absorbent articles are absorbent made of cotton-like pulp between a liquid-permeable top sheet made of perforated or non-porous nonwoven fabric or perforated plastic sheet, and a liquid-impervious leak-proof sheet made of polyethylene or the like. The structure includes a body interposed, and specifically, disposable diapers, urine collection pads, incontinence pads, sanitary napkins and the like can be exemplified.
In the present absorbent article, the absorbent body is constituted by defibrating the pulp original fabric sheet obtained in the paper making process and stacking the defibrated pulverized pulp, and the pulp before defibration. By adding a fragrance to the raw fabric sheet, the fragrance is added to the absorber.
As the fragrance, it is preferable to use a fragrance that emits a scent only upon contact with a body fluid and hardly scents before contact. Specifically, the fragrance component itself reacts with moisture to smell. It is possible to use a material that emits fragrance, a material in which a fragrance is included in an inclusion material, or the like. Among these, while preventing the loss of fragrance due to volatilization, the fragrance is kept low before use, the fragrance is strongly generated from use to after use, and the absorption with scent that emits masking and harmonized effect In order to satisfy the quality required for the article, it is preferable that the fragrance is included in the inclusion substance. This fragrance is added to the absorber by a predetermined method.
As said fragrance | flavor, either a natural fragrance | flavor and a synthetic | combination fragrance | flavor may be used and you may use combining these. Specific examples of the fragrances include Ryusen Incense, Benzo Incense, Sea Mochi Incense, Spirited Cat Incense, Clove Oil, Galvanam, Jasmine Absolute, Labanam, Mate Tea, Merilot, Mimosa, Musk Tonkin, Myrrh, Oak Moss or Moss de Chine, Milk Incense, Bikushi Incense, Natural flavors such as Oris, Bachuri, Rosemary oil, sandalwood oil, vetiver oil, violet leaf absolute, higher alcohol, aldehyde, benzaldehyde, benzoic acid, cinnamic acid, cinnamic aldehyde, cinnamon alcohol, coumarin, ester, indole, Examples include various synthetic fragrances such as ketone, salicylic acid and related compounds, terpenoids, vanillin, and mixtures of two or more thereof, but are not limited thereto. Commercially available products can be widely used as fragrances. The fragrance is preferably a highly volatile fragrance.
In addition, as the fragrance, it is possible to use a fragrance that has a deodorizing effect on the fragrance itself, or a harmonized fragrance that generates a new scent that does not feel unpleasant in harmony with the unpleasant odor of excrement.
Examples of the fragrance component itself that reacts with moisture to produce a scent include water-soluble fragrances (essences) used in beverages and the like obtained by dissolving and extracting a fragrance base with alcohol and water.
Thus, it is preferable to add the fragrance to the original pulp sheet before defibration because it is effective not only for producing a scent but also for adsorbing the odor component of excrement.
In order to add the fragrance to the wet paper, separately in the fragrance blending step, the fragrance is mixed with water or an oil-based solvent, and a fragrance-containing solution to which cyclodextran is added is prepared, and this fragrance-containing solution is sprayed from the spray nozzle. It is preferable to apply.
As a structural example of the said fragrance | flavor containing solution, it can be set as 88.4 weight% of water, 10.3 weight% of cyclodextrans, 1 weight% of fragrance | flavor, and 0.3 weight% of xanthan gum. Here, by adding xanthan gum together with cyclodextran as an inclusion substance, the inclusion of fragrance into cyclodextran increases, and the moisture content temporarily increases immediately after application to wet paper containing moisture. It is possible to suppress the release of the fragrance.

ink:
In order to obtain a good image with high quality even when high-speed recording is performed, a liquid composition containing a fluorine-based nonionic surfactant and cyclodextran is provided.
The fluorine-based nonionic surfactant has a hydrophobic group in which the hydrogen atom of the alkyl chain is substituted with a fluorine atom in its molecular structure, and also has a hydrophilic alkylene oxide chain. Specific examples of the fluorine-based nonionic surfactant include “Zonyl-FSO100”, “FSN100”, “FS3100” (manufactured by Du Pont); “Megafuck F444”, “F477”, “F553” (manufactured by DIC Corporation) and the like.
The fluorine-based nonionic surfactant has a hydrophobic group in which the hydrogen atom of the alkyl chain is substituted with a fluorine atom in its molecular structure, and also has a hydrophilic alkylene oxide chain. Specific examples of the fluorine-based nonionic surfactant include “Zonyl-FSO100”, “FSN100”, “FS3100” (manufactured by Du Pont); “Megafuck F444”, “F477”, “F553” (manufactured by DIC Corporation) and the like.
The fluorine-based nonionic surfactant has a hydrophobic group in which the hydrogen atom of the alkyl chain is substituted with a fluorine atom in its molecular structure, and also has a hydrophilic alkylene oxide chain. Specific examples of the fluorine-based nonionic surfactant include “Zonyl-FSO100”, “FSN100”, “FS3100” (manufactured by Du Pont); “Megafuck F444”, “F477”, “F553” (manufactured by DIC Corporation) and the like.
The content (% by mass) of cyclodextran is preferably 0.1% by mass or more and 30% by mass or less based on the total amount of the liquid composition. Moreover, content (mass%) of cyclodextran is mass ratio (content of cyclodextran / content of nonionic surfactant) with respect to content (mass%) of nonionic surfactant. It is preferably 0 times or less. If the above mass ratio exceeds 8.0 times, the content of cyclodextran becomes excessive, and a large number of cyclodextrans interact with one molecule of surfactant. For this reason, the hydrophilicity of the surfactant increases too much, and the balance between the hydrophobic group and the hydrophilic group changes, and the desired surface tension reducing ability may not be exhibited.
Crown ethers, cryptands, macrocyclic amines, calixarenes, thiacalixarenes, cyclophanes, proteins, DNA, RNA, etc. may be blended to form inclusion compounds with cyclodextrans .
The liquid composition can contain a coloring material. The type of the color material is not particularly limited, and for example, a known dye or pigment can be used. You may use a color material individually by 1 type or in combination of 2 or more types.
As the pigment, a pigment having a hue such as black, cyan, magenta, and yellow can be used. Specific examples of the pigment include carbon black and organic pigments. The content of the pigment in the liquid composition is preferably 0.5% by mass or more and 15.0% by mass or less based on the total mass of the liquid composition. A pigment can be used individually by 1 type or in combination of 2 or more types.
As the pigment, any of a self-dispersed pigment and a resin-dispersed pigment can be used. The self-dispersing pigment is a type of pigment in which a hydrophilic group is introduced on the surface of pigment particles and dispersed in a medium. The resin-dispersed pigment is a type of pigment that is dispersed in a medium using a resin as a dispersant. Examples of the resin dispersion pigment include a resin dispersion pigment using a resin dispersant, a microcapsule pigment in which the pigment particle surface is coated with a resin, and a resin bond in which an organic group containing a resin is chemically bonded to the pigment particle surface. A pigment etc. can be mentioned.
Self-dispersed pigments and resin-dispersed pigments can be used in combination. The resin (resin dispersant) used as the dispersant preferably has a hydrophilic portion and a hydrophobic portion. Examples of the resin dispersant include an acrylic resin obtained by polymerizing a monomer having a carboxy group such as (meth) acrylic acid; a urethane resin obtained by polymerizing a diol having an anionic group such as dimethylolpropionic acid. Can be mentioned.
The acid value of the resin dispersant is preferably 50 mgKOH / g or more and 550 mgKOH / g or less. The weight average molecular weight (Mw) in terms of polystyrene obtained by gel permeation chromatography (GPC) of the resin dispersant is preferably 1,000 or more and 50,000 or less.
The content of the resin dispersant in the liquid composition is preferably 0.1% by mass or more and 10.0% by mass or less based on the total mass of the liquid composition. Further, the content (mass%) of the resin dispersant is a mass ratio (content of resin dispersant / pigment content) to the pigment content (mass%), and is 0.1 times or more and 5.0 times or less. It is preferable that
As the dye, a dye having a hue such as black, cyan, magenta, and yellow can be used. The content of the dye in the liquid composition is preferably 1.0% by mass or more and 20.0% by mass or less based on the total mass of the liquid composition. Specific examples of the dye include acid dyes, direct dyes, basic dyes, and disperse dyes described in the color index (COOLUR INDEX).
The liquid composition preferably contains at least one of a water-soluble resin and resin particles. The water-soluble resin is a resin that can be dissolved in water at a certain concentration or higher. Specifically, the solubility of the water-soluble resin in water at 25 ° C. is preferably 1% by mass or more. Further, the water-soluble resin may have a solubility that is increased by the addition of a water-soluble organic solvent and is dissolved in the liquid composition.
As the water-soluble resin, known water-soluble resins such as naturally derived water-soluble resins and synthesized water-soluble resins can be used. Examples of naturally occurring water-soluble resins include polysaccharides such as starch; proteins such as glue and gelatin. Further, a product obtained by chemically modifying a naturally derived water-soluble resin such as hydroxyethyl cellulose can also be used.
Examples of the synthesized water-soluble resin include polyacrylamide, polyvinyl pyrrolidone, polyalkylene glycol, polyvinyl alcohol, and polyethyleneimine. Among these, a resin obtained by copolymerizing a hydrophobic monomer and a hydrophilic monomer such as a styrene-acrylic acid copolymer is preferable. Such a resin is preferable because the water solubility can be controlled by changing the ratio between the hydrophobic monomer and the hydrophilic monomer or changing the structure (random, graft, block, etc.).
The resin particle is a resin that can be dispersed in a solvent in a state having a particle size. The 50% cumulative volume average particle diameter (D50) of the resin particles is preferably 10 nm or more, more preferably 10 nm or more and 1,000 nm or less, and particularly preferably 100 nm or more and 500 nm or less. D50 of the resin particles can be measured by the following method. First, a measurement sample is prepared by diluting resin particles 50 times (volume basis) with pure water. And about the prepared sample for a measurement, D50 of a resin particle can be measured using a dynamic light scattering type particle size analyzer.
The weight average molecular weight in terms of polystyrene of the resin constituting the resin particles obtained by GPC is preferably 1,000 or more and 2,000,000 or less. The content of the resin particles in the liquid composition is preferably 1.0% by mass or more and 50.0% by mass or less, and 2.0% by mass or more and 40.0% by mass based on the total mass of the liquid composition. More preferably, it is% or less.
Examples of the resin particles include acrylic, vinyl acetate, ester, ethylene, urethane, synthetic rubber, vinyl chloride, vinylidene chloride, and olefin resin particles. Of these, acrylic resin particles and urethane resin particles are preferable.
The monomer used for preparing the resin (acrylic resin) constituting the acrylic resin particles may be any monomer applicable to a polymerization method such as an emulsion polymerization method, a suspension polymerization method, or a dispersion polymerization method. Monomers that can be used in the production of acrylic resin particles include, for example, (meth) acrylic acid, maleic acid, crotonic acid, angelic acid, itaconic acid, fumaric acid and other α, β-unsaturated carboxylic acids and salts thereof; ethyl (Meth) acrylate, methyl (meth) acrylate, butyl (meth) acrylate, methoxyethyl (meth) acrylate, ethoxyethyl (meth) acrylate, diethylene glycol (meth) acrylate, triethylene glycol (meth) acrylate, tetraethylene glycol (meta ) Acrylate, polyethylene glycol (meth) acrylate, methoxydiethylene glycol (meth) acrylate, methoxytriethylene glycol (meth) acrylate, methoxytetraethylene glycol (meth) acrylate, Of α, β-unsaturated carboxylic acid such as methoxypolyethylene glycol (meth) acrylate, cyclohexyl (meth) acrylate, isobornyl (meth) acrylate, N, N-dimethylaminopropyl (meth) acrylate, monobutyl maleate, dimethyl itaconate, etc. Ester compounds; (meth) acrylamide, dimethyl (meth) acrylamide, N, N-dimethylethyl (meth) acrylamide, N, N-dimethylpropyl (meth) acrylamide, isopropyl (meth) acrylamide, diethyl (meth) acrylamide, (meta ) Alkylamido compounds of α, β-unsaturated carboxylic acids such as acryloylmorpholine, maleic acid monoamide, crotonic acid methylamide; styrene, α-methylstyrene, vinyl phenylacetate, benzyl (meta ) Α, β-ethylenically unsaturated compounds having an aryl group such as acrylate and 2-phenoxyethyl (meth) acrylate; ester compounds of polyfunctional alcohols such as ethylene glycol diacrylate and polypropylene glycol dimethacrylate .
The acrylic resin may be a homopolymer obtained by polymerizing a single monomer or a copolymer obtained by polymerizing two or more monomers. The copolymer may be a random copolymer or a block copolymer. Among these, a copolymer obtained by polymerizing a hydrophilic monomer and a hydrophobic monomer is preferable. Examples of hydrophilic monomers include α, β-unsaturated carboxylic acids and salts thereof. Examples of the hydrophobic monomer include an ester compound of α, β-unsaturated carboxylic acid and an α, β-ethylenically unsaturated compound having an aryl group.
The resin (urethane resin) constituting the urethane resin particles is a resin obtained by reacting a polyisocyanate which is a compound having two or more isocyanate groups with a polyol compound which is a compound having two or more hydroxy groups. As the urethane resin, any urethane resin obtained by reacting a known polyisocyanate compound with a known polyol compound can be used as long as it can form resin particles satisfying the above-described conditions.
Examples of the resin particle structure include a multilayer structure such as a single-layer structure and a core-shell structure. Among these, resin particles having a multilayer structure are preferable, and resin particles having a core-shell structure are more preferable. The resin particles having a core-shell structure can separate the function of the core part and the function of the shell part. If resin particles having such a core-shell structure are used, more functions can be imparted to the liquid composition than when resin particles having a single-layer structure are used.
The liquid composition preferably further contains a reactive agent that comes into contact with the ink containing the coloring material to increase the viscosity of the ink. Conventionally, a two-liquid reaction system that records an image by applying ink and a reaction liquid to a recording medium has been studied. In the two-component reaction system, the reactant in the reaction solution quickly increases the viscosity of the ink, so that bleeding and bleeding can be effectively suppressed. For this reason, according to the two-component reaction system, a high-quality image can be recorded even on a non-absorbable or hardly absorbable recording medium.
The reactive agent is a component capable of destabilizing the dispersion or dissolution state of the color material (pigment, dye) in the ink and increasing the viscosity of the ink when in contact with the ink containing the color material. Therefore, when a liquid composition containing a reactant is used in a two-component reaction system, the viscosity of another liquid composition to be contacted and mixed can be increased.
It is preferable to use at least one of a polyvalent metal ion and an organic acid as the reactant. The polyvalent metal ion may be a divalent or higher metal ion. Specific examples of the polyvalent metal ions include divalent metal ions such as Ca ²⁺ , Cu ²⁺ , Ni ²⁺ , Mg ²⁺ , Sr ²⁺ , Ba ²⁺ , and Zn ²⁺ ; Fe ³⁺ , And trivalent metal ions such as Cr ³⁺ , Y ³⁺ , and Al ³⁺ . The polyvalent metal ion can be added to the liquid composition in the form of a salt (polyvalent metal salt) such as hydroxide or chloride, and may be used as an ion generated by dissociation. The polyvalent metal salt is selected from the group consisting of Ca ²⁺ , Cu ²⁺ , Ni ²⁺ , Mg ²⁺ , Zn ²⁺ , Ba ²⁺ , Al ³⁺ , Fe ³⁺ , Cr ³⁺ and Y ³⁺ It is preferable to be composed of at least one polyvalent metal ion and an anion.
The content of polyvalent metal ions in the liquid composition is preferably 3.0% by mass or more and 90.0% by mass or less, and 5.0% by mass or more and 70.70% by mass or more based on the total mass of the liquid composition. More preferably, it is 0 mass% or less.
Specific examples of organic acids include oxalic acid, polyacrylic acid, formic acid, acetic acid, propionic acid, glycolic acid, malonic acid, malic acid, maleic acid, ascorbic acid, levulinic acid, succinic acid, glutaric acid, glutamic acid, fumaric acid Citric acid, tartaric acid, lactic acid, pyrrolidone carboxylic acid, pyrone carboxylic acid, pyrrole carboxylic acid, furan carboxylic acid, pyridine carboxylic acid, coumaric acid, thiophene carboxylic acid, nicotinic acid, oxysuccinic acid, dioxysuccinic acid and the like.
The content of the organic acid in the liquid composition is preferably 3.0% by mass or more and 90.0% by mass or less, and 5.0% by mass or more and 70.0% by mass based on the total mass of the liquid composition. More preferably, it is% or less.
The liquid composition can usually contain an aqueous medium. As the aqueous medium, water or a mixed solvent of water and a water-soluble organic solvent can be used. The content of the water-soluble organic solvent in the liquid composition is preferably 3.0% by mass or more and 50.0% by mass or less based on the total mass of the aqueous medium. Examples of the water-soluble organic solvent include alcohols, glycols, alkylene glycols having 2 to 6 carbon atoms in the alkylene group, polyethylene glycols, nitrogen-containing compounds, and sulfur-containing compounds. . These water-soluble snow solvents can be used alone or in combination of two or more. The water is preferably deionized water (ion exchange water). The content of water in the liquid composition is preferably 5.0% by mass or more and 95.0% by mass or less based on the total mass of the aqueous medium.
The content of the aqueous medium in the liquid composition is preferably 8% by mass or more and 95% by mass or less, and preferably 35% by mass or more and 90% by mass or less, based on the total mass of the liquid composition. Further preferred.
In addition to the above components, the liquid composition can contain various components as necessary. The liquid composition may contain a water-soluble organic compound that is solid at room temperature such as polyhydric alcohols such as trimethylolpropane and trimethylolethane; urea derivatives such as urea and ethyleneurea. Furthermore, in the liquid composition, if necessary, a surfactant other than the fluorine-based nonionic surfactant, a pH adjuster, a rust inhibitor, an antiseptic, an antifungal agent, an antioxidant, an antioxidant, Various components such as an evaporation accelerator and a chelating agent may be contained.

  The liquid composition can be ejected from an ink jet recording head and applied to a recording medium to record an image. Further, the liquid composition can be applied to a liquid component non-absorbing or hardly absorbing recording medium (non-absorbing recording medium or the like) to record an image.

Preferred embodiments of the liquid composition include the following.
(Example 1)
Cyclodextran 0.5% by mass, nonionic surfactant 2% by mass, self-dispersing pigment 4% by mass, resin particle dispersion (benzyl methacrylate-methyl acrylate-acrylic acid copolymer (acid value: 120 mgKOH / g , Weight average molecular weight: 9,000, neutralizing agent: potassium hydroxide)) 5% by mass, glycerin 10% by mass, and the remainder of the water were mixed, stirred thoroughly, and then filtered under pressure with a microfilter to obtain a liquid composition. To prepare.

column:
In order to separate optical isomers that have been difficult to separate conventionally, an optically active column packing material for gas chromatography in which the optical isomer separation liquid phase contains cyclodextran as a stationary phase component is used.
The column packing material is characterized in that the optical isomer separation liquid phase is cyclodextran as a stationary phase, and this can be used alone as a gas chromatography packing material, and conventionally known packing materials such as, for example, OV-1701, OV-225, OV-17, OV-1, SE-30, SF-96, SP-2100, XE-60, etc. can also be used in combination with PEG-20M, FFAP, etc.
In order to fill the column with the packing material for gas chromatography, a conventional method, that is, a packed column method in which the column is supported on a stationary phase carrier or packed into the column, or a capillary column that covers the inner surface of the column only with the stationary phase. The method can be employed as it is. In the packed column system, for example, it can be carried out by uniformly adsorbing a mixture of two or more optical isomer separation liquid phases in advance on a porous carrier such as silica gel, glass beads, diatomaceous earth, and alumina. There is no special restriction | limiting in a porous support | carrier, For example, a spherical support | carrier with a particle size of 1-100 micrometers and a pore size of 50-500 Angstrom can be illustrated preferably. In the capillary column method, for example, a dynamic method in which two or more optical isomer separation liquid phases are mixed in advance on the inner surface of a glass or stainless steel capillary column having an inner diameter of 0.1 to 0.5 mm and a length of 10 to 100 m. Or it can carry out by making it coat uniformly using the said techniques, such as a static method.
The column filler can separate various compounds, and in particular, exhibits an excellent effect in optical resolution of enantiomers, which has been difficult to separate by conventional gas chromatography. The column filler has an excellent feature that the separation of compounds having various functional groups can be separated on the same column.

The following can be mentioned as a preferable aspect of the said column filler.
(Example 1)
A stationary phase liquid obtained by dissolving OV-1701 in a concentration of 3.5% (W / V) and cyclodextran at a concentration of 1.5% in methylene chloride filtered through a membrane filter and then degassed under reduced pressure. Prepare. Using this as a coating solution, a fused silica capillary column is coated by a dynamic method, dried with nitrogen gas, and then aged by gas chromatography to prepare a capillary column.

resin:
In order to have excellent scratch resistance and chipping resistance without surface treatment such as painting, cyclodextran, a linear molecule that includes cyclodextran in a skewered manner, and this linear molecule And a blocking group for preventing the cyclodextrans from detaching, and at least one of the linear molecule and the cyclodextran is a resin containing a hydrophobic polyrotaxane having a hydrophobic property.
In the hydrophobic polyrotaxane, the number of cyclodextrans included in the linear molecule (inclusion amount) is defined as 1 when the maximum inclusion amount that the linear molecule can include cyclodextran is 1. 0.06-0.61 are preferable and 0.11-0.22 are still more preferable. If the inclusion amount is 0.06 to 0.17, hydrophobicity can be imparted to the target polyrotaxane separately from modification of the cyclodextran and selection of a linear molecule described later. If this ratio is less than 0.06, the pulley effect may be insufficient and the elongation of the coating film may decrease. If it exceeds 0.61, the cyclodextrans are arranged too densely, the mobility of the cyclodextrans is lowered, and similarly, the elongation rate of the resin is insufficient and the scratch resistance tends to deteriorate.
Further, the amount of cyclodextran included can be controlled as follows.
As an example, BOP reagent (benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate), HOBt, adamantamine, and diisopropylethylamine are added to DMF (dimethylformamide) in this order. Make a solution. On the other hand, a solution is obtained in which a clathrate complex in which cyclodextran is skewed in a linear molecule is dispersed in a DMF / DMSO (dimethyl sulfoxide) mixed solvent. By mixing these two and changing the mixing ratio of DMF / DMSO at this time, the inclusion amount of cyclodextran can be arbitrarily controlled. The higher the DMF / DMSO ratio, the greater the amount of cyclodextran included.
As a method for introducing the hydrophobic modifying group, the following method can be employed.
As an example, for example, cyclodextran is used as the cyclodextran of polyrotaxane, the hydroxy group of cyclodextran is hydroxypropylated using propylene oxide, ε-caprolactone is added, and 2-ethylhexanoic acid tin is added. Added. The modification rate can be arbitrarily controlled by changing the amount of ε-caprolactone added at this time.
On the other hand, the linear molecule may be substantially linear, and may have a branched chain as long as cyclodextran as a rotor can be included so that it can rotate and exert a pulley effect. Good.
Moreover, although it is influenced also by the magnitude | size of cyclodextran, the length is not specifically limited as long as a cyclic molecule can exhibit a pulley effect.
In addition, as a linear molecule, what has a reactive group in the both ends is preferable, and it becomes possible to react this with the said blocking group easily by this.
Such a reactive group can be appropriately changed according to the type of blocking group employed, and examples thereof include a hydroxyl group, an amino group, a carboxyl group, and a thiol group.
Such a linear molecule is not particularly limited, but is not limited to polyesters such as polyalkylenes and polycaprolactone, polyethers such as polypropylene glycol and polyethylene glycol, polyisoprene, polybutadiene, polytetrahydrofuran, polydimethyl. Mention may be made of siloxane, polyethylene, polypropylene, polyamides, polyacryls and linear molecules having a benzene ring.
Among these linear molecules, polyethylene glycol and polycaprolactone are particularly preferable, and polyethylene glycol is preferably used from the viewpoint of solubility in water or solvent solvents.
In addition, if polycaprolactone is selected as the linear molecule, hydrophobicity can be imparted to the polyrotaxane separately from the modification of the cyclodextran and the control of the maximum inclusion amount.
In addition, the molecular weight of the linear molecule is preferably 1,000 to 100,000, and more preferably 10,000 to 50,000.
If the molecular weight of the linear molecule is less than 1,000, the pulley effect by the cyclodextran cannot be sufficiently obtained and the scratch resistance may be deteriorated. When the molecular weight exceeds 100,000, the compatibility with the resin may decrease, and the transparency may decrease.
In addition, when polycaprolactone is selected as the linear molecule, if the molecular weight is 5,000 to 100,000, hydrophobicity can be favorably imparted to the polyrotaxane.
On the other hand, as long as the blocking group is a group that is arranged at both ends of the linear molecule as described above and can maintain a state in which cyclodextran is penetrated in a skewered manner by the linear molecule, any method can be used. It can be a simple group.
Examples of such a group include a group having “bulkiness” or a group having “ionicity”. Here, the “group” means various groups including a molecular group and a polymer group.
Examples of the group having “bulkyness” include a spherical shape and a side wall-shaped group.
In addition, the ionicity of the group having “ionicity” and the ionicity of the cyclic molecule interact with each other, for example, repelling each other, so that the cyclic molecule is skewed into a linear molecule. Can be held.
Specific examples of such blocking groups include dinitrophenyl groups such as 2,4-dinitrophenyl group and 3,5-dinitrophenyl group, cyclodextrans, adamantane groups, trityl groups, fluoresceins and pyrenes. And derivatives or modified products thereof.
An example of a method for producing a hydrophobic polyrotaxane will be described.
Hydrophobic polyrotaxane is
(1) mixing a cyclodextran with a linear molecule, penetrating through the opening of the cyclodextran with a linear molecule in a skewered manner, and enclosing the cyclodextran with the linear molecule;
(2) a step of preparing both the ends of the obtained pseudopolyrotaxane (both ends of the linear molecule) with a blocking group so that cyclodextran is not detached from the skewered state;
(3) The step of modifying the hydroxyl group of the cyclodextran of the obtained polyrotaxane with a hydrophobic modifying group,
Is obtained by processing.
In the step (1), a hydrophobic polyrotaxane can also be obtained by using a hydroxyl group of cyclodextran previously modified with a hydrophobic modifying group. In that case, in the above step (3) Can be omitted.
The resin can contain a transparent resin and an additive in addition to the hydrophobic polyrotaxane.
Such a transparent resin is not particularly limited as long as it is a colorless transparent or colored transparent resin. Polymethyl methacrylate (PMMA), polycarbonate (PC), polystyrene (PS), polyvinyl chloride (PVC), and the like can be used. Can be mentioned.
In addition, a colored transparent resin obtained by adding a small amount of a pigment (particularly a so-called nano pigment) to these transparent resins can also be used.
In addition, the mixing ratio of the hydrophobic polyrotaxane and the transparent resin in this resin is not particularly limited as long as desired transparency and scratch resistance can be obtained. %, The hydrophobic polyrotaxane can be 1-30%, preferably the hydrophobic polyrotaxane is 10-30%, more preferably the hydrophobic polyrotaxane is 20-30%.
When the hydrophobic polyrotaxane is less than 1%, the scratch effect may be lowered due to a decrease in the pulley effect, and when it exceeds 30%, the compatibility with the transparent resin may be lowered and the transparency may be lowered. .
Specific examples of the additive include an antioxidant, an ultraviolet absorber, a dispersant, and an internal mold release agent.
This resin is suitable for automobiles having excellent scratch resistance and chipping resistance without performing surface treatment such as painting.

The following can be mentioned as a preferable aspect of the said resin.
(Example 1)
To 500 g of a hydroxypropylated polyrotaxane having a hydroxyl group modified with a hydroxypropyl group (molecular weight of a linear molecule of 10 ³ , inclusion ratio of cyclodextran 0.35) is added 10 mL of ε-caprolactone dried with molecular sieves, and room temperature is added. Stir for 30 minutes and soak well. Subsequently, 0.2 mL of 2-ethylhexanoic acid tin is added, and the mixture is reacted at 100 ° C. for 1 to 8 hours. After completion of the reaction, the product is dissolved in 50 mL of toluene, dropped into 450 mL of stirred hexane, precipitated and collected.
PMMA and each polyrotaxane having a modifying group obtained as described above are heated to 80 ° C. and mixed to obtain pellets of each example. The obtained pellet is injection-molded at a mold temperature of 30 ° C. and a cylinder temperature of 210 ° C. for 40 seconds to obtain a transparent plastic test piece of 150 mm (length) × 75 mm (width) × 3 mm (thickness).

Drug delivery composition:
In order to deliver collagen or hyaluronic acid efficiently into the skin of a subject, including cyclodextran bound to a drug selected from the group consisting of collagen and hyaluronic acid, for efficient percutaneous absorption The composition is as follows.
Hyaluronic acid (HA) exists throughout nature and is a combination of repeated disaccharide units of glucuronic acid and N-acetylglucosamine. It is polyionic and has an axial hydrophobic part and a central hydrophilic part. Hyaluronic acid is very sensitive to hyaluronidase and therefore has a short half-life in the body. In order to make hyaluronic acid a wrinkle filling with sufficient sustainability over time, it can be crosslinked.
Collagenous is any natural collagen protein obtained from animal (e.g. human) cells and tissues, recombinantly expressed human collagen proteins (including fragments of full-length collagen), and combinations and / or formulations thereof Including things.
Cyclodextrans bind to the guest compound collagen or hyaluronic acid by adapting the compound to the hydrophobic cavity and forming an inclusion complex.
The composition can further comprise a dermatologically acceptable carrier. A safe and effective amount of the carrier is typically about 50% to about 99.99%, preferably about 80% to about 99.9%, more preferably about 90% to about 98% of the composition, and even More preferably, it is about 90% to about 95%.
The carrier may be in a wide variety of forms. For example, emulsion carriers are useful herein, including but not limited to oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions.
The composition can contain one or more additional skin care agents. Skin care agents include abrasives, absorbents such as fragrances, pigments, colorants / colorants, essential oils, skin sensates, astringents, etc. (e.g. clove oil, menthol, camphor, eucalyptus oil, eugenol). , Menthyl lactate, witch hazel distillate) aesthetic component, anti-acne agent, anti-caking agent, antifoam agent, antimicrobial agent (e.g. iodopropyl butyl carbamate), antioxidant Agents, binders, biological additives, buffers, fillers, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, medicinal astringents, topical analgesics, Thin layer forming agent or thin layer forming material, for example, a polymer (for example, a copolymer of eicosene and vinyl pyrrolidone) to assist the thin layer forming and substantiality of the composition, opacifier, pH adjuster, jet Agent, return Ingredients, sequestering agents, skin bleaching agents and skin lightening agents (e.g. hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin conditioners (e.g. mixed and occlusive) Humectants), skin sedatives and / or therapeutic agents (e.g., panthenol and derivatives (e.g., ethyl panthenol), aloe vera, pantothenic acid and its derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin treatment agents, Thickeners and vitamins and derivatives thereof are mentioned.
The composition is preferably intended to leave the skin or other keratin structure for improvement and / or regulation of the condition of the epidermal tissue to remain for some cosmetic, prophylactic, therapeutic or other benefit, skin lotion, Apply compositions in the form of creams, gels, foams, ointments, pastes, emulsions, sprays, conditioners, tonics, cosmetics, lipsticks, foundations, aftershaves, etc. (i.e. `` leave-on '' compositions) ) Is preferably practiced.

Perfume delivery system:
A perfume composition comprising a combination of specific perfume ingredients to exhibit improved perfume performance, such as excellent odor blocking / reduction of fabric odor under severe soil conditions and in cold water washing The system is a cyclodextran system.
The said fragrance | flavor raw material is the following.
a) 2-ethoxynaphthalene, 2-methoxynaphthalene, 2-cyclohexyloxyethylbenzene, 1,1-diethoxydecane, 1,3,3-trimethyl-2-oxabicyclo [2,2,2] octane, and their 3% to 20%, preferably 3% to 10%, more preferably 3% to 7% of a perfume raw material selected from the group consisting of mixtures;
b) Octanal, nonanal, decanal, dodecanal, 2-methylundecanal, 2-methyldecanal, (2E, 4E) -hexa-2,4-dienal, undeca-10-enal, (E) -dec-2- Enal, (E) -2-nonen-1-al, 2,6,10-trimethylundec-9-enal, (4Z) -5,9-dimethyldec-4,8-dienal, 2,4,6 -Trimethylcyclohex-3-ene-1-carbaldehyde, 1-methyl-4-prop-1-en-2-yl-cyclohexene, 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, 4 -(4-Methylpent-3-enyl) cyclohex-3-ene-1-carbaldehyde, tridec-2-enal, 2,4-dimethyl-3-cyclohexene 1-carboxaldehyde, 1,2-dimethylcyclohex-3-ene-1-carbaldehyde, 2,4-dimethylcyclohex-3-ene-1-carbaldehyde, 4-methoxybenzaldehyde, 3- (1,3 -Benzodioxol-5-yl) -2-methylpropanal, 1,3-benzodioxol-5-carbaldehyde, 3- (4-propan-2-ylphenyl) butanal, 3- (4- tert-butylphenyl) propanal, and 2% to 35%, preferably 5% to 10%, more preferably 2.5% to 8% of perfume raw materials selected from the group consisting of:
c) methyl 2-methylbutanoate, propan-2-yl 2-methylbutanoate, ethyl 2-methylbutanoate, ethyl 2-methylpentanoate, ethylheptanoate, ethyloctanoate, 2- Methylpropylhexanoate, pentylbutanoate, pentylheptanoate, 3-methylbutyl 2-methylpropanoate, hexyl acetate, hexylbutanoate, hexyl 2-methylpropanoate, hexyl 3-methylbutanoate , Hexylpropanoate, ethyl 2-cyclohexylpropanoate, ethyl 3,5,5-trimethylhexanoate, 2,3-dihydroxypropyl 5-hydroxydecanoate, 3-methyl 2-butenyl acetate, 3 -Methyl 2-butenyl acetate, methyl 3-nonenoate, ethyl Ru (E) -dec-4-enoate, ethyl (E) -oct-2-enoate, ethyl (2E, 4Z) -deca-2,4-dienoate, ethyl (E) -oct-3-enoate, 3, 7-dimethyloct-6-enyl acetate, ethyl (E) -dec-2-enoate, [(E) -hex-2-enyl] acetate, [(E) -hex-2-enyl] propanoate, [(E) -Hex-2-enyl] pentanoate, [(Z) -hex-3-enyl] (E) -hex-2-enoate, [(Z) -hex-3-enyl] 2-methylbutanoate, [(Z) -hex-3-enyl] acetate, [(Z) -hex-3-enyl] benzoate, [(Z) -hex-3-enyl] formate, [(Z) -hex-3-enyl ] (Z) -2-methyl But-2-enoate, 2-methylbutyl 2-methylbutanoate, butyl 3-methylbutanoate, [(2E) -3,7-dimethylocta-2,6-dienyl] acetate, [(2E) -3 , 7-dimethylocta-2,6-dienyl] butanoate, [(3E) -3,7-dimethylocta-3,6-dienyl] 3-methylbutanoate, [(2E) -3,7-dimethylocta -2,6-dienyl] propanoate, prop-2-enyl 2-cyclohexyl acetate, prop-2-enyl 3-cyclohexylpropanoate, prop-2-enyl 5-cyclohexylpentanoate, benzyloctanoate, 6 -Pentyl-5,6-dihydropyran-2-one, 8-methyl-1-oxaspiro (4.5) decan-2-one, 5-heptyl Oxolan-2-one, 5-hexyloxolan-2-one, 5-octyloxolan-2-one, 6-[(E) -pent-2-enyl] oxan-2-one, 5-[(Z ) -Hex-3-enyl] oxolan-2-one, 6-butyloxan-2-one, [2a, 5a (S *)]-2,6,10,10-tetramethyl-1-oxaspiro [4.5 ] Decan-6-yl acetate, 2- (phenoxy) ethyl 2-methylpropanoate, (2-tert-butylcyclohexyl) acetate, 3a, 4,5,6,7,7a-hexahydro-4,7-methano- 1 g-indene-5 (or 6) -yl butyrate, methyl 2-methylaminobenzoate, methyl 2-aminobenzoate, diethylbut-2-enedioate, ethyl 3-oxobut Selected from the group consisting of noate, ethyl 2- (2-methyl-1,3-dioxolan-2-yl) acetate, [(4Z) -1-cyclooct-4-enyl] methyl carbonate, and mixtures thereof; 2% to 35%, preferably 5% to 10%, more preferably 5% to 8% perfume raw material;
d) 0% to 10% selected from the group consisting of (E) -4-methyldec-3-en-5-ol, 3,7-dimethylocta-1,6-dien-3-ol and mixtures thereof %, Preferably 2-8% fragrance ingredients,
e) 2-heptylcyclopentan-1-one, O- [2-[(1S) -4-methyl-2-oxocyclohexyl] propan-2-yl] ethanethioate, 2- [2- (4-methyl) -1-cyclohex-3-enyl) propyl] cyclopentan-1-one, naphthalin-2-yl-phenylmethanone, 2-[(2E) -3,7-dimethylocta-2,6-dienyl] cyclopentane -1-one, 2,2,5-trimethyl-5-pentylcyclopentan-1-one, (E) -1- (2,6,6-trimethyl-1-cyclohex-3-enyl) but-2- From the group consisting of en-1-one, (E) -3-methyl-4- (2,6,6-trimethyl-1-cyclohex-2-enyl) but-3-en-2-one and mixtures thereof Selected, 0% ~ 0%, preferably from 2% to 8% of the perfume raw materials,
f) 4-methoxy-2-methylbutane-2-thiol, 2- (4-methyl-1-cyclohex-3-enyl) propane-2-thiol, N- (1,5-dimethyl-8-bicyclo [3. 2.1] octanilidene) hydroxylamine, 2,4,4,7-tetramethyl-6,8-nonadien-3-one oxime, 2-methyldecanenitrile, 3a, 6,6,9a-tetramethyl-2,4 , 5,5a, 7,8,9,9b-octahydro-1H-benzo [e] [1] benzofuran and mixtures thereof, 0% to 0.5% of perfume ingredients;
including.
Cyclodextran is used to improve perfume delivery. Usually, a complex (inclusion compound) of a perfume and cyclodextran is formed. Such a complex may be formed in advance, may be formed in situ, or may be formed on or in the surface of the site. Without being bound by theory, it is balanced by loss of water, especially when other auxiliary ingredients (eg, surfactants) are not present at such high concentrations that they compete for the perfume and the cyclodextran lumen. The state can move to the cyclodextran-fragrance complex side. The Bloom effect may be obtained if contact with water or an increase in water content occurs at a later time. Cyclodextrans may be pre-filled with a fragrance or added separately from the fragrance to obtain the desired fragrance stability, accumulation, and release effects.

  The system can be used in baby care, beauty care, clothing and home care, family care, feminine care, health care products. Such products include diapers, bibs, wipes; products and / or methods related to the treatment of hair (human, dog and / or cat) including decolorization, coloring, dyeing, conditioning, shampooing, styling; Personal cleansing; cosmetics; skin care including application of creams, lotions, and other topical products for consumer use; and shaving products, air care, car care, dishwashing, fabric conditioning (flexible Fabrics in home and care areas, including laundry cleaning, laundry and rinsing additives and / or care, hard surface cleaning and / or treatment, and other consumer or commercial cleaning, etc., Hard surface and any other surface treatment products and / or Method; toilet paper, facial tissue, products and / or methods relating to paper handkerchiefs, and / or paper towels; tampons, and feminine napkins and the like.

External preparation composition:
In order to obtain an external preparation composition exhibiting temperature sensitivity, cyclodextran is combined with a hydrophobically modified compound having a long-chain alkyl group in the molecule.
The external preparation is a final form used by the user, and means one containing the composition for external preparation. Therefore, if the external preparation is a cream or the like, the composition for external preparation may further contain an oil phase component. However, in the present invention, the external preparation composition may be distributed and used as a final product as it is, or the external preparation may be a use form containing 100% by mass of the external preparation composition. . Examples of such external preparations include preparations such as gels and lotions.
The compounding amount of cyclodextran used in the composition for external preparation is preferably about 0.001 to 50% by mass, more preferably about 0.01 to 25% by mass, further based on the total amount of the composition for external preparation. Preferably it is about 0.15-15 mass%, Most preferably, it is about 0.2-8 mass%.
The amount of cyclodextran contained in the composition for external use (total amount) is preferably about 2 to 1000 parts by mass with respect to 100 parts by mass of the hydrophobically modified compound having a long chain alkyl group in the molecule, About 20-800 mass parts is more preferable, and about 40-600 mass parts is still more preferable.
The hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably at least one compound selected from the group consisting of an alkyl-modified carboxyvinyl polymer, a hydrophobically modified polyether urethane, and a hydrophobically modified alkyl cellulose.
As alkyl-modified carboxyvinyl polymer, acrylic acid / alkyl methacrylate copolymer, (meth) acrylic acid / (meth) alkyl acrylate copolymer, (meth) acrylic acid / (meth) acrylic acid alkyl / (meth) acrylic Polyoxyethylene alkyl ether copolymer, (meth) acrylic acid / (meth) alkyl acrylate / itaconic acid polyoxyethylene alkyl ether copolymer, (meth) acrylic acid / (meth) acrylic acid / (meth) It is preferable to use a compound such as polyoxyethylene alkyl ether crosspolymer of acrylic acid or (meth) acrylic acid / (meth) acrylic acid alkyl / vinyl neodecanoate crosspolymer.
Examples of acrylic acid / alkyl methacrylate copolymers include Carbopol 1342, Pemulen TR-1 ((acrylates / alkyl acrylate (C10-30)) crosspolymer, Acrylates / C10-30 Alkyl Acrylate Crosspolymer ), Pemulen TR-2 ((Acrylates / alkyl acrylate (C10-30)) crosspolymer, Acrylates / C10-30 Alkyl Acrylate Crosspolymer) (Good rich) and the like are preferably used.
As the (meth) acrylic acid / (meth) acrylic acid alkyl copolymer, for example, Aculin 33A (Acrylates Copolymer) (trade name, manufactured by Rohm and Haas) is preferably used.
As (meth) acrylic acid / (meth) acrylic acid alkyl / (meth) acrylic acid polyoxyethylene alkyl ether copolymers, for example, Aculins 22 (Acrylates / Steareth-20 Methacrylate Copolymer), Aculin 28 (Acrylates / Beheneth-25 Methacrylate) Copolymer) (trade name: manufactured by Rohm and Haas) or the like is preferably used.
(Meth) acrylic acid / (meth) acrylic acid alkyl / itaconic acid polyoxyethylene alkyl ether copolymer, for example, STRUCTURE 2001 (Acrylates / Steareth-20 Itaconate Copolymer), STRUCTURE 3001 (Acrylates / Ceteth-20 Itaconate Copolymer) ( It is preferable to use a trade name, manufactured by Akzo Nobel Co., Ltd.
(Meth) acrylic acid / (meth) acrylic acid alkyl / (meth) acrylic acid polyoxyethylene alkyl ether crosspolymer, for example, Aculin 88 (Acrylates / Steareth-20 Methacrylate Crosspolymer) (trade name: manufactured by Rohm and Haas) ) Etc. are preferably used.
As the (meth) acrylic acid / alkyl (meth) acrylate / vinyl neodecanoate cross-polymer, for example, Aculins 38 (Acrylates / Vinyl Neodecanoate Crosspolymer) is preferably used.
Hydrophobic modified polyether urethane is an associative thickener. The associative thickener is a copolymer having a hydrophilic group as a skeleton and having a hydrophobic portion at the terminal, and the hydrophobic portions of the copolymer are associated with each other in an aqueous medium to exhibit a thickening action. In such an associative thickener, the hydrophobic portions of the copolymer are associated with each other in an aqueous medium, and the hydrophilic portion has a loop shape or a bridge shape, and exhibits a thickening action.
As the hydrophobic modified polyether urethane, for example, Adecanol GT-700 manufactured by Asahi Denka Kogyo Co., Ltd. is preferably used. Adecanol GT-700 is a hydrophobically modified polyether urethane of PEG-240 / decyltetradeceth-20 / hexamethyl diisocyanate (PEG-240 / HDI COPOLYMER BIS-DECYLTETRADECETH-20 / ETHER).
The hydrophobically modified alkyl cellulose is preferably at least one compound selected from the group consisting of alkyl group-modified hydroxyethyl cellulose (HEC) and alkyl group-modified hydroxypropylmethyl cellulose (HPMC). Hydrophobized modified alkyl cellulose is hydroxyalkyl alkyl cellulose. It is preferable to use a cellulose derivative treated with a modifier having an alkyl group having 6 to 26 carbon atoms. It is preferable to use hydroxyethyl cellulose modified with an alkyl group having 6 to 26 carbon atoms.
As alkyl group-modified hydroxyethyl cellulose, Aqualon (Natrosol Plus Grade) 330CS (registered trademark) (C16 alkyl, stearyl-modified hydroxyethyl cellulose), Berolcell (Berol Nobel) Bermocell It is preferable to use EHM100 (registered trademark), sodium stearoxy PG hydroxyethyl cellulose sulfonate (registered trademark, Poise 310) manufactured by Kao Corporation, stearyl-modified hydroxypropylmethyl cellulose, and the like.
Hydrophobized modified alkyl cellulose is a long chain that is a hydrophobic group in a cellulose ether derivative.
Those having an alkyl group introduced are preferred.
As an example of the hydrophobically modified alkyl cellulose, trade name: Sangelose manufactured by Daido Kasei Kogyo Co., Ltd. can be preferably exemplified. Sangelose (hydrophobized HPMC) is a cellulose ether in which C18 (hydrophobic group) is added to hydroxypropyl methylcellulose (HPMC).
Hydrophobized modified alkyl cellulose is a powdery component, and the average particle size is preferably about 20 to 800 μm, more preferably about 50 to 600 μm, still more preferably about 80 to 300 μm, and particularly preferably about 100 to 200 μm. is there.
The composition for external preparation contains a hydrophobically modified compound having a long-chain alkyl group in the molecule. The composition for external preparation can contain the compound individually by 1 type, and can also contain it in combination of 2 or more types. The blending amount is the blending amount if it is a single type (one compound), and the total amount if it is a combination of two or more types (plural compounds).
The blending amount of the hydrophobized and modified compound having a long-chain alkyl group in the molecule in the composition for external preparation is preferably about 0.1 to 20% by mass, more preferably based on the total amount of the composition for external preparation. Is about 0.1 to 10% by mass, more preferably about 0.1 to 8% by mass, and particularly preferably about 0.2 to 5% by mass.
In the composition for external preparation, for the purpose of supplementing or enhancing effects such as no stickiness when used as an external preparation, ease of application to the skin, good use feeling, etc., fatty acids and / Or a salt thereof (hereinafter also referred to as “fatty acid (salt)”) may be blended. Fatty acid (salt) is a powdery component. Since the fatty acid (salt) is uniformly dispersed in the composition for external preparation, when applied to the skin surface as an external preparation, it is possible to prevent impairing the feeling of use such as roughness. Further, it is prevented from scattering during handling, and handling is easy.
The fatty acid (salt) can be used without particular limitation as long as it can be used as an external preparation (for example, cosmetics). For example, stearic acid, calcium stearate, magnesium stearate (hereinafter referred to as stearic acid and / or a salt thereof (hereinafter also referred to as “stearic acid (salt)”)) described in the 16th revision Japanese Pharmacopoeia Manual is used. can do. In addition, sodium stearate or the like can be used.
In the composition for external preparation, a polyhydric alcohol may be further blended from the viewpoint of smoothing the physical properties when used as an external preparation and the stability of the product. The polyhydric alcohol is preferably a polyhydric alcohol having 2 to 6 carbon atoms and 2 to 3 oxygen atoms. Polyhydric alcohols include ethylene glycol, diethylene glycol, propylene glycol, 1,3-propanediol, dipropylene glycol, 1,3-butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 3-methyl- 1,3-butanediol, glycerin and the like are preferred.
In the composition for external preparations, in addition to the above components, optional components usually used in cosmetics can be contained. As optional ingredients, hydrocarbons such as squalane, liquid paraffin, liquid oils such as olive oil, macadamia nut oil, castor oil, solid fats such as coconut oil, palm oil, shea fat, waxes such as beeswax, carnauba wax, lanolin, Higher alcohols such as stearyl alcohol, behenyl alcohol, isostearyl alcohol, synthetic ester oils such as cetyl octanoate, isopropyl palmitate, glyceryl tri-2-ethylhexanoate, dimethylpolysiloxane, decamethylcyclopentasiloxane, silicone resin, amino-modified Silicone oil such as polysiloxane, lipophilic nonionic surfactant such as glyceryl monostearate, propylene glycol monostearate, sorbitan monostearate, decaglyceryl monostearate, POE-glycerin mono Isostearate, POE-sorbitan tetraoleate, POE-behenyl ether, hydrophilic nonionic surfactants such as coconut oil fatty acid monoethanolamide, sodium stearate, N-stearoyl-L-sodium glutamate, POE-oleyl ether phosphorus Anionic surfactants such as sodium acid, sodium lauroyl sarcosine, sodium lauroylmethylalanine, cationic surfactants such as stearyltrimethylammonium chloride, dimethylaminopropylamide stearate, benzalkonium chloride, palm oil fatty acid amidopropyl betaine, Amphoteric surfactants such as lauryl dimethylaminoacetic acid betaine, lower alcohols such as ethanol and isopropanol, water soluble high content such as xanthan gum, hydroxyethyl cellulose, carboxyvinyl polymer, etc. Sequestering agents such as disodium edetate, powder components, UV absorbers, antioxidants, pH adjusters, organic amines, preservatives (phenoxyethanol, glycerin ethylhexyl ether, methylparaben, etc.), bactericides, anti-inflammatory agents , Astringents, whitening agents, vitamins, amino acids, blood circulation promoters, activators, excipients (such as maltitol, lactose, dextrin, starch), refreshing agents, various extracts, fragrances, water and the like. Of course, the composition for external preparation of the present invention is not limited to the above components.
The blending amount of the other components varies depending on each component, but is preferably about 0.1 to 20% by mass, more preferably about 0.2 to 10% by mass, and still more preferably based on the total amount of the composition for external preparation. Is about 0.5-5 mass%. The composition for external preparation can adjust hardness, elongation, etc., becomes easy to apply to the skin, and has an excellent feeling of use as an external preparation.
The composition for external preparations can adjust hardness, elongation, etc. by including an appropriate amount of water, ethanol, isopropyl alcohol, propylene glycol, butylene glycol, glycerin, and other polyhydric alcohols, making it easy to apply to the skin. In addition, the usability as an external preparation is excellent.
The amount of water, ethanol, isopropyl alcohol, or a polyhydric alcohol such as propylene glycol, butylene glycol, glycerin and the like varies depending on each component, but is preferably about 50 to 95% by mass with respect to the total amount of the composition for external use. More preferably, it is about 60-90 mass%, More preferably, it is about 70-85 mass%.
The composition for external preparation can be produced by adding and dissolving a hydrophobically modified compound having a long-chain alkyl group in the molecule and cyclodextran in a solvent such as water. As a result, by forming an inclusion complex in a solution, it is possible to produce a composition for external use that has excellent storage stability and can be easily applied to the skin.
The composition for external use can be used in the form of a lotion, emulsion, cream, ointment, sheet or the like as an external preparation for body (skin care cosmetic). It is also possible to cover the skin with the composition for external use as a pack cosmetic. It is possible to produce a body makeup product using the external preparation composition as a makeup composition. The composition for external preparation is for cosmetics such as lotion, cosmetic liquid, pack, mascara, eyeliner, eye shadow, foundation, UV care cosmetics, lip such as lipstick, lip balm, lip gloss, lipstick, lip treatment Can be used for cosmetics (lip products), lip pencils, eye pencils, eyebrows makeup products, nail varnishes, nail care products, etc.
The composition for external use can also be used for pharmaceutical compositions such as eye drops, orally disintegrating tablets and sustained-release preparations.
The composition for external use can further contain a medicinal component to form a pharmaceutical composition.
Sympathomimetic drugs: adrenaline, noradrenaline, ethylephrine, naphazoline, phenylephrine, methoxamine, midodrine, isoprenaline, isoproterenol, dobutamine, denopamine, trimethoquinol, salbutamol, terbutaline, tulobuterol, fenotemalol, clenbuterol, procaterol, clenbuterol, clenbuterol , Isoxsuprine, tyramine, amphetamine, methamphetamine, ephedrine, methylephedrine, dopamine, docarpamine, amedinium or a salt thereof.
Sympathetic blockade: ergotamine, ergomethrin, phentolamine, torazoline, prazosin, bunazosin, terazosin, urapidil, doxazosin, tamsulosin, silodosin, naphthopidyl, alprenolol, oxprenolol, propranolol, bufetrol, pindolol, carteolol, timolol Isoroll, nipradilol, atenolol, metoprolol, bisoprolol, labetalol, amosulalol, arotinolol, carvedilol, reserpine, guanethidine, α-methyldopa, clonidine, guanabenz or a salt thereof.
Parasympathomimetic drugs: acetylcholine, bethanechol, carbachol, methacholine, pyro
Carpine, muscarin, physostigmine, neostigmine, distigmine, pyridosti
Gumin, ambenonium, edrophonium, pilocarpine, carpronium, cevimeline
Or its salt.
Parasympathetic blockade: Homatropin, tropicamide, cyclopentrate, propantherin, butylscopolamine, mepenzolate, prifinium, pyrenzepine, ipratropium, oxitropium, piperidylate, propiverine, oxybutynin, trihexyphenidyl, biperidene, pyroheptin, prozaminol, profenaminol , Methixene or a salt thereof.
Autonomic ganglion blockers: hexamethonium, trimetaphane, nicotine or its salts.
Local anesthetics: cocaine, procaine, oxybuprocaine, tetracaine, ethyl aminobenzoate, lidocaine, dibucaine, mepivacaine, oxesazein, xylocaine, or a salt thereof.
Muscle relaxants: tubocurarine, pancuronium, vecuronium, kissamethonium, dantrolene, pridinol, mephenesin, chlorzoxazone, fenprobamate, metcarbamol, chlormezanone, pridinol mesylate, afroqualone, chlorphenesin, tizanidine, tolperisone, eperisone, baclofen or salts thereof etc.
Intravenous anesthetics: thiopental, thiamylal, propofol, midazolam, droperidol, ketamine or salts thereof.
Hypnotics: flurazepam, haloxazolam, quazepam, nitrazepam, flunitrazepam, estazolam, nimetazepam, brotizolam, rilmazaphone, lormetazepam, triazolam, zolpidem, zopiclone, bromovaleryl urea, barbital, phenobarbital, tomobarbital Or its salt.
Analgesics and antitussives: morphine, codeine, papaverine, noscapine, dihydrocodeine, oxycodone, diacetylmorphine, pethidine, methadone, levorphanol, fentanyl, remifentanil, pentazocine, butorphanol, buprenorphine, naloxone, levalorphan, dextromethorphan, dextromethorphan Guaifenesin, pentoxyberine, benzonate, oxymorphone, cloperastine, or a salt thereof.
Antiepileptic drugs: phenobarbital, primidone, phenytoin, carbamazepine, ethosucside, trimetadione, diazepam, clonazepam, nitrazepam, valproic acid, gabapentin, sultiam, zonisamide or a salt thereof.
Antiparkinson drugs: levodopa, carbidopa, benserazide, entacapone, bromcryptin, pergolide, cabergoline, talipexol, pramipexole, amantadine, selegiline, trihexyphenidyl, biperidene, prophenamine, pyroheptin, methixene, salt, mazachicol, etc.
Anti-Alzheimer's disease drugs: donepezil, galantamine, rivastigmine, memantine or a salt thereof.
Schizophrenia treatment: chlorpromazine, fluphenazine, thioridazine, haloperidol, bromperidol, spiperone, haloperidol decanoate, sulpiride, risperidone, perospirone, olanzapine, quetiapine, clozapine, aripiprazole, prochlorperazine, trifloperazine, zotepine Or its salt.
Anti-anxiety drugs: etizolam, diazepam, oxazolam, ethyl loflazepate, clothiazepam, lorazepam, tandospirone, hydroxyzine, oxazepam, medazepam, temazepam, fludiazepam, meprobamate, chlordiazepoxide or salts thereof.
Antidepressants: imipramine, clomipramine, amitriptyline, nortriptyline, desipramine, amoxapine, maprotiline, mianserin, cetipiline, trazodone, fluvoxamine, paroxetine, sertraline, milnacipran, duloxetine, mirtazapine, noxipline, or a salt thereof.
Anti-vertigo: dimenhydrinate, diphenidol, betahistine or its salts.
Cardiotonic drugs: dichitoxin, digoxin, methyldigoxin, deslanoside, dobutamine, denopamine, dopamine, docarpamine, colforsin daropate, aminophylline, milrinone, olprinone, pimobendan, bucladecin, transbiooxocamphor, telefilol, ethinephrine or its salts.
Antiarrhythmic drugs: quinidine, procainamide, disopyramide, azimarin, cybenzoline, pyrmenol, lidocaine, mexiletine, aprindine, phenytoin, propaphenone, flecainide, pilsicainide, propranolol, alprenolol, bupretrol, oxprenolol, pindolol, carteolol , Isoroll, atenolol, acebutolol, metoprolol, bisoprolol, amiodarone, sotalol, nifekalant, verapamil, diltiazem, bepridil or a salt thereof.
Vasodilators / antihypertensive drugs: nitroglycerin, isosorbide nitrate, nicorandil, nifedipine, amlodipine, nitrendipine, nicardipine, felodipine, cilnidipine, manidipine, diltiazem, captopril, lisinopril, alacepril, enalapril, temocapril, imidapril tansartan Lexetyl, olmesartan medoxomil, azilsartan, aliskiren, hydralazine, bosentan, ethyl icosapentate, nicomol, niceritrol, isoxsuprine, torazoline, hexobenzine, bamethane, nilvadipine, trapidil, dirazep, beraprost, alprostadine or a salt thereof.
Antihypertensive drugs: phenylephrine, midodrine, methoxamine, ethylephrine, ephedrine, dihydroergotamine, amedinium or a salt thereof.
Diuretics: Acetazolamide, Furosemide, Bumetanide, Torasemide, Azosemide, Piretanide, Hydrochlorothiazide, Trichloromethiazide, Spironolactone, Canrenoic acid, Eplerenone, Triamterene, Isosorbide, Methycrothiazide, Hydroflumethiazide, Ethiazide, Furopenthiadiide, Or its salt.
Drugs for dysuria: tamsulosin, silodosin, naphthopidyl, prazosin, terazosin, urapidil, betanecol, neostigmine, distigmine, oxendrone, chlormadinate, allylestrenol, guestnolone caproate or its salt.
Drugs for frequent urination: propiverine, oxybutynin, solifenacin, imidafenacin, tolterodine, imipramine, clomipramine, amitriptyline, clenbuterol, mirabegron, flavoxate, terolidine or a salt thereof.
Expectorants: bromhexine, acetylcysteine, ethylcysteine, methylcysteine, carbocysteine, ambroxol, senega, onji, kyoto, chlorfedianol, picoperidamine or salts thereof.
Bronchial asthma medications: theophylline, aminophylline, ipratropium, oxitropium, beclomethasone propionate, fluticasone propionate, dexamethasone, prednisolone, budesonide, trimethoquinol, salbutamol, terbutaline, procaterol, salmeterol, tubuterol, tulobrolol , Formoterol, indacaterol, methoxyphenamine or a salt thereof.
Anti-gastric / duodenal ulcer drugs: pirenzepine, propantheline, butylscopolamine, cimetidine, ranitidine, famotidine, nizatidine, oxathidine acetate, proglumide, oxesasein, omeprazole, lansoprazole, rabeprazole, sucralfate, teprexane, cetraxate, rebatepide , Sulpiride, misoprostol, enprostil, irsogladine, loxatidine acetate, magnesium oxide, synthetic aluminum silicate or a salt thereof.
Stomach and laxatives: metoclopramide, domperidone, mosapride, sennoside, picosulfate, bisacodyl, gentian, assembly, auren, oats, fennel, cinnamon, ginger, salamander, carmellose, dioctylsodium sulfosuccinate, lactulose, oxidized Magnesium, magnesium sulfate, magnesium hydroxide or a salt thereof.
Antidiarrheal agents: atropine, loperamide, trimebutine, opium, mepenzolate, albumin tannate, bismuth hyponitrite, natural aluminum silicate, berberine, nadirix acid or its salt.
Antiemetics: chlorpromazine, sulpiride, domperidone, metoclopramide, granisetron, ondansetron, azasetron, oxesazein, dimenhydrinate, promethazine, aprepitant, apomorphine, tocone (emetine, cephrine) or a salt thereof.
Liver / pancreatic drugs: interferon preparations, lamivudine, glycyrrhizin, protoporphyrin, psychosaponin, lactulose, dehydrocholic acid, ursodeoxycholic acid, furopropion, chenodeoxycholic acid, nafamostat, urinalistatin, gabexate, camostat, trepibuton or its salts etc.
Reproductive organ drugs: Sildenafil, Vardenafil, Tadalafil, Udenafil, Mirodenafil, Ergomethrin, Methylergomethrin, Oxytocin, Dinoprostone, Dinoprost, Gemeprost, Ritodrine, Isoxpurin, Piperidorate or its salt.
Anti-glaucoma drugs: pilocarpine, distigmine, latanoprost, isopropyl unoprostone, bunazosin, acetazolamide, dorzolamide, timolol, carteolol, levobanolol, nipradilol, dipivefrin or a salt thereof.
Eye diagnostics (miotics / mydriatics): phenylephrine, homatropine, tropicamide, cyclopentrate, pilocarpine or salts thereof.
Drugs for skin diseases: tacalcitol, etretinate, urea, methoxalene, lysozyme, alprostadil, alprostadil alphadex, tretinointocopheryl, trafermin or a salt thereof.
Hormone drugs, hormone substitutes, antihormone drugs, ortachoids: corticotropin releasing hormone, thyroid stimulating hormone releasing hormone, gonadotropin releasing hormone, luteinizing hormone releasing hormone, growth hormone releasing hormone, prolactin releasing hormone, prolactin releasing Inhibitory hormone, corticotropin, thyroid stimulating hormone, follicle stimulating hormone, luteinizing hormone, growth hormone, corticorelin, prothyrelin, gore relin, buserelin, goserelin, nafarelin, leuprorelin, cetrorelix, ganirelix, somatrelin, terguride, somatostatin , Octreotide, prolactin, somatropin, oxytocin, vaspressin, desmopressin, thyroxine, triiodothyronine, calcitonin, para Rumone, liothyronine, levothyroxine, thiamazole, propylthiouracil, hydrocortisone, prednisolone, pregnenolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, fluocinolone acetonide, trityrostan, testosterone, testosterone, testosterone, testosterone, testosterone, testosterone , Chlormadinone, Allylestrenol, Oxendron, Flutamide, Bicalutamide, Finasteride, Estradiol, Estriol, Ethinylestradiol, Clomiphene, Tamoxifen, Toremifene, Mepithiostane, Anastrozole, Exemestane, Progesterone, Medroxyprogesterone, Didrogestosterone Danazol, desogestrel, norgestrel, levonorgestrel, human chorionic tropine, gastrin, cholecystokinin, secretin, glucagon, insulin, melatonin, gastric inhibitory peptide, adrenaline, noradrenaline, aldosterone, dopamine, desoxycorticosterone, arachidonic acid, Leukotriene A4, Leukotriene B4, Leukotriene C4, Leukotriene D4, Leukotriene E4, Prostaglandin G2, Prostaglandin H2, Prostaglandin I2, Prostaglandin E2, Prostaglandin D2, Prostaglandin F2α, Thromboxane A2, Thrombo Xanthan B2, serotonin, histamine, angiotensin, bradykinin, renin, endothelin, γ-aminobutyric acid, various cytokines, phosphatidylcholine, Scan inositol, PAF (platelet activating factor), PIP2 (phosphatidylinositol diphosphate), galactocerebroside, gangliosides, Gesutonoron caproic acid, hexestrol, erythropoietin or derivatives thereof.
Antidiabetics: Insulin preparations, tolbutamide, acetohexamide, chlorpropamide, gliclazide, glibenclamide, glimepiride, nateglinide, mitiglinide, metformin, buformin, pioglitazone, acarbose, voglibose, miglitol, sitagliptin, vildaglipeta Or its salt.
Drugs for treating dyslipidemia: pravastatin, simvastatin, fluvastatin, atorvastatin, cholestyramine, colestimide, ezetinib, gamma oryzanol, soysterol, probucol, clofibrate, bezafibrate, fenofibrate, nicomol, niceritrol, dextran sulfate ester, icosapentate 2-chloro-3- [4- (2-methyl-2-phenylpropoxy) phenyl] propionate [Chem. Pharm. Bull., 38, 2792-2796 (1990)], clinofibrate, soysterol or its Salt etc.
High uric acid and gout treatment: colchicine, allopurinol, febuxostat, probeneshi
De, benzbromarone, bucolol or a salt thereof.

Osteoporosis treatment: estradiol, raloxifene, elcatonin, salmon calcitonin, ipriflavone, calcitriol, alphacalcidol, menatetrenone, etidronate, alendronate, risedronate, teriparatide or a salt thereof.

Hemostatic drugs: phytonadione, menatetrenone, thrombin, hemocoagulase, tranexamic acid, carbazochrome or salts thereof.

Antithrombotic drugs: heparin, dalteparin, danaparoid, warfarin, argatropane,
Urokinase, alteplase, monteplase, aspirin, ozagrel, icosapen
Ethyl tomate, sarpogrelate, ticlopidine, clopidogrel, beraprost, syros
Tazole, dipyridamole or its salt.
Hematopoietic drugs: sideferon, cyanocobalamin, hydroxocobalamin, mecobalamin, folic acid, metenolone, nandrolone, erythropoietin preparation, pyridoxal phosphate ester, pyridoxine, filgrastim, lenograstim, nartograstim, mirimostim or a salt thereof.
NSAIDs (non-steroidal anti-inflammatory drugs): aspirin, salicylamide, indomethacin, indomethacin farnesyl, acemetacin, sulindac, piroxicam, ampiroxicam, tenoxicam, meloxicam, diclofenac, felbinac, ibuprofen, naproxen, loxoprofen, flurbiprofen, flurbiprofen Prophenaxetyl, ketoprofen, mefenamic acid, flufenamic acid, etodolac, celecoxib, tiaramid, epilysole, salicylic acid, sulpyrine, aminopyrine, phenacetin, phenylbutazone, ketophenylbutazone, benzydamine, mepyrizole, tinolidine, isopropylantipyrine, sazapyrine, clofesone Or its salt.
Immunosuppressive drugs: cyclosporine, tacrolimus, azathioprine, mizoribine, mycophenolate mofetil, cyclophosphamide, gusperimus, muromonab-CD3, basiliximab or a salt thereof.
Rheumatoid arthritis drugs: gold thiomalate, auranofin, D-penicillamine, bucillamine, methotrexate, leflunomide, actarit, lobenzalit, salazosulfapyridine or its salts.
Anti-allergic drugs: cromoglycic acid, tranilast, pemirolast, amlexanox, diphenhydramine, chlorpheniramine, clemastine, promethazine, cyproheptadine, azelastine, ketotifen, oxatomide, mequitazine, epinastine, fexofenadine, cetirizine, evastine, olotatherazine, olotatherazine Ramatroban, pranlukast, montelukast, zafirlukast, ibudilast, suplatast, tripelenamine, methodirazine, clemizole, diphenylpyralin, alimemazine or a salt thereof.
Antibiotics: benzylpenicillin, sultamicillin, pheneticillin, cloxacillin, ampicillin, bacampicillin, amoxicillin, piperacillin, cephalothin, cephazoline, cephalexin, cefaclor, cefothiam, cefuroxime xefiril, cefoxime cefothepef , Ceftazidime, cefodizime, cefixime, cefdinir, cefpodoxime proxetil, cefditoren pivoxil, cefcapene pivoxil, cefepime, cefpirom, cefozopran, cefotaxin, cefmetazole, cefbuperazone, cefminoxem, latamopecef Aztreonam, Carmonam, Ncomycin, leonam, imipenem, vanipenem, meropenem, faropenem, biapenem, doripenem, teicoplanin, fosfomycin, streptomycin, kanamycin, tobramycin, fradiomycin, gentamicin, amikacin, arbekacin, spectinomycin, chloramphenicol, erythromycin, clarimycin Roxithromycin, azithromycin, spiramycin, josamycin, midecamycin, acetylspiramycin, roquitamycin, tetracycline, minocycline, doxycycline, lincomycin, clindamycin, mupirocin, linezolid, polymyxin B, colistin, sulfamethoxazole, salazosulfa Pyridine, sulfadimethoxine, sulfadochi , Nadirixic acid, norfloxacin, moxifloxacin, garenoxacin, sitafloxacin, ofloxacin, enoxacin, ciprofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, gatifloxacin, pullrifloxacin, pazufloxacin, sulbactam, tazobactam , Quinupristin, dalfopristin, clavulanic acid, pibmesilinum, terisromycin, isoniazid, pyrazinamide, rifampicin, ethambutol, paraaminosalicylic acid, diphenylsulfone, clofazimine, lancacidins [J. AntiBiotics, 38, 877-885 (1985)], pipemide Acid trihydrate, dibekacin, cannendomycin, libidomycin, dibekacin, sisomycin, oxytetracycline, lorite Tracycline, ticarcillin, cephaloridine, cefothiam hexetyl, cefsulosin, moxalactam, thienamycin, or a salt thereof.
Antiprotozoan / parasitic drugs: quinine, mefloquine, sulfadoxine, pyrimethamine, metronidazole, tinidazole, spiramycin acetate, pentamidine, santonin, pyrantel, mebendazole, ivermectin, diethylcarbamazine, praziquantel, albendazole, levamisole or salts thereof.
Antifungal drugs: amphotericin B, nystatin, itraconazole, clotrimazole, ketoconazole, fluconazole, miconazole, micafungin, terbinafine, butenefin, flucytosine, griseofulvin or a salt thereof.
Antiviral drugs: acyclovir, valacyclovir, ganciclovir, vidarabine, foscalnet, amantadine, oseltamivir, zanamivir, laninavir octanoate, peramivir, zidovudine, didanosine, lamivudine, sanylvudine, abacavir, nevirapine, efavirenz, devilavirdin , Indinavir, nelfinavir, fosamprenavir, lopinavir, raltegravir, interferon preparation, ribavirin or a salt thereof.
Antineoplastic agents: cyclophosphamide, ifosfamide, busulfan, thiotepa, melphalan, nimustine, ranimustine, lomustine, carmustine, mercaptopurine, fludarabine, fluorouracil, tegafur, doxyfluridine, capecitabine, cytarabine, cytarabine occivin, enocitabine , Methotrexate, folinate, levofolinate, doxorubicin, daunorubicin, epirubicin, adriamycin, idarubicin, bleomycin, mitomycin C, actinomycin D, vincristine, vinblastine, vindesine, vinorelbine, paclitaxel, docetaxento, irinotecante, irinotecante Anastrozole Letrozole, flutamide, chlormadinone ester, medroxyprogesterone acetate, leuprorelin, goserelin, cisplatin, carboplatin, nedaplatin, oxaliplatin, L-asparaginase, hydroxycarbamide, dacarbacin, temozolomide, procarbazine, melphalan, cladribine, nelarabine, Fludarabine, pemetrexed, pentostatin, eribulin, sobuzoxane, vinorelbine, vindesine, aclarubicin, amrubicin, idarubicin, epirubicin, dinostatin stimamarer, pirarubicin, bepromycin, mitoxantrone, exemestane, estramustine, mitotane, mepithioxane , Thalidomide, neocalcinostatin, cytosine Arajinoshido, tetrahydrofuryl-5-fluorouracil, picibanil, lentinan, bestatin, mitoxantrone, aminoglutethimide, or a salt thereof.
Molecular targeted therapeutic drugs (low molecular weight compounds): Imatinib, gefitinib, erlotinib, dasatinib, lapatinib, nilotinib, sorafenib, sunitinib, crizotinib, axitinib, temsirolimus, everolimus, bortezomib, tamibarotene, toretinobu
Diagnostic and testing agents: amidotrizoic acid, meglumine, iotalamic acid, meglumine of iotalamic acid, meglumine of iotroxic acid, iopromide, iomeprol, iopamidol, iohexol, ioxirane, iotrolan, iodixanol, gadodiamide, sulfobromophthalein, indocyanine green, indigo carmine, Paraaminohippuric acid, phenolsulfonephthalein, inulin, creatinine, evans blue, tetragastrin, tuberculin, edrophonium, orthotolidine or a salt thereof.
Antidote / antagonist: Dimercaprol, edetic acid, D-penicillamine, trientine, defiloxamine, amyl nitrite, thiosulfate, pralidoxime, atropine, nalorphine, naloxone, levalorphan, flumazenil, dimorphoramine, holinato, protamine, cysteine , Mesna, dimesna, pyridoxine, pyridoxal phosphate, disulfiram, cyanamide or a salt thereof.
Herbal medicines: Aki, Ireisen, Inchinko, Ayaka, Yaku, Engosaku, Ogi, Ogo, Twilight, cherry bark, oren, long-distance, onion, gyoyo, kashiyu, kakkon, talc, karokon , Karonin, licorice, kikyo, citrus fruit, chrysanthemum flower, citrus peel, kyoto, annin (Kujin), candy (Kei-gai), Keishi (Kei-shi), jellyfish (Kou-i), safflower (Kou-kai), Kosuke (Koubushi), glutinous rice (Kou-bei), Koboku (Kou-Boku), cow knee (Goshitsu), Kureyu, Goshiboshi, Sesame (sesame), Gomi (Goshishi), Saiko (Saiko), Spicy (Saishin), Fine tea (Saicha) , Yamasuko, Sanshiko, Sansyuyu, Mountains (Sansho), acid soy sauce, mountain medicine (sanyaku), earth yellow (jio), earth bone skin (jikoppi), shibane (shikon), shizurishi, shakuyaku (shakuyaku) ), Car front child, shredded sand, ginger, wheat, sesame, shingi, shingi, shrine (Shingiku), gypsum (Gypsum), senkyu, mae-hu (zenko), river bone (senkotsu), retreat (zentai), mulberry white skin (sohakuhi), sugi (sokuku) , Soyo, Daio, Daiso, Takusha, Chikujo, Chimo, Chika, Chotou, Chorei, Chinpi, Tennansei, Tenma, Tenmon Fuyu, Togashi Fuyu, Toki, Tomoni ), Tochu, Dokatsu, Carrot, Shinobu Dough, Shinobi winter, shellfish mother, malt (bakuga), bakumon winter (bakumondo), light load (haka), half summer (hange), lily (bakugou), bakukushi , White birch, biwayo, bunko, bukkuri, tsushi (bushi), buoyed, bukkake, windbreak (bofufu) ), Bokuso, peony skin, oysters (mare), mao, mashinin, kokutsu, moka, moss (yakumoso) ), Well garlic, longan meat, dragonbone, ryutan, ryokyo, rengo, lotiniku, etc. .
Vitamins: Vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, biotin, pantothenic acid, vitamin C, and derivatives thereof.
Amino acids: Glycine, alanine, serine, threonine, valine, leucine, asparagine, aspartic acid, isoleucine, proline, glutamine, glutamic acid, phenylalanine, tryptophan, histidine, arginine, tyrosine, methionine, cysteine, lysine and derivatives thereof.
Animal drugs: Aivlosin, Spiramycin, Aspoxycillin, Amoxicillin, Oxytetracycline, Ampicillin, Erythromycin, Kitasamycin, Cloxacillin, Chloramphenicol, Dicloxacillin, Josamycin, Cedecamycin, Cefazolin, Cefalonium, Cefthioful, Cefuroxime, Tylosincin, Tiamcin Mycin A, Terdecamycin, Nystatin, Nanafurosine, Nafcillin, Novobiocin, Hygromycin B, Bicozamycin, Tetracycline, Benzylpenicillin, Fosfomycin, Oleandomycin, Milosamycin, Mecillinam, Monensin, Chlortetracycline, Spectinomycin, Doxycycline, Lincomycin, Dexamethasone, Apra Leucine, kanamycin, streptomycin, gentamicin, colistin, fradiomycin, piromidic acid or a derivative thereof and salts.
Others: meclofenoxate, thiaprid, ifenprodil, nicergoline, fasudil, sumatriptan, dutasteride, oxyfedrine, protochelol, aloclamide, cinepazide maleate, cyclandrate, cinnarizine, pentoxyphyllin, ifenprodil, rotenone, amital, Antimycin A, valinomycin, gramicidin A, oligomycin, edaravone, citicoline, methylphenidate, modafinil, mazindol, picrotoxin, pentetrazole, strychnine, carperitide, dilazep, doxapram, pirenoxine, glutathione, naphazoline, hyaluronic acid, acetaminophen, Teseleukin, sermoleukin, cilastatin, betamipron, pyrimethamine, gimeracil, o Racil, uracil, hydroxycam, diaserine, megestrol acetic acid, nicergoline, diethyl benzylphosphonate, etc.Phenolsulfophthalein derivative, benzothiopyran or benzothiepine derivative, thienoindazole derivative, fumagillol derivative, P38MAP kinase inhibitor (WO00 / 64894 Etc.), matrix metalloproteinase inhibitor (MMPI), ischemic disease therapeutic agent, immune disease therapeutic agent, angiogenesis therapeutic agent, retinopathy therapeutic agent, retinal vein occlusion therapeutic agent, senile circle Plate-like macular degeneration treatment, cerebral vasospasm treatment, cerebral thrombosis treatment, cerebral infarction treatment, cerebral obstruction treatment, intracerebral hemorrhage treatment, subarachnoid hemorrhage treatment, hypertensive encephalopathy treatment, transient Cerebral ischemic attack treatment, multiple infarct dementia treatment, arteriosclerosis treatment, Huntington's disease treatment, Treatment for brain tissue disorder, Treatment for optic neuropathy, Treatment for ocular hypertension, Treatment for retinal detachment, Treatment for arthritis, Treatment for anti-sepsy, Treatment for anti-septic shock, Treatment for atopic dermatitis, Treatment for allergic rhinitis, Congenital Drugs for heart disease, drugs for lymphadenitis, drugs for Crohn's disease, drugs for ulcerative colitis, drugs for irritable bowel syndrome, drugs for renal failure, labor inducers, fertility drugs, labor pain promoting drugs, labor pain suppressing drugs , Forced abortion drug, prostatic hypertrophy drug, endometrial cancer drug, breast cancer drug, chronic obstructive pulmonary disease drug, brain tumor drug, migraine drug, hepatitis drug, ascites drug, edema drug, Meniere Disease treatment, skin pigmentation treatment, leprosy treatment, agrochemical detoxification, pressure ulcer treatment, osteoarthritis treatment, osteomalacia (rickets) treatment, ringworm disease treatment, etc.
The external composition can contain the following additives.
Excipients: sugar alcohols (maltitol, xylitol, sorbitol, erythritol, mannitol, etc.), allose, talose, growth, glucose, altrose, mannose, galactose, idose, ribose, lyxose, xylose, arabinose, apiose, erythrose, Threose, glyceraldehyde, cedoheptulose, coliose, psicose, fructose, sorbose, tagatose, ribulose, xylulose, erythrulose, dihydroxyacetone, trehalose, isotrehalose, cordobiose, sophorose, nigerose, laminaribiose, maltose, cellobiose, thiomaltose, thiomaltose , Lactose, sucrose, sodium chloride, starch, reduced palatinome, carbonates ( Calcium phosphate, kaolin, crystalline cellulose, silicic acid, methylcellulose, sodium alginate, gum arabic, talc, phosphates (potassium hydrogen phosphate, calcium hydrogen phosphate, sodium hydrogen phosphate, dipotassium phosphate, diphosphate phosphate) Sodium, potassium dihydrogen phosphate, calcium dihydrogen phosphate, sodium dihydrogen phosphate), calcium sulfate, calcium lactate, oligosaccharides (such as lactulose, raffinose, lactosucrose).
Plasticizers: polyhydric alcohols such as glycerin, ethylene glycol and propylene glycol; various waxes such as monostearin, PEG4000, PEG6000 and PEG20000; organic fatty acids such as stearic acid and magnesium stearate.
Surfactant: Triethyl citrate, Tween 80, HCO 60, triacetin, etc.
Viscosity modifier: simple syrup, glucose solution, starch solution, gelatin solution, etc.
Binder: Hydroxypropyl cellulose, polyvinyl alcohol, polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxyvinyl polymer, crystalline cellulose, powdered cellulose, crystalline cellulose / carme Sodium loose, shellac, methylcellulose, ethylcellulose, potassium phosphate, gum arabic powder, pullulan, pectin, dextrin, corn starch, pregelatinized starch, hydroxypropyl starch, gelatin, xanthan gum, carrageenan, tragacanth, tragacanth powder, polyethylene glycol and the like.
Disintegrants: starch, dried starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, sodium carboxymethyl starch, methylcellulose, carmellose calcium, low-substituted hydroxypropylcellulose, sodium starch glycolate, partially pregelatinized starch, alginic acid Sodium, agar powder, sodium bicarbonate, calcium carbonate, etc.
Absorption enhancers: quaternary ammonium salts, sodium lauryl sulfate and the like.
Adsorbent: starch, lactose, kaolin, bentonite, colloidal silicic acid, etc.
Lubricant: Magnesium stearate, calcium stearate, talc, magnesium oxide, colloidal silica, boric acid powder, polyethylene glycol, etc.
Antioxidant: Dispersing agent such as sucrose fatty acid ester, sorbitan fatty acid ester, saponin.
Ascorbic acid, tocopherol, etc.
Acidulant: lactic acid, citric acid, gluconic acid, glutamic acid and the like.
Fluidizer: silicon dioxide and the like.
Sweeteners: sucralose, acesulfame potassium, aspartame, glycyrrhizin, etc.
Perfume: peppermint oil, eucalyptus oil, cinnamon oil, fennel oil, clove oil, orange oil, lemon oil, rose oil, fruit flavor, mint flavor, peppermint powder, d, l-menthol, l-menthol, etc.
In order to facilitate the control of the dissolution rate of medicinal ingredients, the pharmaceutical composition preferably contains a disintegrant, a binder and the like.
That's right.
Eye drops:
The content of the hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably about 0.1 to 20% by mass, more preferably about 0.1 to 10% by mass, based on the total amount of eye drops. More preferably, it is about 0.1-8 mass%, Most preferably, it is about 0.2-5 mass%. There is an advantage of increasing the viscosity of eye drops.
The hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably at least one compound selected from the group consisting of an alkyl-modified carboxyvinyl polymer, a hydrophobically modified polyether urethane, and a hydrophobically modified alkyl cellulose.
The content of cyclodextran is preferably about 0.005 to 10% by mass, more preferably about 0.01 to 5% by mass, and still more preferably about 0.02 to 2% by mass with respect to the total amount of eye drops. It is particularly preferably about 0.03 to 1% by mass.
The compounding amount of cyclodextran is preferably about 2 to 80 parts by mass, more preferably about 3 to 40 parts by mass with respect to 100 parts by mass of the hydrophobically modified compound having a long chain alkyl group in the molecule. About 6-20 mass parts is still more preferable. There is an advantage of forming an inclusion complex.
The content of the medicinal component can be appropriately selected according to bioavailability. The dosage of the pharmaceutical composition can be appropriately selected depending on the content of the medicinal ingredient and the bioavailability. The content of the medicinal component may be about 0.1 to 90% by mass with respect to the total amount of eye drops. It is preferable to contain about 0.1 to 100,000 parts by mass of a medicinal component with respect to 100 parts by mass of cyclodextran.
An eye drop can be produced by dissolving and mixing a hydrophobically modified compound having a long-chain alkyl group in the molecule, cyclodextran and a medicinal component in a solvent.
Orally disintegrating tablets:
The content of the hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably about 0.001 to 20% by mass, more preferably 0.001 to 10% by mass, based on the total amount of the orally disintegrating tablet. The degree is more preferably about 0.001 to 5% by mass, and particularly preferably about 0.001 to 1% by mass. There is an advantage as a binder.
For example, in the case of a 150 mg orally disintegrating tablet, the hydrophobically modified compound having a long-chain alkyl group in the tablet molecule (such as Sangelose) is preferably about 0.009 mg (0.006% by mass).
The hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably at least one compound selected from the group consisting of an alkyl-modified carboxyvinyl polymer, a hydrophobically modified polyether urethane, and a hydrophobically modified alkyl cellulose.
The content of cyclodextran is preferably about 5 to 50% by mass, more preferably about 10 to 40% by mass, and still more preferably about 15 to 30% by mass, particularly preferably based on the total amount of orally disintegrating tablets. Is about 15 to 20% by mass.
In the case of orally disintegrating tablets, cyclodextran is used for two purposes: interaction with a medicinal ingredient and interaction with a hydrophobically modified compound having a long-chain alkyl group in the molecule (such as Sangelose). It is preferable to add excessively. For example, in the case of a 150 mg orally disintegrating tablet, the cyclodextran in the tablet is preferably about 25 mg (16.7% by mass).
The compounding amount of cyclodextran is preferably about 200,000 to 400,000 parts by weight, based on 100 parts by weight of hydrophobically modified compound having a long chain alkyl group in the molecule, and 250,000 to 300,000. About a mass part is more preferable, and about 270,000-280,000 mass part is still more preferable. There is an advantage of inclusion complex formation.
The content of the medicinal component can be appropriately selected according to bioavailability. The dosage of the pharmaceutical composition of the present invention can be appropriately selected according to the content of the medicinal ingredient and the bioavailability. The content of the medicinal component may be about 0.1 to 90% by mass with respect to the total amount of the orally disintegrating tablet. It is preferable to contain about 0.1 to 100,000 parts by mass of a medicinal component with respect to 100 parts by mass of cyclodextran.
Orally disintegrating tablets can be produced by wet granulating a mixture of hydrophobically modified compounds having a long-chain alkyl group in the molecule, cyclodextran and medicinal ingredients (wet granulation method) . Wet granulation is a method in which medicinal ingredients, binders and excipients are wet-granulated, dried and sized, then mixed with an appropriate amount of lubricant and tableted by a tableting machine. . Specifically, the medicinal ingredients, excipients and binder are granulated in a conventional manner using purified water using a high-speed stirring granulator or fluidized bed granulator. The wet granulation method is preferable when a medicinal component having poor content uniformity and compression moldability is used. Orally disintegrating tablets can also be produced by dry granulation.
Sustained release formulation:
The content of the hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably about 0.001 to 20% by mass, more preferably 0.001 to 10% by mass, based on the total amount of the sustained-release preparation. The degree is more preferably about 0.001 to 5% by mass, and particularly preferably about 0.001 to 1% by mass. There is an advantage as a binder.
For example, in the case of a 150 mg orally disintegrating tablet, the hydrophobically modified compound having a long-chain alkyl group in the tablet molecule (such as Sangelose) is preferably about 0.009 mg (0.006% by mass).
The hydrophobically modified compound having a long-chain alkyl group in the molecule is preferably at least one compound selected from the group consisting of an alkyl-modified carboxyvinyl polymer, a hydrophobically modified polyether urethane, and a hydrophobically modified alkyl cellulose.
The content of cyclodextran is preferably about 5 to 50% by mass, more preferably about 10 to 40% by mass, and still more preferably about 15 to 30% by mass, particularly preferably based on the total amount of the sustained-release preparation. Is about 15 to 20% by mass.
In the case of a sustained-release preparation, cyclodextran is preferably added in excess for the two purposes of interaction with a medicinal ingredient and interaction with sangelose. For example, in the case of a 150 mg sustained-release preparation, the amount of cyclodextran in the tablet is preferably about 25 mg (16.7% by mass).
The compounding amount of cyclodextran is preferably about 200,000 to 400,000 parts by weight, based on 100 parts by weight of hydrophobically modified compound having a long chain alkyl group in the molecule, and 250,000 to 300,000. About a mass part is more preferable, and about 270,000-280,000 mass part is still more preferable. There is an advantage of inclusion complex formation.
The content of the medicinal component can be appropriately selected according to bioavailability. The dosage of the pharmaceutical composition can be appropriately selected depending on the content of the medicinal ingredient and the bioavailability. The content of the medicinal component may be about 0.1 to 90% by mass with respect to the total amount of the sustained-release preparation. It is preferable to contain about 0.1 to 100,000 parts by mass of a medicinal component with respect to 100 parts by mass of cyclodextran.
Sustained-release preparations can produce tablets by wet granulating a mixture of hydrophobically modified compounds having a long-chain alkyl group in the molecule, cyclodextran and medicinal ingredients (wet granulation method) . Wet granulation is a method in which medicinal ingredients, binders and excipients are wet-granulated, dried and sized, then mixed with an appropriate amount of lubricant and tableted by a tableting machine. . Specifically, the medicinal ingredients, excipients and binder are granulated in a conventional manner using purified water using a high-speed stirring granulator or fluidized bed granulator. The wet granulation method is preferable when a medicinal component having poor content uniformity and compression moldability is used. The sustained-release preparation can also be produced by a dry granulation method.
In addition, the pharmaceutical composition is used in a dosage form such as tablets, powders, fine granules, fine granules, granules, capsules, suppositories, ointments, plasters, poultices, aerosols and the like by conventional methods. You can also.

The following can be mentioned as a preferable aspect of the said pharmaceutical composition.
(Example 1)
Glimepiride (2 mg), crospovidone (50 mg), mannitol (60 mg), crystalline cellulose (10 mg), cyclodextran (25 mg) and magnesium stearate remaining amount are mixed to obtain a pharmaceutical composition of 150 mg per tablet.
(Example 2)
An eye drop containing 0.1% by mass of diclofenac sodium, 0.1% by mass of cyclodextran, and 0.5% by mass of hydrophobically modified alkyl cellulose is obtained.

Promotion of GLP-1 secretion:
In order to promote the secretion of GLP-1 (Glucagon-like peptide-1), a GLP-1 secretion promoter containing cyclodextran as an active ingredient is used.
GLP-1 secretion promoters promote the secretion of GLP-1 that exhibits various physiological actions. When a GLP-1 secretion promoter is administered to a living body, the physiological actions of GLP-1 (increase of insulin secretion, suppression of glucagon secretion, suppression of gastric excretion and gastric acid secretion, through secretion promotion of endogenous GLP-1 It is possible to enhance or improve the suppression of appetite and feeding, promotion of pancreatic β-cell proliferation, improvement of learning / memory ability, etc. (Gastroenterology 2007, 132: 2131-57)). Therefore, the drug of the present invention can prevent or improve diabetes, obesity, postprandial hyperglycemia or neurodegenerative diseases such as dementia, improve neuropathy associated with diabetes, suppress glucagon secretion, suppress gastric excretion and gastric acid secretion, appetite, It is effective for suppressing feeding and promoting proliferation of pancreatic β cells. Here, “prevention” refers to preventing or delaying the onset / onset of a disease (disorder) or its symptoms or reducing the risk of onset / onset. On the other hand, “improvement” means that a disease (disorder) or a symptom thereof is alleviated (lightened), improved, ameliorated, or cured (including partial healing).
A particularly important use of GLP-1 secretion promoters is prevention or amelioration of diabetes and obesity. The form of the GLP-1 secretion promoter is not particularly limited, but is preferably a pharmaceutical, a quasi drug or a food.
The pharmaceutical composition and the quasi-drug composition can be formulated according to a conventional method.
In the case of formulating, other pharmaceutically acceptable ingredients (for example, carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological Salt water and the like). As the excipient, lactose, starch, sorbitol, D-mannitol, sucrose and the like can be used. As the disintegrant, starch, carboxymethylcellulose, calcium carbonate and the like can be used. Phosphate, citrate, acetate, etc. can be used as the buffer. As the emulsifier, gum arabic, sodium alginate, tragacanth and the like can be used. As the suspending agent, glyceryl monostearate, aluminum monostearate, methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, sodium lauryl sulfate and the like can be used. As the soothing agent, benzyl alcohol, chlorobutanol, sorbitol and the like can be used. As the stabilizer, propylene glycol, ascorbic acid or the like can be used. As preservatives, phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben, and the like can be used. As preservatives, benzalkonium chloride, paraoxybenzoic acid, chlorobutanol and the like can be used.
The dosage form in the case of formulating is also not particularly limited. For example, the pharmaceutical composition or medicament of the present invention as a tablet, powder, fine granule, granule, capsule, syrup, injection, external preparation, suppository or the like. An quasi-drug composition can be provided.
The pharmaceutical composition contains an active ingredient in an amount necessary for obtaining an expected therapeutic effect or preventive effect (that is, a therapeutically effective amount). Similarly, the quasi-drug composition contains an active ingredient in an amount necessary for obtaining the expected improvement effect, prevention effect, and the like. The amount of the active ingredient contained in the pharmaceutical composition or quasi-drug composition generally varies depending on the dosage form and form, but the amount of the active ingredient is, for example, from about 0.1% by weight to about 95% by weight so that a desired dosage can be achieved. Set within the range of%.
The pharmaceutical composition and quasi-drug composition are oral or parenteral (enteral, intravenous, intraarterial, subcutaneous, intramuscular or intraperitoneal injection, transdermal, nasal, transmucosal, Applied to the subject. The “subject” here is not particularly limited, and includes humans and non-human mammals (pet animals, livestock, poultry, laboratory animals. Specifically, for example, mice, rats, guinea pigs, hamsters, monkeys, cows, pigs) , Goats, sheep, dogs, cats, chickens, quails, etc.). In a preferred embodiment, the application subject is a human.
The dosage and usage of the pharmaceutical composition and the quasi-drug composition are set so as to obtain the expected effect. In setting an effective dose, the symptom, age, sex, weight, etc. of the subject of application are generally considered. A person skilled in the art can set an appropriate dose in consideration of these matters. As the administration schedule, for example, once to several times a day, once every two days, once every three days, etc. can be adopted. In the preparation of the administration schedule, the symptom to be applied, the effect duration of the active ingredient, etc. can be taken into consideration.
One embodiment of the GLP-1 secretion promoter is a food composition containing a GLP-1 secretion promoter. Examples of food compositions include general foods (cereals, vegetables, meat, various processed foods, confectionery, milk, soft drinks, alcoholic beverages, etc.), nutritional supplements (supplements, nutritional drinks, etc.), food additives, pet animals And food supplements for pet animals. In the case of a dietary supplement or food additive, it can be provided in the form of powder, granule powder, tablet, paste, jelly, liquid or the like. By providing it in the form of a food composition, it becomes easy to ingest the GLP-1 secretion promoter daily or continuously.
The food composition preferably contains an amount of a GLP-1 secretion promoter that can be expected to have a therapeutic or prophylactic effect. The amount added can be determined in consideration of the medical condition, health condition, age, sex, weight, etc. of the person to whom it is used.

Sphingolipid:
In order to improve the taste and the like of sphingolipid, the oral composition containing sphingolipid is combined with (a) cyclodextran and (b) oat stem and / or leaf to form an oral composition. .
Sphingolipid is a general term for complex lipids containing sphingoids (sphingoid bases), which are long-chain alcohols having amino groups. Specifically, the sphingoids are classified into ceramides in which fatty acids are bonded to acid amides, sphingoglycolipids in which saccharides are bonded to the ceramides, and sphingophospholipids in which phosphoric acid and a base are bonded. These sphingolipids are known to exist widely in the living world, and are used in various applications such as pharmaceutical applications as well as cosmetic applications for the purpose of improving the functional deterioration of the stratum corneum.
Among the sphingolipids, it is preferable to use glucosylceramide, which is a kind of glycosphingolipid. This is because the raw material of glucosylceramide is derived from plants, especially cereals, so the raw materials are easy to obtain, and glucosylceramide is highly stable against pH fluctuations and heat fluctuations, and is difficult to change during processing. It is because it is easy to use as an oral composition.
Sphingolipids are derived from raw materials such as animals, plants, and microorganisms, such as animals such as cattle, pigs, horses, cottonseed, sugar beet, sugarcane, rapeseed, sugarcane, sesame, peanuts, soybeans, corn, rice, Plants such as wheat, pineapple, eggplant, tangerine, and apple, mushrooms such as tamogi, food such as milk, yeast, and the like. Among these, it is preferable to use rice as a raw material. This is because rice is actively produced as a staple food especially in Asian countries, and it is easy to obtain raw materials, and compared to other raw materials, the bitterness, astringency, and sashimi of sphingolipids (glucosylceramide) obtained are high. Because it is weak, even if the amount of sphingolipid in the composition is large, the taste and aroma can be improved, and the function of the sphingolipid is easily obtained.
The shape of the sphingolipid is not particularly limited, and the raw material containing the sphingolipid may be used as it is, or the raw material is subjected to processing such as crushing and pulverization, separated or extracted from the raw material, or artificially synthesized You may use processed materials, such as a thing. The shape of the sphingolipid is preferably blended into compositions of various shapes and is preferably powdered such as powders and granules having high versatility.
The crushing and pulverizing method for obtaining the sphingolipid from the raw material is not particularly limited, and may be either wet or dry, and the pulverizing conditions and the processing apparatus are not particularly limited, and commercially available apparatuses can be used as appropriate. Examples of the apparatus to be used include a high-pressure homogenizer, an ultrasonic pulverizer, an airflow pulverizer, a high-speed rotational impact pulverizer, a ball mill or a bead mill. These treatments may be repeated a plurality of times as necessary so that the physical properties such as the particle diameter of the processed product are within a preferable range, or a plurality of treatments may be combined.
Moreover, the extraction / separation method and the synthesis method of the sphingolipid from the raw material are not particularly limited, and can be appropriately selected according to the purpose. Examples of the extraction method include a method in which an extraction solvent usually used by those skilled in the art, such as ethanol, water, and hydrous ethanol, is added, and the mixture is heated and extracted as necessary.
The sphingolipid raw material processed product may be mixed with excipients such as silicon dioxide, extenders, binders, thickeners, emulsifiers, etc., and molded into granules or tablets. In addition, those dissolved or dispersed in a solvent such as water (purified water or the like) or edible oil (corn oil or the like) may be used.
There is no restriction | limiting in particular in content of sphingolipid in a composition, According to various conditions, such as a purpose, a shape, and a use object, the content can be set suitably in a wide range. For example, 0.00001 to 98 mass%, preferably 0.0001 to 10 mass%, more preferably 0.0001 to 1 mass% is selected with respect to the composition.
The barley stalk and / or leaves are not particularly limited as long as they are barley stalks and leaves, and any barley, wheat, rye, buckwheat or the like can be used as the barley. Wheat stalks and / or leaves are mostly insoluble fiber, antihypertensive, adsorbing harmful substances, improving intestinal environment, suppressing cholesterol absorption, preventing postprandial blood glucose spikes, superoxide dismutase (SOD) ) And the like. As long as the wheat stalk and / or leaves are normally available, the type, variety, and production area of the wheat are not particularly limited.
Among the types of barley, barley stems and / or leaves are preferable because they are rich in vitamins, minerals, and insoluble dietary fiber, and more preferably young leaves. Barley varieties are not particularly limited.
The type and variety of wheat stems and / or leaves to be used may be only one type or a combination of two or more types.
The shape of the stem and / or leaf of the wheat is not particularly limited, and the harvested stem and / or leaf may be used as it is, or the wheat stem and / or leaf is subjected to processing such as crushing and grinding, Processed products such as those obtained by separating and extracting extracts from stems and / or leaves, and those obtained by squeezing wheat stems and / or leaves may be used. The shape of wheat stems and / or leaves is preferably blended into compositions of various shapes and is preferably powdered such as powders and granules having high versatility.
A processing method such as crushing / pulverization of wheat stalks and / or leaves is not particularly limited, and may be either wet or dry, and the pulverization conditions and processing equipment are not particularly limited, and conventionally known processing methods are used. be able to. As processing methods, for example, moisture is removed by natural drying or drying, finely pulverized with a mill, crusher, stone mill, grinder, etc., harvested stems and / or leaves are freeze-dried to remove moisture, and then pulverized Examples thereof include a method, a method of squeezing harvested stems and / or leaves, and drying them into powder. In particular, the harvested stems and / or leaves are preferably blanched either before or after drying. The wheat stem and / or leaves are preferably dried so that the water content is 10% by mass or less, preferably 5% by mass or less. These treatments may be repeated a plurality of times as necessary so that the physical properties such as the particle diameter of the processed product are within a preferable range, or a plurality of treatments may be combined.
Moreover, the extraction / separation method and the synthesis method of the extract from the stem and / or leaf of wheat are not particularly limited, and can be appropriately selected according to the purpose. Examples of the extraction method include a method in which an extraction solvent usually used by those skilled in the art, such as ethanol, water, and hydrous ethanol, is added, and the mixture is heated and extracted as necessary.
The method of squeezing from wheat stems and / or leaves is not particularly limited, and squeezing methods commonly used by those skilled in the art can be applied.
Wheat stalks and / or processed leaves may be formed by mixing with excipients such as silicon dioxide, extenders, binders, thickeners, emulsifiers, etc., and water (purification). Water or the like and edible oil (such as corn oil) dissolved or dispersed in a solvent may be used.
The particle diameter of the processed product of the wheat stem and / or leaf is not particularly limited, but in the case of powder, for example, 0.01 to 1000 μm, preferably 0.1 to 300 μm, more preferably 1 to 100 μm is selected. . As the particle size of the powder becomes smaller than 1 μm, the processing tends to become difficult, and when it becomes smaller than 0.01 μm, this tendency becomes remarkable, which is not preferable. Further, when the particle size of the powder is larger than 100 μm, it tends to be easy to feel roughness when taken orally as a powdered beverage, and when it is larger than 1000 μm, this tendency becomes remarkable.
In the case of granules, for example, 0.01 to 10000 μm, preferably 0.1 to 3000 μm, more preferably 1 to 1000 μm is selected. As the particle size of the granule becomes smaller than 1 μm, granulation tends to become difficult, and as the particle size becomes smaller than 0.01 μm, this tendency becomes remarkable, which is not preferable. In addition, as the particle size of the granule becomes larger than 1000 μm, it tends to be difficult to dissolve or disperse when ingesting as a powdered beverage, and the versatility as a composition tends to be low, and when it exceeds 10,000 μm, this tendency Is not preferable because it becomes remarkable.
The content of barley stems and / or leaves in the composition is not particularly limited, and the content can be appropriately set in a wide range according to various conditions such as purpose, shape, and intended use. For example, 0.0001 to 99 mass%, preferably 0.001 to 90 mass%, more preferably 0.001 to 60 mass% is selected with respect to the composition of the present invention.
There is no restriction | limiting in particular in content of the cyclodextran in a composition, According to various conditions, such as an objective, a shape, and a use object, the content can be suitably set in a wide range. For example, 0.0001 to 90 mass%, preferably 0.001 to 90 mass%, more preferably 0.001 to 50 mass% is selected with respect to the composition.
The compounding ratio (weight ratio) of cyclodextran compounded with sphingolipid and oat stalk and / or leaf is not particularly limited, and can be appropriately set according to conditions such as the purpose and the object of use. For example, sphingolipid: cyclodextran: wheat = 1: 0.01-40000: 0.01-20000, preferably 1: 0.01-4000: 0.01-2000, more preferably 1: 0.1 500: 0.1-200 is selected.
In the composition, saccharides can be further used. Examples of the saccharide include monosaccharides, disaccharides, oligosaccharides, polysaccharides, and sugar alcohols. For example, monosaccharides such as glucose, fructose and galactose; disaccharides such as maltose, sucrose, lactose and trehalose; fructooligosaccharides, xylooligosaccharides, soybean oligosaccharides, galactooligosaccharides, isomaltoligosaccharides, whey oligosaccharides, raffinose, etc. Oligosaccharides; polysaccharides such as starch, glycogen, cellulose, hemicellulose, pectin, dextrin, indigestible dextrin, cyclodextrin; erythritol, xylitol, ribitol, arabitol, galactitol, sorbitol, mannitol, paratinite, lactitol, maltotriitol, Examples thereof include sugar alcohols such as isomaltoritol, reduced maltose and reduced palatinose, and derivatives thereof.
The composition may contain other components in addition to the sphingolipid, wheat stem and / or leaf, and cyclodextran.
Examples of the other components include proteins such as gelatin and collagen peptides; water-soluble dietary fibers such as alginic acid, indigestible dextrin, guar gum, guar gum, glucomannan, polydextrose, and fucoidan; cellulose, hemicellulose, pectin, and lignan. Insoluble dietary fibers such as glucan, gargagenan, agarose, chitin and chitosan; minerals such as calcium, magnesium and iron; mucopolysaccharides such as N-acetylglucosamine, hyaluronic acid and chondroitin sulfate; milk, fermented milk, skim milk powder, etc. Dairy products; soy milk products such as soy milk, soy milk powder; plants or plant processed products such as lemon, apple, tomorrow, kale, sweet potato, sweet potato foliage, potato, carrot, pumpkin, bitter melon, tomato, green pea, morroheia; Etc. S; lactic acid bacteria can be formulated natto, butyric acid bacteria, Aspergillus, microorganisms such as yeast. Furthermore, high-sweetness sweeteners such as stevia, acesulfame potassium, sucralose, aspartame, and thaumatin, which are usually used in the food field as needed; acidulants such as citric acid, lactic acid, gluconic acid, and apples; colorants such as titanium oxide Thickeners such as gum arabic and xanthan gum; brighteners such as shellac; agents for producing talc, silicon dioxide, cellulose, calcium stearate, etc .; vitamins such as vitamin A, vitamin C, vitamin E, royal jelly, protein, chitosan And nutritional supplements such as lecithin.
Other ingredients other than these include various excipients, binders, lubricants, stabilizers, diluents, extenders, thickeners, emulsifiers, colorants, fragrances, food additives, seasonings, etc. Can be mentioned. The content of other components can be appropriately selected according to the form of the composition.
The shape at the time of ingesting the composition is not particularly limited, and specific shapes include, for example, powders and granules, tablets (chewable), spheres, capsules, caplets, bowls, bars, plates Shapes such as solid, block, wafer, biscuit, gummy, etc .; semi-solids such as gel, cream, jelly, etc .; fluids such as syrup and liquid. The capsule-like oral composition includes soft capsules and hard capsules, and the liquid oral composition includes carbonated drinks, coffee drinks, tea-based drinks, mineral water, flavored water, sports / functional drinks, fruit drinks, milk This includes beverages, milk beverages, soy milk beverages, vegetable beverages, nutritional beverages (mini-drinks) and the like. The composition may be an oral composition such as a dentifrice or mouthwash.
The composition is preferably made into a powdered beverage such as green juice that is dissolved in water or the like. By making it into a powdered beverage, the production can be facilitated, the composition is excellent in stability and versatility, and unlike a capsule or a tablet, many compositions can be taken at a time.
The particle size of the oral composition in the case of a powdered beverage is not particularly limited, but when granulated, for example, 0.01 to 10000 μm, preferably 0.1 to 3000 μm, more preferably 1 to 1000 μm is selected. . As the particle size of the granule becomes smaller than 1 μm, granulation tends to become difficult, and as the particle size becomes smaller than 0.01 μm, this tendency becomes remarkable, which is not preferable. In addition, as the particle size of the granule becomes larger than 1000 μm, it tends to be difficult to dissolve or disperse when ingesting as a powdered beverage, and the general versatility as a composition tends to be low. Is not preferable because it becomes remarkable.
The composition is not particularly limited as to its ingestion method, ingestion amount, number of ingestions, ingestion time, and ingestion target. Moreover, it can select suitably according to various factors and objectives, such as age of an ingestion individual, a body weight, a constitution.

The following can be mentioned as a preferable aspect of the said composition.
(Example 1)
Glucosylceramide 18 mg, barley young leaf powder 1 g, and cyclodextran 1 g are dissolved in water 100.

Herbal preparations:
In order to produce a crude drug formulation, the crude drug is extracted with cyclodextran-containing water or water, the extract is concentrated under reduced pressure in the presence of cyclodextran, and this is spray-dried.
Herbal medicines are not particularly limited, but salmon jutsu, magnolia, chenke, licorice, shredded sand, garlic, dry-growth, large kyoko, glaze, cinnamon, oyster musk, mahuang, gauze, half-summer, clove, wood incense , Agarwood, frankincense etc. One or more of these can be used.
The extract is preferably a slurry-like soft extract having a water content of 20 to 50% by mass.
Cyclodextran-containing water contains 0.01 to 4 mass%, preferably 0.1 to 2 mass% of cyclodextran.
The cyclodextran-containing water used for the extraction is applied in an amount of 2 to 100 times, preferably 4 to 30 times, the raw material crude drug.
The extraction temperature is from room temperature to about 100 ° C. Preferably it is the range of 60-90 degreeC.
The time required for extraction is generally about 30 minutes to 3 hours, preferably 1 to 2 hours.
The extract is heated to 60 ° C., the solvent is removed under reduced pressure of 10 to 700 mmHg, and a slurry-like soft extract is produced from the concentrate. In the extract, cyclodextran is 0.01 to 0.1 times by mass with respect to the raw crude drug.
The time required for concentration under reduced pressure varies depending on the reduced pressure conditions and the like, but is generally about 30 minutes to 2 hours.
In the spray drying, the soft extract obtained in the above step is sprayed from a nozzle in a hot air stream at around 100 to 200 ° C. to perform drying.
The dry powder obtained in this way is an excipient such as starch, lactose, calcium carbonate or calcium phosphate, a binder such as gum arabic, carboxymethylcellulose, hydroxypropylcellulose or crystalline cellulose, or a lubricant such as magnesium stearate or talc. It can be mixed with disintegrants such as a bulking agent, carboxymethyl calcium, talc, and synthetic aluminum silicate, and can be made into preparations such as capsules, powders, fine granules and tablets by a conventional method.
The following can be mentioned as a preferable aspect of said manufacture.
(Example 1)
2.4 kg of cyclodextran is added to 383 l of the crude drug extract and concentrated under reduced pressure at 40-45 ° C./70 mmHg. This gives 38 kg of soft extract.

Odor-absorbing aqueous composition:
About 0.1% to about 5% cyclodextran to absorb the odor of the inanimate surface, essentially free of soiling or staining material and essentially free of perfume. A stable odor-absorbing aqueous composition comprising an aqueous carrier, essentially free of materials that stain or stain the fabric, and essentially free of perfume, with a pH greater than about 3 The composition is as follows.
The cavities inside the cyclodextrans in the composition remain essentially unfilled in the composition (the cyclodextran remains uncomplexed) and the cyclodextran does not appear when the composition is applied to the surface. It should be able to absorb various odor molecules. The availability of solubilized and uncomplexed cyclodextrans is essential for effective and efficient odor control performance.
Typical concentrations of cyclodextran are about 0.1% to about 5%, preferably about 0.2% to about 4%, more preferably about 0.3% to about 3%, most preferably About 0.5% to about 2%. Compositions having higher concentrations of cyclodextran may leave an unacceptable visible stain on the fabric as the solution evaporates from the fabric.
To avoid or minimize the occurrence of fabric stains, it is preferred to treat the fabric at a concentration of less than about 5 mg of cyclodextran per mg of fabric and treat at a concentration of less than about 2 mg of cyclodextran per mg of fabric. More preferably.
The composition can include a solubilized water-soluble antimicrobial preservative. Antimicrobial preservatives include organic sulfur compounds, halogenated compounds, cyclic organic nitrogen compounds, low molecular weight aldehydes, quaternary compounds, dehydroacetic acid, phenyl and phenoxy compounds, and mixtures thereof.
The pH of the composition is from about 3 to about 10, preferably from about 4 to about 8, and more preferably from about 4.5 to about 7.
The aqueous carrier is preferably water.
The composition may further contain optional components such as metal salts, water-soluble cation and anionic polymers, water-soluble bicarbonates, zeolites, activated carbon, and mixtures thereof.
Unpleasant odors are, for example, cigarette odors, cooking and food odors, environmental odors such as body odors, amines, acids, alcohols, aldehydes, phenols, polycyclic compounds, indoles, aromatic compounds , Based on organic molecules having functional groups such as polycyclic aromatic compounds, thiols, mercaptans, sulfides and disulfides.
Articles include curtains, carpets, clothing, shoes, and the like.
These compositions are placed in a nebulizer. The nebulizer is any manually operated device for generating a spray of droplets as known in the art, for example, trigger, pump, non-aerosol, self-pressurizing And aerosol type spray devices. The nebulizer is substantially free of foaming clear odor-absorbing aqueous compositions. It is preferred that the particle size of at least about 80%, more preferably at least about 90% of the droplets is greater than about 30 μm.
The nebulizer can be an aerosol nebulizer. The aerosol nebulizer includes a container composed of any of the usual materials used in the manufacture of aerosol containers. The nebulizer should be able to withstand internal pressures in the range of about 20 to about 110 psig, more preferably about 20 to about 70 psig.

Preferred embodiments of the odor absorbing composition include the following.
(Example 1)
An aqueous solution containing 1.0% by mass of cyclodextran and 0.001% by mass of Kathon (registered trademark) CG.

The composition of the present invention can be used in medicines, cosmetics, foods and drinks, inks, hygiene products, conductive liquids, resins, columns and the like.
The composition of the present invention is used for solubilization of poorly soluble compounds, masking of foods and drinks, stabilization of foods and drinks, drying of components unsuitable for drying, deodorizing unpleasant odors, sustained release of fragrances, etc. it can.

that's all

Claims (17)

  A composition comprising one or more selected from the group consisting of cyclodextran and derivatives thereof.   The composition according to claim 1, wherein the derivative of cyclodextran is an α-1,3-branched cyclodextran in which 1 to several glucoses are linked to cyclodextran by α-1,3-linkages.   The composition according to claim 1, wherein the composition comprises an unbranched cyclodextran and an α-1,3-branched cyclodextran in which 1 to several glucoses are linked to cyclodextran by α-1,3-linkages. object.   A pharmaceutical comprising the composition according to any one of claims 1 to 3.   Cosmetics containing the composition according to any one of claims 1 to 3.   Food / beverage products containing the composition in any one of Claims 1-3.   An ink comprising the composition according to claim 1.   A sanitary product comprising the composition according to any one of claims 1 to 3.   A conductive liquid comprising the composition according to claim 1.   A resin comprising the composition according to claim 1.   A column comprising the composition according to claim 1.   A method for solubilizing a hardly soluble compound, comprising mixing the composition according to claim 1 and a hardly soluble compound.   A method for masking a food or drink, comprising mixing the composition according to any one of claims 1 to 3 with the food or drink.   A method for stabilizing a food or drink, comprising mixing the composition according to any one of claims 1 to 3 with the food or drink.   A method for drying a component unsuitable for drying, comprising mixing a component unsuitable for drying and the composition according to any one of claims 1 to 3, followed by drying.   A method for deodorizing an unpleasant odor, characterized in that an article that emits an unpleasant odor is sprayed with a solution containing the composition according to any one of claims 1 to 3.   A method for sustained release of a fragrance, comprising mixing the fragrance and the composition according to claim 1.